[Document -1] guidanc industri irrit bowel syndrom clinic evalu drug treatment us depart health human servic food drug administr center drug evalu research cder may 2012 clinicalmed guidanc industri irrit bowel syndrom clinic evalu drug treatment addit copi avail offic commun divis drug inform center drug evalu research food drug administr 10903 new hampshir ave bldg 51 rm 2201 silver spring md 209930002 tel 3017963400 fax 3018478714 email druginfofdahhsgov httpwwwfdagovdrugsguidancecomplianc egulatoryinformationguidancesdefaulthtm us depart health human servic food drug administr center drug evalu research cder may 2012 clinicalmed tabl content introduct 1 ii background 2 iii evolut pro measur ib clinic trial 2 iv provision endpoint trial design ib clinic trial 4 1 trial design 4 2 trial endpoint 5 3 trial popul 6 4 efficaci asur 7 5 definit respond 7 v futur develop ib pro instrument 11 vi conclus 11 refer 12 contain nonbind recommend guidanc industry1 irrit bowel syndrom clinic evalu drug treatment guidanc repres food drug administrati on fda current think topic creat confer right pe rson oper bind fda public use altern approach approach satisfi requir applic statut regul want discuss alterna tive approach contact fda staff respons implement guidanc identifi appropri fda staff call appropri number list titl page guidanc introduct guidanc intend assist pha rmaceut industri investig develop drugs2 treatment irrit bowel syndrom ib ib diagnosi assess clinic statu depend mainli evalu ib sign symptom known patient captur clinic alli import sign symptom associ ib reliabl measur treatment benefit challeng ing guidanc industri patientreport outcom measur use medic product develop support label claim pro guidance3 defin term treatment benefit effect treatment patient surviv feel function guidanc address two main topic sectio n iii discuss evolut patientreport outcom pro measur primari endpoint ib clinic trial section iv provid set provision endpoint trial design commend sponsor may appli ib clinic trial pro measur continu evolv guidanc also discuss section v futur develop ib pro instru ment fda qualif process fda collabor critic path institut recommend provid guidanc consist good measur scie nce reflect fda guidanc 1 guidanc prepar divis gastroenterolog inborn error product studi endpoint label develop team center drug evalu research cder food drug administr 2 purpos guidanc refer drug includ human drug therapeut biolog product unless otherwis specifi 3 updat guidanc period make sure recent version guidanc check fda drug guidanc web page httpwwwfdagovdrugsguidancecompliancereg ulatoryinformationgu idancesdefaulthtm 1 contain nonbind recommend goal efficaci endpoint ib clinic trial assess treatment effect core diseasedefin sign symptom ib welldefin reliabl way endpoint avail provi sional endpoint assess sugg sted guidanc use evalu treatment benefit ib clinic trial guidanc appli ib indic ib diarrhea ibsd ib constip ibsc sponsor contac divis gast roenterolog inborn error product discuss endpoint assessm ent trial design propos ib popul discuss guidanc ie mix irrit bowel syndrom unsubtyp irrit bowel syndrom fda guidanc document includ guid anc establish legal enforc respons instead guidanc describ th e agenc current thinki ng topic view recommend unless spec ific regulatori stat utori requir cite use word agenc guidanc mean someth suggest recommend requir ii background ib complex condit well link readili measur physiolog abnorm despit advanc understandi ng basic neuroenter mechan role effector transmitt braingut axi reliabl biolog marker ib yet indentifi 4 pro measur sign symptom condit current avail measur adequ de fine treatment effect clinic trial iii evolut pro measur ib clinic trial adequ measur trea tment benefit captur th e signific sign symptom ib primari challeng designi ng clinic trial evalu efficaci drug condit defin critic sign sy mptom relev patient select develop adequ assess tool measur improv decrement import ant sign symptom past ib clinic trial commonli use singleitem patientreport rate overal chang condit primari efficaci endpoint5 singleitem patientreport rate chang use primari endpoint specif ib sign symptom often includ separ secondari endpoint detail tabl 1 exampl singleitem patientreport rate ch ang includ questi on pose patient adequ relief satisfactori relief singl item subject global assessmen relief ib symptom usual patientreport rate chang requir patient averag either specif symptom eg abdomin pain discom fort sign symptom ib 4 see refer number 18 referenc es section end guidanc 5 see refer number 923 refer nce section end guidanc 2 contain nonbind recommend week time compar averag period past typica lli trial entri tabl 1 describ primari endpoint use sever ib clinic trial although endpoint may well captur dire ction chang trial control blind could provid use informati effect treatm ent sever specif sign symptom tabl 1 primari endpoint use ib clinic trial drug indic primari endpoint question singleitem use assess efficaci respons alosetron adequ relief past 7 day adequ relief binari yesno ibsd 1 ib pain discomfort tegaserod satisfactori satisfactori relief overal ib binari yesno ibsc2 relief subject global assess relief sga symptom last week satisfactori relief abdomin discomfort pain last week pleas consid felt past treatment period regard ib particular overal wellb symptom abdomin paindiscomfort alter bowel habit compar way usual felt enter trial would rate relief symptom past week binari yesno 5point likert scale lubiproston modifi would rate relief ib symptom 7point likert scale ibsc 3 version sga abdomin discomfortpain bowel habit ib symptom past week compar felt enter trial 1 see refer number 914 refer section end guidanc 2 see refer number 1522 refer section end guidanc 3 see refer number 23 refer section end guidanc note pro guidanc defin treatment benefit effect treatment patient surviv feel function pro instrument defin captur patient perspect respect th e diseas condit inter st appropri measur effect treatment clinic trial particularli desir effect treatment sign symptom known patient consist fda regul drug approv effect treat ment must base substanti evid includ evid method assess subject respons welldefin reliabl 21 cfr 314126b6 pro guidanc set forth fda review principl determin whether assess welldefin ie valid adequ develop ie reliabl sensit interpret measur intend measur reflect pro guidanc type pro instrument consid appropri data collect support label claim evolv consid appropri past exampl longer recommend singl gener item ask patient rate chang overal ib symptom primari endpoi nt support efficaci claim singl gener item adequ cap ture whether benefit achiev import sign symptom exampl si ngle item queri patient 3 contain nonbind recommend overal ib experi like captur situat patient stool frequenc improv abdomin pain improv even worsen recognit limit use si ngleitem patientreport rate overal chang primari endpoint base principl es explain pro guidanc recommend develop multiitem pr instrument pro measur captur clinic import sign symptom ib target popul eg ibsc ibsd chang previou score calcul drug develop specif improv one major si gn symptom ib eg abdomin pain base drug mechan action still import assess import sign symptom document drug neg affect compon ultim drug indic reflect find clinic trial iv provision endpoint tr ial design ib clinic trial welldefin reliabl pro instrument measur clinic import sign symptom associ ib subtyp would ideal pr imari efficaci assess tool clinic trial use support label claim time instrument avail recogn take time develop ad equat instrument meantim great need develop effect therapi patient ib therefor appropri pro instrument develop sponsor consid strategi discuss follow section design ib c linic trial section set forth provision sta ndard regard 1 tria l design 2 tria l endpoint 3 trial popul 4 efficaci measur 5 definit respond follow discuss tabl 2 summ ariz provision standard ibsc ibsd trial design includ primari endpoint patient entri criteria respond definit tabl 2 intend summari discuss guidanc sponsor refer text guidanc full detail 1 trial design clinic sign symptom associat ed ibsc ibsd significantli differ two condit ordi narili studi separ clinic trial random placebocontrol trial design shoul includ 1 2week singleblind openlabel screen period 1 2week screen period use establish presenc persist tria l entri criteria train patien ts mode pro data collect select trial screen period also use select patient specifi level sever sign sympto ms therapi administ chronic continu basi recommend treatment period least 8 week durat follow random withdraw design ddress need mainten treatment prevent sign symptom recurr 4 contain nonbind recommend therapi intermitt administra tion schedul sponsor provid repeat cours therapi demonstr sustain effi caci time character safeti intermitt repeat administr 2 trial endpoint support indic treatment ib recommend primari endpoint measur effect treatment tw major ib sign symptom abnorm defec abdomin pain6 primari efficaci analysi comparison respons rate investig drug placebo ibsc defec compon pr opos primari endpoint evalu assess stool frequenc stool frequenc measur number complet spontan bowel movement csbm per week readili de fine use defin treatment respons chronic constip c linic trial clinic relev ibsc patient ibsd defec compon pr opos primari endpoint evalu assess stool consistency7 bristol stool form scale reproduc figur 1 provid pictori verbal de scription stool consist nd form appropri instrument captur stool consist ib trials8 figur 1 bristol stool form scale 6 see refer number 24 refer section end guidanc 7 see refer number 25 26 refer section end guidanc 8 see refer number 27 refer section end guidanc 5 contain nonbind recommend stool frequenc evalua ted key secondari endpoint use weekli number csbm stool consist rather stool frequenc recomm end primari endpoint ibsd clinic alli relev better correla ted sign symptom diarrhea current insuffici data adequ quantifi qualifi concept urgenc base patient perspect th us support use compon primari endpoint definit treatment respons adequ urgenc assess tool develop stool urgenc assess explor endpoint ibsd trial second compon primari endpoint ibsc ibsd trial abdomin pain although previou ib clinic trial use item assess abdomin pain discomfort clear whether th e abdomin pain abdomin discomfort experienc patient ib synonym two differ nt symptom although adequ qualit trial fulli address question clinic data provid review fda suggest abdomin pain discomfort may differ symptom assess differ question frank pain seem symptom experienc signific intens discomfort chronic pa literatur suggest pain intens may clinic ly relev assess pain frequency9 recommend abdomin pain intens prim ari pain assess ib trial abdomin discomfort evalu secondari endpoint recommend evalu abdomin pain intens use 11point e 0 10 numer rate scale ask pati ent daili rate worst abdomin pain past 24hour 10 type pain assess use assess pain somat viscer neuropath chronic pain conditions11 drug specif develop treat one major sign symptom ib identifi primari endpoint clinic trial identif singl sign symptom interest ba sed mechan action drug key efficaci endpoint assess clinic trial secondari endpoint demonstr signific clinic mean ing chang target singl endpoint could serv basi approv long import symptom sign worsen treatment 3 trial popul base upon evolut ib diagnost crit eria prospect ib c linic trial enrol patient meet subtyp specif rome iii ib diagnost criteria12 addit patient enter trial clinic manifest ib assess 9 see refer number 28 refer section end guidanc 10 see refer number 28 29 refer section end guidanc 11 see refer number 30 refer section end guidanc 12 see refer number 25 refer section end guidanc 6 contain nonbind recommend trial defin treatment respons manifest present suffici intens make demonstr clinic eaning improv possibl light compon primari endpoint ibsc nd ibsd previous de scribe recommend trial entri criteria includ follow ibsc abdomin pain intens weekli averag worst daili past 24 hour abdomin pain score 30 0 10 point scale stool frequenc fewer three csbm per week ibsd abdomin pain intens weekli averag worst daili past 24 hour abdomin pain score 30 0 10 point scale stool consist least one stool consi tenci type 6 type 7 bristol stool score bss least 2 day per week 4 efficaci measur sponsor choos format daili sign symptom assess eg interact voic respons person digit assist ant patient evalua te ib sign symptom daili basi throughout tr ial assess respons sponsor consid two distinct approach 1 examin differ nce averag score averag chang baselin score tr eat untreat group 2 examin differ respons rate treat untreat group respons prospect defin repres effect consid ere clinic meaning mani instanc effect drug effect measur 5 definit respond definit respond use analys primari endpoint prospect describ protocol st atist analysi plan pati ent categor overal respond patient achiev prespecifi improv weekli daili respons least 50 percent week day treatment eg 612 week 4284 day recommend defin weekli daili respons ib set follow 7 contain nonbind recommend ibsc13 patient categor weekli respond patient weekli respond pain intens stool frequenc abdomin pain intens weekli respond r defin patient experi decreas weekli averag worst abdomin pain past 24 hour score measur daili least 30 percent co mpare baselin weekli averag stool frequenc weekli respond de fine patient experi increas least one csbm per week baselin ibsd patient categor weekli respond patient weekli respond pain intens stool consist abdomin pain intens weekli respond r defin patient experi decreas weekli averag worst abdomin pain past 24 hour score least 30 percent compar ed baselin stool consist weekli respond defin patient experi 50 percent greater reduct number day per week least one stool consist type 6 7 compar baselin patient categor daili respond patient respond pain intens stool consist abdomin pain intens daili respond defin patient experi decreas worst abdomin pain past 24 hour score least 30 percent compar baselin stool consist daili respond defi ned patient whose stool consist ie bss less 5 fo r bowel movement day bowel movement ibsd either weekli respond da ili respond definit may accept drug intend target one major ib sign symptom base mechan action recommend follow respond definit abdomin pain ibsc abdomin pain intens weekli respond r defin patient experi decreas weekli averag worst abdo minal pain past 24 hour score least 30 percent compar baselin st ool frequenc ibsc unchang improv compar baselin 13 ibsc patient daili bowel movement even though abdomin pain may occur frequent daili respons criteria relev patient popul 8 contain nonbind recommend abdomin pain ibsd abdomin pain intens weekli respond r defin patient experi decreas weekli averag worst abdo minal pain past 24 hour score least 30 percent compar baselin number da ys per week least one stool consist type 6 7 baselin decreas number stool type 6 7 hose day remain unchang decreas abdomin pain intens daili respond defin patient experi decreas worst abdomin pain past 24 hour score least 30 percent compar baselin whose stool con istenc day less 5 bowel movement bowel movement constip ibsc stool frequenc respond defin patient experi increas least one csbm per week baselin nd abdomin pain unchang improv compar baselin diarrhea ibsd stool consist respond defin patient experien ce 50 percent greater reduct number day least one st ool consist type 6 7 compar baselin bdomin pain unchang improv comparison baselin respond definit describ guidanc support adequ content valid unclear repres clinic ly meaning chang abdomin pain abnorm defec patient ib abdomin pain respond definit greater equal 30 pe rcent reduct abdomi nal pain intens compar baselin primarili base publish literatur concern chr onic pain conditions14 therefor recommend conduct addit respond anal yse evalu greater reduct abdomin pain intens treatment ie greater equal 40 andor 50 percent reduct abdomin pain intens compar baselin addit would use examin cumul distribut sever gnitud abdomin pain intens reduct associ treatment eg 30 percent 40 pe rcent 50 percent well particular reduct eg 100 percent pain intens reduct secondari endpoint although recommend pa tient rate chang primari endpoint singl gener item adequ captur th e treatment effect clinic import sign symptom ib us eful defin clini calli meaning chang anoth measur anchorbas appr oach relat chang score measur differ specif measur its lf therefor r ecommend includ patient rate chang anchor exploratori endpoint conjunct endpoint includ guidanc global assess k patient evalu current ib 14 see refer number 31 refer section end guidanc 9 contain nonbind recommend statu compar current ib sign symptom anoth point time baselin statu exampl assess includ follow question could ask patient weekli basi would rate abdomin pa overal th e past 7 day would rate constip ib sc diarrhea ibsd overal past 7 day would rate ib sign sy mptom overal past 7 day sponsor consid likert scale respons option 2 significantli reliev 1 moder reliev 0 unchang 1 moder wors 2 significantli wors tabl 2 summari recommend provis al primari endpoint entri criteria respond definit indic primari endpoint entri criteria respond definit ibsc abdomin pain intens stool frequenc abdomin pain intens weekli averag worst abdomin pain past 24 hour score 30 0 10 point scale stool frequenc 3 csbm per week abdomin pain intens decreas weekli averag worst abdomin pain past 24 hour score least 30 compar baselin stool frequenc increas 1 csbm per week compar baselin ibsd abdomin pain intens stool consist abdomin pain intens weekli averag worst abdomin pain past 24 hour score 30 0 10 point scale stool consist least 2 day per week least one stool consist type 6 type 7 bss see figur 1 detail abdomin pain intens weekli respond defin decreas weekli averag worst abdomin pain past 24 hour score least 30 compar baselin daili respond defin decreas worst abdomin pain past 24 hour score least 30 compar baselin stool consist weekli respond defin decreas least 50 number day per week least one stool consist type 6 7 compar baselin daili respond defin patient whose stool consist less 5 bowel movement day bowel movement drug may design improv one major sign symptom ib detail pleas refer discuss section iv guidanc 10 contain nonbind recommend v futur develop ib pro instrument octob 2010 publish th e draft guidanc industri qualif process drug develop tools15 drug develop tool ddt intend ed potenti use time multipl drug develop program includ limit biomark clinic outcom assess includ pro instrument fda qualif conclus within state context use result assess ddt reli upon specif interpret app licat drug develop regulatori decisionmak qualif process provid effici ent mean ddt develop qualif requir signific work form ation collabor group may lessen resourc burden upon individu al compani one collabor group pro consortium form 2008 critic path institut publicpriv partnership pro consortium charg task effi cientli collabor develop reliabl interpret instrument avail public domain sponsor use medic product clinic trial collabor includ mber fda industri academia profession organ patient advo caci group government agenc addit inform pro consortium found httpwwwcpathorg activ particip pro consor tium other consult advic stage qualif develop pro measur sign symptom ibsc ibsd qualifi ib subtypespecif pro measur replac provision endpoint describ guidanc fda recommend measur treatment benefit use ibsc ibsd clinic trial vi conclus provision endpoint trial design reco mmendat guidanc current accept use evalu drug fo r treatment ibsd ibsc recommend assist drug develop develop treatment address need patient ib import work develop welldefin reliabl pro instrument fda qualif continu 15 final guidanc represen fda current think topic recent version guidanc check fda drug guidanc web page httpwwwfdagovdrugsguidancecompliancereg ulatoryinformationguid ancesdefaulthtm 11 contain nonbind recommend refer 1 mayer ea bradesi l chang et al 2008 function gi disord anim model drug develop gut 57384404 2 camilleri nj talley 2004 pathophysiol ogi basi understand symptom complex therapeut target neurogastroenterol motil 16135142 3 andresen v vm montori j keller et al 2008 effect 5hydroxytryptamin serotonin type 3 antagonist symptom relief constip nonconstip irrit bowel syndrom systemat review metaana lysi random control trial clin gastroenterol hepatol 6545555 4 heaton kw j radvan h cripp et al 1992 defec frequenc time stool form gener popul prospect studi gut 33818824 5 horikawa h mieno inou et al 1999 gastrointestin motil patient irrit bowel syndrom studi use radi opaqu marker scand j gastroenterol 3411901195 6 sadik r po stotzer simrn et al 2008 gastrointestin transit abnorm frequent detect patient unexplain gi symptom tertiari centr neurogastroenterol motil 20197205 7 gorard da gw libbi mj farth 1995 effect tricycl antidepress small intestin motil health diarrhea predomin irrit bowel syndrom dig di sci 408695 8 camilleri l chang 2008 challeng therapeut pipelin irrit bowel syndrom end point regul hurdl gastroenterolog 13518771891 9 jone rh g holtmann l rodrigo et al 199 9 alosetron reliev pain improv bowel function compar mebeverin fema le nonconstip ib patient aliment pharmacol ther 1314191427 10 camilleri ea mayer da drossman et al1999 improv pain bowel function femal ib alosetron 5ht3 receptor antagonist aliment pharmacol ther 1311491159 11 camilleri ar northcutt kong et al 2000 efficaci safeti alosetron women ib randomis placeboc ontrol trial lancet 35510351040 12 camilleri wy chey ea mayer et al 20 01 random control clinic trial serotonin type 3 receptor antagonist alosetr women diarrheapredomin ib arch intern med 16117331740 12 contain nonbind recommend 13 chey wd wy chey heath et al 2004 l ongterm safeti efficaci alosetron women sever diarrheapredomin ant ib j gast roenterol 9921952203 14 chang l vz ameen ge duke et al 2005 doserang phase ii studi efficaci safeti alosetron men diarrhea predomin ib j gastroenterol 100115123 15 kellow j oy lee fy chang et al 2003 asiapacif doubleblind placebo control random studi evalu effi caci safeti toler tegaserod patient ib gut 52671676 16 nyhlin h c bang j elsborg et al 2004 doubleblind placebo control random studi evalu efficaci safeti tolerab iliti tegaserod patient ib scand j gastroenterol 39119126 17 mullerlissn g holtmann p rueegg et al 2005 tegaserod eff ectiv initi retreat ib constip aliment pharmacol ther 211120 18 tack j mullerlissn p bytzer et al 2005 random control trial assess efficaci safeti repeat tegaserod therapi women irrit bowel syndrom constip gut 5417071713 19 fri c begling n gilgen bobalj et al 2005 tegaserod safe welltoler effect treatment patient n ondiarrhea ib eur j gastroenterol hepatol 17421427 20 novick j p miner r kraus et al 2002 random doubleblind placebocontrol trial tegaserod femal patient sufferi ng ibsc aliment pharmacol ther 161877 1888 21 mullerlissn sa fumag kd bardha n et al 2001 tegaserod 5ht4 receptor partial agonist reliev symptom ib patient abdomin pain bloat constip aliment pharmacol ther 1516551666 22 mullerlissn g koch nj talley et al 2004 subject global assess relief appropri method assess impact treatment ibsrel symptom clinic trial j clin epidemiol 56310316 23 drossman da w chey r pana et al 2007 lubiproston significantli improv symptom relief rate adult ib gastroenterolog 13225862587 24 longstreth gf wg thompson wd che la houghton f mearin rc spiller 2006 function bowel disord ga stroenterolog apr1305148091 25 rome endpoint outc ome confer 2009 httpwwwromecriteriaorgmeetin gseventsendoutconfprogramcfm 13 contain nonbind recommend 26 talley nj 2009 green light fda fo r new drug develop irrit bowel syndrom function dyspepsia j gastroenterol 10413391341 27 lewi sj kw heaton 1997 stool form scal e use guid intestin transit time scand j gastroenterol 3299204 28 turk dc rh dworkin et al 2003 core ou tcome domain chronic pain clinic trial immpact recommend pain 106337345 29 cleeland cs km ryan 1994 pain assess global use brief pain inventori ann academ medicin 232129138 30 dworkin rh et al 2005 core outcom measur chronic pain clinic trial immpact recommend pain 113919 31 dworkin rh et al 2008 interpret clin ical import treatment outcom chronic pain clinic trial immp act recommend pain 92105121 14 6212019
[Document -2] gastroparesi clinic evalu drug treatment guidanc industri draft guidanc guidanc document distribut comment purpos comment suggest regard draft document submit within 60 day public feder regist notic announc avail draft guidanc submit electron comment httpswwwregulationsgov submit written comment docket manag staff hfa 305 food drug administr 5630 fisher lane rm 1061 rockvil md 20852 comment identifi docket number list notic avail publish feder regist question regard draft document contact maureen dewey 301 7960845 us depart health human servic food drug administr center drug evalu research cder august 2019 clinicalmed revis 1 gastroparesi clinic evalu drug treatment guidanc industri addit copi avail offic commun divis drug inform center drug evalu research food drug administr 10001 new hampshir ave hillandal bldg 4th floor silver spring md 20993 0002 phone 8555433784 301 7963400 fax 3014316353 email druginfofdahhsgov httpswwwfdagovdrugsguid complianc regulatori informationguid drug us depart heal th human servic food drug administr center drug evalu research cder august 2019 clinicalmed revis 1 tabl content introduct 1 ii background 2 iii endpoint trial design gastroparesi clinic trial 3 trial design 3 b trial popul 4 c approach outcom assess measur 5 trial endpoint 6 1 primari endpoint 6 2 secondaryoth endpoint 6 3 defin clinic meaning within patient chang sign symptom score 6 e statist consider 7 ref erenc 9 contain nonbind recommend draft implement 1 gastroparesi 1 clinic evalu drug treatment 2 guidanc industry1 3 4 5 6 7 draft guidanc final repres current think food drug 8 administr fda agenc topic establish right person 9 bind fda public use altern approach satisfi requir 10 applic statut regul discuss altern approach contact fda staff respons 11 guidanc list titl page 12 13 14 15 16 introduct 17 18 purpos guidanc assist sponsor clinic develop drug 19 treat idiopath diabet gastroparesis2 specif guidanc address fda 20 current recommend regard clinic trial design clinic endpoint assess 21 support develop gastroparesi drug 22 23 draft guidanc intend serv focu continu discuss among 24 respons fda divis offic new drug pharmaceut sponsor academ 25 commun public3 26 27 guidanc revis draft guidanc industri name issu juli 2015 28 chang previou draft reflect fda current think develop clinic 29 outcom assess tool statist consider use tool assess primari 30 secondari efficaci endpoint 31 32 guidanc address detai led patient report outcom pro instrument 33 develop valid topic address guidanc ndustri patient 34 1 guidanc prepar divis gastroenterolog inborn error product center drug evalu research food drug administr 2 purpos guidanc refer drug includ h uman drug therapeut biolog product unless otherwis specifi 3 addit consult guidanc sponsor encourag contact divis discuss specif issu aris develop drug treat gastroparesi contain nonbind recommend draft implement 2 report outcom measur use medic product develop support label claim 35 decemb 2009 4 36 37 detail regard statist analysi clinic trial design address ich 38 guidanc industri e9 statist principl clinic trial septemb 1998 e10 39 choic control group relat issu clinic trial may 2001 respect 40 41 gener fda guidanc document establish legal enforc respons 42 instead guidanc describ agenc current think topic view 43 recommend unless specif regulatori statutori requirem ent cite use 44 word agenc guidanc mean someth suggest recommend 45 requir 46 47 48 ii background 49 50 gastroparesi disord character delay gastric empti dge absenc 51 mechan bstruction symptom chronic episod exacerb parkman et al 52 2004 idiopath form disord account greatest number case 53 karamanoli et al 2007 predominantli affect young adult femal gastroparesi also 54 frequent associ diabet diabet gastroparesi like occur 55 impair neural control gastric motil parkman et al 2004 addit acut 56 hyperglycemia potenti slow gastric empti decreas effect prokinet 57 drug camilleri 2010 58 59 core sign symptom gastroparesi nausea 92 96 percent vomit 68 88 60 percent postprandi full 54 77 percent earli satieti 42 86 percent upper 61 abdomin pai n 36 85 percent hoogerwerf et al 1999 anaparthi et al 2009 patient may 62 experi combin sign symptom vari degre sever pain 63 preval patient idiopath gastroparesi patient diabet 64 gastroparesi patient diabet gastroparesi may experi derang 65 glucos control unpredict gastric empti alter absorpt oral 66 administ hypoglycem drug 67 68 sign symptom gastroparesi overlap gastrointestin condit 69 gastroparesi may incorrectli diagnos bowel obstruct function dyspepsia irrit 70 bowel syndrom peptic ulcer diseas patient sign symptom sugg tive 71 gastroparesi find dge absenc obstruct altern diagnosi provid 72 critic support diagnosi gastroparesi assess use either gastric 73 empti scintigraphi gastric e mpti breath est smartpil motil test system 74 75 urgent medic need develop safe effect therapi treat patient 76 gastroparesi 77 78 4 updat guidanc period make sure recent version guidanc check fda guidanc web page httpswwwfdagovregulatori informationsearch fdaguid document contain nonbind recommend draft implement 3 iii endpoint rial design gastroparesi clinic 79 trial 80 81 primari efficaci assessmen ts adequ well control trial must well defin 82 reliable5 gastroparesi symptomat condit welldefin reliabl pro 83 instru ment easur clin ical import ign sy mptom gastroparesi would 84 ideal p rimari efficaci ass sment tool clinic trial use support label claim 85 treat gastroparesi 6 howev current awar measur 86 appropri pro instru ment gastroparesi becom avail abl ponsor consid 87 strategi discuss follow section design gastroparesi clinic tri al 88 sponsor may also wish review fda center drug evalu research clinic 89 outcom assess coa drug develop tool qualif program web page 90 inform qualifi tool tool current develop 91 92 sponsor may wish includ evalu well defin pro instrument assess relev 93 import sign symptom earli drug develop evalu result 94 doserang phase 2 trial stand alon nonintervent studi support futur use 95 phase 3 trial encourag earli regular discuss fda regard 96 develop pro instrument 97 98 gastroparesi manifest one core sign symptom effect new drug 99 intend treat gastroparesi core sign symptom assess earli p hase 100 trial shoul help inform core sign andor symptom includ 101 prespecifi endpoint intend support label claim base sign symptom 102 treatment like improv import show even drug intend treat 103 subset core sign symptom base mechan drug worsen 104 remain sign symptom gastroparesi exampl drug may expect improv 105 gastroparesi relat nausea vomit abdomin pain base mechan 106 action scenario clinic studi demonstr nausea vomit improv 107 treatment worsen symptom abdomin pain postprandi full 108 earli satieti 109 110 follow section provid recommend regard trial design trial popul 111 outcom ssessment measur trial endpoint statist consider 112 113 trial design 114 115 gener trial design consist rando mize doubl blind placeb ocontr oll trial 116 hould includ 1 2week screen period screen period use 117 investig establish presenc persist tri alentri criteria patient 118 gain experi complet pro instrument employ trial demonstr adequ 119 5 21 cfr 314126 6 see guidanc industri patient report outcom measur use medic product develop support label claim contain nonbind recommend draft implement 4 understand complianc complet instrument screen period 120 assess gastroparesi sign symptom serv baselin valu use 121 analys primari endpoint see section iii trial endpoint fda recommend 122 baselin assess period least 7 day primari endpoint measur chang 123 sign symptom baselin treatment period least 12 week durat 124 125 trial design address need mainten treat ment prevent recurr ign 126 symptom 127 128 endpoint assess base patient daili report avoid recal error 129 protocol state whether rescu medic ie protocol specifi therapi continu 130 exacerb symptom standard across studi site allow daili diari 131 collect throughout entir trial 132 133 addit recommend random control long term safeti studi 12 month 134 durat appropri prespecifi provis rescu medic hould 135 conduct submit new drug applic 136 137 b trial popul 138 139 idiopath diabet gastroparesi pa tient studi separ clinic trial 140 gener diabet gastroparesi patient experi core sign symptom patient 141 idiopath gastroparesi individu sign symptom may occur often 142 greater sever one popul compar degre diabet control 143 also confound result fulli describ safeti efficaci p opul recommend 144 separ trial idiopath diabet gastroparesi close relat condit 145 singl phase 3 trial popul demonstrat ion reliabl clinic meaning 146 result may support approv indic 7 147 148 recom mend trial entri crite ria includ follow 149 150 trial popul clinic diagnosi idiopath diabet 151 gastroparesi individu trial base document histori gastroparesi 152 symptom exclus potenti etiolog dge abel et al 2008 153 parkman et al 2004 optim abil demonstr treatment effect 154 trial enrol patient higher symptom sever moder sever 155 current accept definit gast roparesi sever 156 sponsor provid justif sever index select includ 157 defin moder sever symptom 158 159 diabet gastroparesi patient control stabl blood glucos level 160 patient prone acut hyperglycem event may confound interpret 161 therapeut effect drug 162 163 7 see guidanc industri provid clinic evid effect human drug biolog product may 1998 contain nonbind recommend draft implement 5 patient opioid exclud pioid use may affect gastrointestin 164 motil potenti confound result 165 166 c approach utcom assess measur 167 168 well defin reliabl pro instrument measur clinic import sign 169 symptom gastroparesi avail recommend five core sign 170 symptom gastroparesi nausea vomit postprandi full earli satieti 171 abdomin pain includ endpoint well control clinic trial karamanoli et al 172 2007 hoogerwerf et al 1999 anaparthi et al 2009 ponsor identifi empir 173 justifi questionnair item word use assess sign symptom 174 gastroparesi includ trial8 175 176 sponsor propos primari endpoint definit see section iii trial endpoint 177 method measur five sign symptom describ pilot 178 propos instrument phase 2 trial provid opportun evalu abil f 179 instrument detect chang provid guidelin interpret clinic meaning 180 within patient chang confirm endpoint definit pilot result inform plan 181 implement propos instrument phase 3 trial word 182 questionnair care thought question request overlap 183 measur concept eg postprandi full earli satieti concept 184 welldefin interpret consist way patient ie questionnair 185 includ definit postprandi full earli satieti term may vari 186 interpret among patient e ach core sign symptom separ measur 187 document clinic trial 188 189 sponsor also specifi mode data collect use patient 190 record daili sign symptom eg electron diari 191 192 sign symptom except vomit rate sever exampl question 193 request item respons rang 0 symptom 4 ost sever symptom 194 0none 1mild 2moder 3sever 4veri sever numer rate scale 195 0 10 0 reflect absenc symptom 10 reflect worst possibl 196 symptom experi possibl rate scale consist across core ign 197 symptom recommend report vomit daili symptom diari 198 measur frequenc rather sever frequenc report exact number 199 time 24 hour period clear definit consid one time 200 vomit provid patient ensur consist within patient 201 report number time vomit occur sever nausea postprandi 202 full earli satieti abdomin pain record base patient worst 203 experi 24 hour period 204 205 8 see guidanc industri patient report outcom measur use medic product develop support label claim contain nonbind recommend draft implement 6 tria l endpoint 206 207 1 primari endpoint 208 209 chang patient report sign symptom score form basi primari 210 efficaci assess therapeut trial idiopath diabet gastroparesi primari 211 endpoint base pati nt core sign symptom subset gastric 212 empti time use primari efficaci endpoint chang gastric 213 empti time associ chang cli nical import ign 214 symptom patient gastroparesi 215 216 primari endpoint measur chang sign symptom baselin 217 analysi plan includ evalu treatment effect throughout 12 week studi 218 period 219 220 recommend use endpoint base core sign symptom may 221 base pre specifi core sign symptom symptom sever summari score 222 exclud vomit vomit frequenc collect continu variabl primari 223 endpoint limit singl sign symptom sponsor propos summari 224 score evalu question level request level respons determin whether 225 individu question request overli influenc total score current 226 evid recommend one approach score base sever 227 analyz separ base frequenc eg vomit 228 229 2 secondari endpoint 230 231 fda recommend chang baselin individu sign symptom 232 assess part primari endpoint measur secondari endpoint therefor 233 primari secondari endpoint includ evalu five core sign 234 sympt om chang g astric empti time measur secondari endpoint desir 235 abel et al 2008 prespecifi plan address analysi remain core sign 236 symptom includ primari endpoint 237 238 3 defin clinic meaning within patient chang sign symptom 239 score 240 241 aid interpret result ponsor determin amount chang 242 meaning patient total summari score individu sign symptom score 243 ideal base actual data establish advanc phase 3 trial 244 clinic meaning within patient chang threshold may prespecifi two 245 clinic meaning chang threshold interest one clinic import improv 246 baselin one clinic import deterior baselin depend 247 propos mechan action drug trial object propos threshold spe cifi 248 level improv n five core sign symptom spe cifi 249 level improv n subset core sign symptom worsen core sign 250 contain nonbind recommend draft implement 7 symptom would inconsist expect clinic benefit taken account 251 evalu benefit risk 252 253 recommend use anchor base approach typic use phase 2 trial data 254 estim clinic meaning chang approach recommend includ phase 2 255 3 trial multipl anchor scale patient global impress sever pgi 256 patient global impress chang pgic scale intent provid accumul 257 evid help interpret clinic meaningfu l within patient score chang contrast 258 pgic scale pgi scale subject recal error also use assess chang 259 baselin data pgi scale prefer anchor scale pgic scale howev 260 perf ct anchor scale help includ multipl anchor scale anchor base 261 analys 262 263 follow item could ask patient follow assess schedul 264 recal period prespecifi endpoint baselin exampl pgi scale 265 266 pleas choos respons best describ sever gastroparesi 267 symptom insert appropri recal period 268 269 sponsor consid follow respons option item 0none 1mild 270 2moder 3 sever 4 ever 271 272 follow item could ask weekli patient exampl pgic scale 273 274 pleas choos respons best describ overal chang 275 gastroparesi symptom sinc st art take studi medic 276 277 sponsor consid follow respons option item much better littl better 278 chang littl w ors uch w ors 279 280 sponsor determin clinic meaning within patient chang threshold rang use 281 anchor base method eg patient global impress scale anchor supplement 282 empir cumul distribut function ecdf within patient score chang separ 283 ecdf curv gener meaning anchor categori eg improv 284 chang worsen use data pool across trial arm 285 286 e statist consider 287 288 evalu daili diari assess creat trial adequ number 289 assess avail sponsor determin number base evid 290 deriv particular pro assess use trial exampl weekli summari 291 score use gener sponsor provid assess fro least 4 7 day 292 howev evid particular pro assess may support need data 293 higher number day instrument provid r eliabl result 294 295 contain nonbind recommend draft implement 8 efficaci analysi plan clearli defin patient take rescu medic 296 consid final analysi sponsor also propos met hod handl miss 297 data includ miss rescu medic data miss pro dat question request 298 instrument level analysi plan sponsor consid iffer approach 299 trial initi properti approach evalu 300 301 recommend sponsor analyz prim ari secondari endpoint continu 302 ordin variabl recommend use percent age chang gener tradit 303 respond analysi would appropri unl target respons complet resolut 304 sign symptom addit w e encourag use baselin valu 305 covari improv effici primari secondari endpoint analys 306 307 addit sponsor submit support descript analys ie graph ecdf 308 within patient chang baselin primari secondari endpoint treatment arm 309 fda review 310 contain nonbind recommend draft implement 9 ref erenc 311 312 abel tl rk bernstein cutt g farrugia j forster wl hasler rw mcc allum kw olden 313 hp parkman cr parrish pj pasricha cm prather ee soffer r twillman ai vi nik 2006 314 treatment gastroparesi multidisciplinari clinic review neurogastroenterol motil 315 18263283 316 317 abel tl camilleri k donoho wl hasler hc lin ah nauer rw mccallum nowak 318 ml nusynowitz hp parkman p shreve la szarka wj snape ha zi essman 2008 319 consensu recommend gastric empti scintigraphi joint report 320 american neurogastroenterolog motil societi societi nuclear medicin 321 j gastroenterol 103753 763 322 323 anaparthi r n pehlivanov j gradi h yimei pj pasricha 2009 gastroparesi 324 gastroparesi like yndrome respons herapi ts predictor dig di sci 325 5451003 1010 326 327 hoogerwerf wa pj pasricha kalloo mm schuster 1999 pain verlook 328 symptom g astroparesi j gastroenterol 9410291033 329 330 karamanoli g p caenepeel j art j tack 2007 determin ymptom p attern 331 idiopath ever elay g astric empti gastric e mpti r ate p roxim tomach 332 dysfunct gut 5629 36 333 334 parkman hp wl hasler rs fisher 2004 american gastroenterolog associ 335 technic review diagnosi treatment gastroparesi gastroenterolog 336 1275 1592 1622 337 338 parkman hp k yate wl hasler l nguyen pj pasricha wj snape g farrugia kl koch j 339 call tl abel rw mccallum l lee unalp arida j tonascia f hamilton 2011 340 similar differ b etween iabet diopath gastroparesi clin gastroenterol 341 hepatol 910561064 342 16856dftdocx 120922
[Document -3] pulmonari tuberculosi develop drug treatment guidanc industri draft guidanc guidanc document distribut comment purpos comment suggest regard draft document submit within 60 day public feder regist notic announc avail draft guidanc submit electron comment httpswwwregulationsgov submit written comment docket manag staff hfa 305 food drug administr 5630 fisher lane rm 1061 rockvil md 20852 comment identifi docket number list notic avail publish feder regist question regard draft document contact ramya gopinath ramyagopinathfdahhsgov us depart health human servic food drug administr center drug evalu research cder decemb 20 22 clinic antimicrobi revis 1 pulmonari tuberculosi develop drug treatment guidanc industri addit copi avail offic commun divis drug inform center drug evalu research food drug administr 10001 new hampshir ave hillandal bldg 4th floor silver spring md 20993 0002 phone 8555433784 301 7963400 fax 3014316353 email druginfofdahhsgov httpswwwfdagovdrugsguidancecomplianceregulatoryinformationguidancesdrug us depart health human servic food drug administr center drug evalu research cder decemb 20 22 clinic antimicrobi revis 1 contain nonbind recommend draft implement tabl content introduct 1 ii background 2 iii develop program 2 gener consider 2 1 earli phase clinic develop consider 2 eba 3 b phase 2 evalu 3 2 efficaci consider 3 3 safeti consider 3 b specif efficaci trial consider 4 1 trial design 4 2 trial popul 5 3 inclus exclus criteria 6 4 random stratif blind 7 5 specif popul 7 pediatr popul 7 b pregnant femal 8 c specif popul 9 6 dose select 9 7 choic compar 9 8 efficaci endpoint 9 9 trial procedur time assess 11 entri visit 11 b visit therapi therapi complet 12 10 statist consider 12 11 acceler approv consider 13 c consider 13 1 microbiolog consider 13 vitro studi 13 b vivo anim model 14 c drug resist crossresist 14 type cultur media identifi tuberculosi 15 e differenti relaps reinfect new infect 15 2 relev nonclin safeti consider 15 3 pkpd consider 16 phase 1phase 2 pk trial 16 b drug interact 16 c exposur respons 17 vitro hollow fibe r system model 17 4 foreign clinic data 17 5 data standard tb 17 6 label consider 18 refer 19 appendix 21 contain nonbind recommend draft implement 1 pulmonari tuberculosi 1 develop drug treatment 2 guidanc industry1 3 4 5 6 draft guidanc final repres current think food drug 7 administr fda agenc topic establish right person 8 bind fda public use altern approach satisfi requir 9 applic statut regul discuss altern approach contact fda staff respons 10 guidanc list titl page 11 12 13 14 introduct 15 16 purpos guidanc assist sponsor clinic develop investig 17 drug treatment pulmonari tuberculosi tb section 505 feder food 18 drug cosmet act fdc act 21 usc 355 fda regul 21 cfr part 312 19 part 601 2 specif guidanc provid fda current recommend 20 regard overal develop program new investig drug drug use 21 combin approv drug new treatment regimen includ one 22 investig drug support indic treatment pulmonari tb guidanc 23 address develop drug latent tb infect extrapulmonari tb 24 25 sponsor also refer guidanc industri codevelop two new 26 investig drug use combin june 2013 3 sponsor encourag discuss 27 fda program pathway facilit drug develop ight applic 28 develop program4 29 30 guidanc revis replac draft guidanc industri name issu 31 novemb 2013 revis includ detail regard nonclin model earli phase 32 studi trial design consider includ demonstr efficaci use superior 33 noninferior ni trial design addit updat made regard inclus 34 pediatr subject trial endpoint safeti consider label appendix 35 contain ni margin justif also updat 36 1 guidanc prepar divis anti infect center drug evalu research food drug administr 2 purpos guidanc refer drug includ human drug therapeut biolog product unless otherwis specifi 3 updat guidanc period make sure recent version guidanc check fda guidanc web page httpswwwfdagovregulatori informationsearch fdaguid document 4 see guidanc industri expedit program seriou condit drug biolog may 2014 contain nonbind recommend draft implement 2 37 guidanc contain discuss gener issu statist analysi clinic 38 trial design topic address intern council harmonis ich 39 guidanc industri e9 statist principl clinic trial septemb 1998 e10 40 choic control group relat issu clinic trial may 2001 ich e10 41 respect 42 43 gener fda guidanc document establish legal enforc respons 44 instead guidanc describ agenc current think topic view 45 recommend unless specif regulatori statutori requir cite use 46 word sho uld agenc guidanc mean someth suggest recommend 47 requir 48 49 50 ii background 51 52 infect caus mycobacterium tuberculosi tuberculosi diagnos unit 53 state endem mani part world resist multipl drug coinfect 54 human immunodefici viru hiv pose challeng manag tb drug 55 new mechan action impr ove safeti profil fewer drug drug interact 56 treatment shorten combin regimen need manag tb 57 58 59 iii develop program 60 61 gener consider 62 63 1 earli phase clinic develop consider 64 65 nonclin evalu provid valuabl inform develop investig 66 drug see section iiic1 microbiolog consider section iiic2 relev nonclin 67 safeti consider section iiic3 pkpd consider 68 69 activ antimycobacteri drug evalu trial earli bactericid activ eba 70 andor phase 2 trial evalu microbiolog al outcom earli ime point 71 combin regimen sponsor evalu contribut drug treatment 72 effect 5 evalu phase 2 clinic develop nonclin studi see 73 section iiic1 microbiolog consider treatment pulmonari tb includ 74 one drug treatment regimen sponsor may develop one investig 75 drug part new combin regimen sponsor consult agenc earli 76 develop regard plan demonstr contribut investig drug 77 part combin regimen 78 79 5 recommend guidanc relev demonstr contribut individu new investig drug effect combin regimen consist requir 21 cfr 30050 fixedcombin prescriptio n drug human contain nonbind recommend draft implement 3 eba 80 81 applic investig drug studi eba trial evalu quantit 82 count viabl tuberculosi daili collect sputum provid inform 83 bactericid activ antimycobacteri drug trial intend evalu 84 antimycobacteri activ investig drug alon combin brief time 85 cours eg 7 14 day eba trial provid preliminari evid contribut 86 drug treatment effect combin regi men appropri subject 87 enrol eba trial includ immunocompet subject treatment nave adul subject 88 low risk infect ion drug resist tb subject evid extra pulmonari 89 diseas begin standard ofcar treatment pulmonari tb complet 90 eba trial 91 92 b phase 2 evalu 93 94 sponsor conduct phase 2 trial assess antimycobacteri activ n 95 investig drug regimen addit feasibl phase 2 develop program 96 includ dose rang studi studi assist determin appropri dose 97 regimen taken phase 3 phase 2 exploratori endpoint includ limit 98 follow 1 8 week evalu absenc acid fast bacilli afb sputum 2 99 time sputum cultur neg tuberculosi 3 symptom improv andor 4 100 biomark intend predict clinic benefit agenc recommend part phase 2 101 trial design sponsor includ long term follow collect clinic endpoint 102 addit earlier time point 103 104 2 efficaci consider 105 106 investig drug evalu efficaci ad combin gimen 107 alreadi approv drug addit entir new combin regimen compris 108 investig drug evalu efficaci singl adequ well control trial 109 subject pulmonari tb support ed confirmatori evid eg evid 110 antimycobacteri activ nonclin data eba p hase 2 trial may provid evid 111 effect singl trial demonstr clinic meaning statist robust 112 treatment effect 6 see section iii b specif efficaci trial consider 113 discuss regard efficaci consider 114 115 3 safeti consider 116 117 evalu safeti profil investig drug challeng 118 patient pulmonari tb often comorbid condit sponsor evalu potenti 119 drug drug interact may occur c oadministr antimycobacteri 120 drug concom itant medic eg antiretrovir drug 121 6 see draft guidanc industri demonstr substanti evid effect human drug biolog product decemb 2019 final guidanc repres fda current think topic recent version guidanc check fda guidanc web page httpswwwfdagovregulatori informationsearch fdaguid document contain nonbind recommend draft implement 4 122 hepatotox qt interv prolong common advers reaction 123 antimycobacteri drug sponsor evalu nvestigat ional drug potenti 124 caus hepatotox qt prolong arrhythm ias7 8 125 126 sponsor discuss size preapprov safeti databas fda drug 127 develop assess risk benefit subject unmet medic need 128 smaller safeti databas approxim 300 subject treat greaterlong 129 propos intend dose durat may suffici safeti signal identi fie larger 130 safeti databas may need 131 132 b specif efficaci trial consider 133 134 1 trial design 135 136 sponsor use follow trial design demonstr superior 137 138 regimen includ one investig drug compar standard 139 regimen efficaci demonstr show superior investig drug 140 regimen standard regimen9 141 142 investig drug plu optim background regimen obr compar 143 match placebo plu obr e fficaci demonstr show 144 superior investig drug regimen placebo contain regimen 145 optim background antimycobacteri treatment base epidemiolog 146 inform vitro suscept test avail 147 148 sponsor use follow trial design demonstr ni 149 150 investig drug regimen compar standard regimen ni would 151 demonstr show investig regimen perform within prespecifi 152 margin perform standard regimen 153 154 investig drug replac one drug st andard combin regimen 155 investig drug regimen perform within accept ni margin 156 base known quantit reliabl contribut drug 157 7 see guidanc f industri drug induc liver injuri premarket clinic evalu juli 2009 8 see ich guidanc industri e14 clinic evalu qtqtc interv prolong pr oarrhythm potenti non antiarrhythm drug octob 2005 e14 clinic evalu qtqtc interv prolong pr oarrhythm potenti non antiarrhythm drug question answer r3 june 2017 s7b nonclin evalu potenti delay ventricular repolar qt interv prolong human pharmaceut octob 2005 m3r2 nonclin safeti studi conduct human clinic trial market author pharmaceut januari 2010 9 see guidanc industri codevelopmen two new investig drug use combin contain nonbind recommend draft implement 5 replac standard regimen ni trial design determin efficaci 158 contribut investig drug regimen 159 160 interpret result ni trial reli justifi ni margin margin 161 highli depend specif design ni trial includ control regimen base 162 part data f rom previous conduct trial evalu histor e videnc ensit 163 drug e ffect hesd estim effect activ control 10 appendix contain 164 exampl n ni margin justif trial 4month regimen drug suscept tb 165 166 fda estim exact numer treatment effect standard regimen 2 167 month treatment ethambutol isoniazid rifampin pyrazinamid follow 4 168 month treatment isoniazid rifampin abbrevi terminolog 2ehrz4hr 169 patient wi th drug suscept pulmonari tb howev consid histor data 170 manag outcom patient pulmonari tb era antibacteri drug 171 therapi highli success result follow treatment 2ehrz4hr support 172 select ni margin base larg degre clinic benefit exampl 173 given success rate 2ehrz4hr exceed 90 percent numer treatment effect 174 like far exceed 10 percent nahid et al 2016 refor base clinic judgement 1 0 175 percent ni margin clinic relev appropri preserv treatment effect 176 ni trial determin efficaci n investig drug regimen whole base 177 comparison 6month standard regimen 178 179 depend new investig drug regimen studi design ni trial potenti impact 180 eg abil fulfil unmet medic need safeti profil regimen may 181 appropri set wider ni margin still plan trial design feasibl provid 182 reason preapprov safeti databas agenc en courag ponsor discuss 183 clinic trial design ni margin justif fda11 184 185 superior trial ni trial assess activ investig drug regimen 186 whole sponsor also need address ad contribut compon 187 regimen 9 may accomplish nonclin trial eba studi phase 2 trial 188 andor part pivot efficaci trial 189 190 2 trial populati 191 192 trial popul includ adult subject appropri pediatr subject 193 pulmonari tb presenc extrapulmonari diseas may requir longer durat 194 treatment pulmonari tb assess endpoint evalu extrapulmonari 195 site trial includ subject either drug suscept drug resist pulmonari tb 196 depend anticip effect antimycobacteri drug evalu 197 198 10 see ich e10 discuss hesd 11 see also articl four month moxifloxacin base regimen drug sensit tuberculosi gillespi et al 2014 contain nonbind recommend draft implement 6 protocol specifi subject handl vitro suscept result 199 avail conduct trial analysi result 200 201 enrich strategi regard trial drug resist tb includ focu contact 202 subject drug resist tb subject area high prevalen ce drug resist 203 subject relap e previou treatment subject diseas progress 204 standard regimen 205 206 3 inclus exclus criteria 207 208 fda r ecommend follow inclus criteria subject pulmonari tb 209 210 presenc afb sputum specimen detect smear microscopi rapid 211 diagnost test microbiolog diagnosi tb confirm cultur 212 least one sputum sampl obtain time enrol 213 214 chest radiograph ic find consist activ pulmonari tb exampl cavitari 215 lesion apic infiltr hilar lymphadenopathi 216 217 minimum two follow sign symptom present least 218 2 week 219 220 sputum product 221 222 cough 223 224 one episod hemoptysi 225 226 fever eg oral temperatur greater equal 380 degre celsiu least 227 two occas 228 229 pleurit chest pain 230 231 weight loss 232 233 night sweat 234 235 use rapid diagnost noncultur test may help identifi subject enrol tb 236 trial test use fda clear sponsor provid suffici inform 237 perform characterist test determin analyt valid studi 238 239 fda r ecommend follow exclus criteria subject pulmonari tb 240 241 one week therapi current episod activ tb unless enrol 242 trial target drug resist tb document lack respons therapi 243 base clinic microbiolog find 244 contain nonbind recommend draft implement 7 245 signif icant concurr ill hiv eg lung cancer may affect outcom 246 assess 247 248 unwil ness compli recommend local public health author 249 manag patient pulmonari tb 250 251 4 random stratif blind 252 253 trial random doubl blind unless sponsor provid scientif 254 adequ explan blind accomplish trial singl blind open 255 label sponsor discuss potenti bias fda bias 256 address trial fulli blind sponsor maintain maximum 257 possibl level blind trial blind assessor blind databas databas 258 lock etc 259 260 sponsor consid tratif subject base certain baselin characterist eg 261 presenc absenc cavitari diseas hiv infect sponsor includ 262 protocol discuss analys account stratifi randomization12 263 264 5 specif popul 265 266 pediatr popul 267 268 fda encourag sponsor begin discuss pediatr clinic develop 269 plan earli feasibl addit safeguard 21 cfr part 50 subpart 270 enrol children cl inic investig affect time design trial support 271 pediatr drug develop accord requir sponsor enrol 272 pediatr subject trial suffici safeti antimycobacteri activ pharmacokineti c pk 273 efficaci data adult subject avail appropri dose regimen pediatr 274 subject characterized13 sponsor includ dolesc subject pulmonari 275 tb phase 3 clinic trial appropriate14 276 277 sponsor must submit pediatr studi plan later 60 calendar day date 278 endofphas 2 meet time agre upon fda sponsor unless 279 12 see draft guidanc industri adjust covari random clinic trial drug biolog product may 2021 final guidanc repres fda current think topic 13 exampl see articl toward earlier inclus children tuberculosi tb drug trial consensu statement expert panel nachman et al 2015 14 see guidanc industri develop anti infect drug product pediatr popul decemb 2021 contain nonbind recommend draft implement 8 investig drug grant orphan designation15 pedi atric formul 280 develop begin soon result adult phase 2b trial known 281 sponsor determin appropri dose regimen 282 283 extrapol adult efficaci treatment pulmonari tb pediatr popul 284 accept pediatr popul except young children 285 differ clinic pathophysiolog characterist sponsor provid pk safeti 286 inform suffici number pediatr subject support appropri dose 287 treatment children pulmonari tb cohort pediatr studi defin base 288 chronolog age weight base criteria particularli oral drug studi drug across 289 pediatr spectrum agesweight conduct parallel rather sequenti 290 unless specif safeti pk properti warrant differ approach existi ng 291 anim studi identifi potenti development concern target organ toxicolog 292 pharmacolog juvenil anim toxic test may appropri 16 17 293 294 pediatr develop plan new tb investig drug could includ children live 295 hiv provid safeti drug drug interact issu manag 296 297 sponsor discuss pediatr develop program fda especi 298 includ young children eg younger 5 year age differ 299 clinic manifest eg increas likelihood extrapulmonari diseas 300 pathophysiolog characterist 301 302 b pregnant femal 303 304 sponsor includ pregnant femal clinic trial femal reproduct toxic 305 studi standard batteri genotox test conduct 18 infant born 306 femal subject receiv investig drug follow investig 307 appropri length time sponsor discuss durat fda trial 308 conduct19 309 15 see section 505b e2a fdc act 21 usc 355 ce2a addit inform see guidanc industri pediatr studi plan content process submit initi pediatr studi plan amend initi pediatr studi plan juli 2020 ich guidanc industri e11 clinic investig medicin product pediatr popul decemb 2000 16 see guidanc industri nonclin safeti evalu pediatr drug product februari 2006 17 support principl 3r reduc refin replac anim use test feasibl encourag sponsor consult review divis consid use nonanim test method believ su itabl adequ valid feasibl consid altern method could assess equival anim test method 18 see draft guidanc industri pregnant women scientif ethic consider inclus clinic trial april 2008 final guidanc repres fda current think topic 19 recommend regard treatment women pregnanc breastfeed see american thorac societi center diseas control prevent infecti diseas societi america guidelin treatment tb nahid et al 2016 avail httpswwwcdcgovmmwrpreview mmwrhtmlrr5211a1htm contain nonbind recommend draft implement 9 310 c spe cific popul 311 312 sponsor includ trial geriatr subjects20 subject renal insuffici diabet 313 mellitu subject hepat impair feasibl high incid tb 314 patient coinfect hiv subject hiv includ trial 315 316 6 dose select 317 318 select dose regimen evalu phase 3 clinic trial sponsor 319 consid target pkpharmacodynam pd paramet eg area curveminimum 320 inhibitori concentr mic maxim concentr mic time mic base 321 vitro model see ection iii c1a vitro studi anim model tb result 322 earli clinic trial eg eba andor trial afb clearanc sputum earli time point 323 result exposur respons evalu pkpd evalu includ evalu 324 base free drug concentr 325 326 7 choic compar 327 328 choic compar background regimen depend part subject popul 329 sponsor enrol trial eg likelihood infect drug suscept drug 330 resist tuberculosi ge neral sponsor choos compar regimen contain 331 fda approv drug repr esent standard care trial initi ponsor 332 discuss fda use compar regimen base local practic outsid 333 unit st ate use drug fda approv 334 335 8 efficaci endpoint 336 337 sponsor use follow efficaci endpoint clinic trial investig drug 338 intend treat pulmonari tb 339 340 primari clinic efficaci endpoint compris surviv evalu 341 tuberculosi growth serial sputum cultur examin fix time point 342 follow random treatment arm includ period follow 343 complet plan treatment period fda defin c linic success 344 failur follow 345 346 clinic success assign subject aliv achiev tuberculosi cultur 347 neg serial sputum examin experi relaps recurr 348 pulmonari tb otherwis meet definit clinic failur gener 349 20 see ich guidanc industri e7 studi support special popul geriatr august 1994 e7 studi support special popul geriatr question answer februari 2012 contain nonbind recommend draft implement 10 protocol defin serial sputum examin occur everi 2 week month 350 treatment everi 3 month follow complet treatment21 351 352 clinic failur defin one follow 353 354 protocol defin clinic progress pulmonari diseas treatment 355 356 switch antimycobacteri therapi toler issu clinic 357 progress pulmonari tb 358 359 sign symptom activ tb includ radiograph worsen compar 360 baselin find result reiniti antimycobacteri thera py 361 follow up22 362 363 death treatment follow 364 365 growth tuberculosi sputum cultur outlin follow 366 367 failur achiev tuberculosi cultur neg serial sputum specimen 368 treatment period 369 370 failur maintain cultur neg statu fter specif time point defin 371 trial gener expect time two consecut neg 372 sputum cultur taken least 28 day apart therapi follow 373 374 growth tuberculosi extrapulmonari site trial 375 376 surrog endpoint base result tuberculosi sputum cultur 377 treatment demonstr treatment effect sputum cultur convers 378 posit neg treatment either time toconvers analysi fix 379 time point eg 2 month random could consid surrog 380 endpoint reason like predict clinic benefit acceler approv 381 statutori regulatori provis 23 addit consider relat acceler 382 approv regard verif descript clinic benefit includ 383 durabl treatment effect discuss section iiib11 acceler approv 384 consider sponsor obtain erial cultur specif time point 385 treatment eg everi 2 week everi month time sputum cultur convers 386 time first steril cultur verifi tuberculosi cultur neg 387 21 protocol defin ed time serial examin sputum cultur may differ clinic practic often depend local treatment guidelin respiratori isol procedur 22 circumst antimycobacteri therapi may restart though diagnost uncertainti whether relaps occur therapi subsequ stop altern diagnosi establish protocol defin durat retreat therapi use defin clinic failur avoid label trial subject situat failur 23 section 506c fdc act 21 cfr 314510 21 cfr 60141 contain nonbind recommend draft implement 11 least two subsequ consecut sputum specimen taken least 14 day apart eg 388 three consecut neg sputum cultur sputum cultur evalu either 389 solid liquid media see section iiib11 acceler approv consider 390 391 secondari exploratori endpoint sponsor consid follow 392 393 well defin reliabl evalu symptom includ 394 clinic trial secondari exploratori endpoint f note symptom evalu 395 certain patient popul may difficult interpret exampl among 396 patient coinfect hiv experi immun reconstitut inflammatori 397 syndrom non hiv infect individu paradox reaction rangaka et al 398 2012 399 400 molecular biochem evalu ascertain whether posit cultur 401 tuberculosi drug treatment repres relaps reinfect eg 402 exploratori endpoint analysi treat relaps baselin tuberculosi 403 infect failur origin studi treatment treat reinfect new 404 tuberculosi isol success origin studi treatment 405 406 9 trial procedur es time assess 407 408 entri visit 409 410 sponsor obtain baselin demograph inform current medic complet 411 physic e xamin entri visit addit sponsor obtain follow 412 entri 413 414 clinic sign symptom pulmonari tb eg cough sputum product episod 415 hemoptysi fever pleurit chest pain weight loss night sweat 416 417 baselin safeti laboratori evalu 418 419 hiv serolog hiv posit viral load cd4 cell count 420 421 imag result standard posterior anterior view later chest radiograph 422 comput ed tomographi scan describ extent sever pulmonari diseas 423 424 sputum specimen afb smear mycobacteri cultur obtain one 425 follow spontan expector nduction hyperton salin bronchoscopi 426 gastric lavag eg pediatr subject applic baselin specimen 427 quantit cultur collect standard manner eg singl earli 428 morn induc sputum pool 24 hour sputum 429 430 contain nonbind recommend draft implement 12 b visit therapi therapi complet 431 432 gener clinic assess occur weekli biweekli first month 433 therapi follow monthli assess therapi complet complet 434 therapi assess occur approxim everi 3 month assess 435 primari efficaci endpoint complet eg 12 month random ass essment 436 sign symptom advers effect laboratori test appropri occur 437 visit addit target physic examin perform 438 439 therapi sponsor obtain putum specimen afb smear cultur least 440 monthli depend investig drug regimen design shorter interv 441 specimen collect eg 2 week may appropri certain period trial 442 443 subject abl expector sputum spontan follow visit therapi 444 complet sponsor consid method obtain sputum eg sputum induct 445 446 10 statist consider 447 448 gener sponsor includ protocol detail statist al analysi plan state 449 trial hypothes efficaci analysi method 450 451 sponsor consid follow definit analysi popul 452 453 safeti popul subject receiv least one dose investig 454 drug trial 455 456 intent totreat itt popul random subject 457 458 microbiolog itt icroitt popul random subject posit 459 cultur tuberculosi pretreat prerandom sampl trial 460 intend focu subject drug resist tb sponsor choos primari 461 analysi micro itt popul random subject posit cultur 462 drug resist isol tuberculosi pretreat prerandom sampl 463 464 perprotocol popul random subject posit cultur 465 pretreat sampl achiev prespecifi level complianc protocol 466 eg presenc high percentag follow visit 467 468 gener analysi popul greatest interest determin efficaci 469 micro itt popul addit sponsor evalu consist result efficaci 470 itt per protocol popul notabl differ outcom 471 itt perprotocol popul sponsor investig reason 472 differ 473 474 subject follow complet durat trial even discontinu 475 investig drug sponsor make everi effort minim loss follow 476 contain nonbind recommend draft implement 13 throughout trial given miss data nonetheless like occur protocol 477 state miss data handl primari efficaci analysi addit ly 478 statist analysi plan defin addit method handl miss data studi 479 report includ n assess depend trial result specif method 480 handl miss data 481 482 improv precis treatment effect estim infer sponsor consid 483 adjust prespecifi baselin factor anticip pro gnostic outcom 484 random stratifi baselin covari analysi account stratifi 485 random 486 487 11 acceler approv consider 488 489 circumst approv 21 cfr part 314 subpart h 21 cfr part 601 subpart 490 e may applic drug develop treatment tb provid clinic 491 meaning benefit exist treatment endpoint base convers sequenti 492 tuberculosi sputum cultur neg eg percent convers prespecifi time 493 point use surrog endpoint reason like predict clinic benefit 494 walli et al 2010 walli et al 2013 phillip et al 2013 walli peppard hermann 2015 495 walli pepp ard 2015 phillip et al 2016 meyvisch et al 2018 sponsor may consid 496 surrog endpoint eg biomark also reason like predict clinic 497 benefit drug approv acceler approv fda requir sponsor 498 studi drug verifi describ clinic benefit24 includ durabl 499 treatment effect sponsor consid sputum cultur convers surrog 500 endpoint reason like predict clinic benefit consult agenc 501 clinic trial plan 502 503 c consider 504 505 1 microbiolog consider 506 507 sponsor nvestig drug evalu treatment tb support 508 data vitro vivo anim model microbiolog studi studi may 509 provid data inform select regimen antimycobacteri drug evalu 510 clinic trial assess contribut drug investig drug regimen 511 512 vitro studi 513 514 vitro studi encompass follow 515 516 investig drug activ inhibit growth kill metabol activ 517 dormant intracellular stage tuberculosi 518 519 24 21 cfr 314510 drug 21 cfr 60141 biolog product contain nonbind recommend draft implement 14 suscept test metabol activ bacilli drug suscept laboratori 520 strain laboratori strain known pattern drug resist clin ical isol 521 repres differ geograph region 522 523 standard method suscept test recommend 524 clinic laboratori standard institut clsi25 525 526 nonstandard method employ trial prior submiss fda review 527 complet descript method perform characterist assay 528 actual laboratori test done 529 530 establish q ualiti control paramet suscept test 531 determin vitro activ 26 532 533 two new investig drug evalu simultan sponsor 534 conduct factori design studi evalu new investig ation drug provid 535 result fda9 fda encourag est multipl strain tuberculosi 536 see section iiic3d vitro hollow fiber system model method assess 537 contribut individu drug combin regimen 538 539 b vivo anim model 540 541 appropri anim model serv import bridg identif 542 vitro antimycobacteri effect investig drug initi clinic trial 543 pk assess chang drug suscept anim model studi may inform clinic 544 trial design sponsor consid evalu investig drug 545 combin investig drug use differ anim mode ls one 546 strainisol tuberculosi studi mycobacteri burden steril activ vivo 547 studi conduct use factori design use clinic relev exposur provid 548 inform contribut individu drug combin regimen 549 550 c drug resist cross resist 551 552 sponsor examin pot ential tuberculosi isol develop resist 553 investig drug appropri vitro andor anim model evalu 554 potenti cross resist drug class class use treatment 555 tb resist demonstr import identifi mechan resist 556 25 exampl ee guidanc industri fda class ii special control guidanc document antimicrobi suscept test ast system august 2009 clsi suscept test mycobacteria nocardia aerob actinomycet approv standard third edit avail httpsclsiorgstandardsproductsmicrobiologydocumentsm24 recent version class ii special control guidanc document check fda class ii special control guidanc document web page httpswwwfdagovmed evicesguid document medic devic andradi emit productsclass iispeci control document 26 detail see guidanc industri microbiolog data system antibacteri drug develop analysi present februari 2018 contain nonbind recommend draft implement 15 sponsor attempt evalu clinic signific chang phenotyp eg 557 vitro suscept investig drug genotyp observ nonclin studi 558 correl chang efficaci outcom 559 560 type cultur media identifi tuberculosi 561 562 solid media eg lwenstein jensen medium middlebrook 7h10 7h11 agar media 563 liquid media eg myco bacteria growth indic tube cultur assay method use 564 identifi character tuberculosi sponsor includ newer molecular 565 methodolog detect tuberculosi suscept profil trial microbiolog 566 evalu sponsor specifi method use cultur identifi tuberculosi 567 well vitro suscept test method employ trial 568 569 baselin evalu agenc recommend use solid liquid media 570 advantag approach 1 rapid observ mycobacteri growth liquid 571 media eg less 2 week 2 growth pure cultur solid media alreadi 572 underway biochem ical confirm tuberculosi b evalu 573 vitro suscept 574 575 evalu subject treatment aft er treatment complet sponsor use 576 solid liquid cultur media within clinic trial cultur meth odolog among trial site 577 consist evalu subject trial type cultur evalu 578 inform secondari exploratori endpoint eg quantit cultur techniqu 579 580 e differenti relaps reinfect new infect 581 582 secondari analysi sponsor aim util mole cular method evalu whether 583 clinic failur caus relaps origin infect develop new 584 infect especi subject live endem area method use 585 clinic trial sponsor shoul includ detail method use well perform 586 characterist assay clinic protocol 587 588 2 relev nonclin safeti consider 589 590 combin regimen remain standard care treatment tb individu drug 591 may develop treatment activ diseas although would use part 592 combin regimen nonclin studi character safeti profil individu drug 593 combin regimen support clinic trial approv market applic 594 vari depend inform avail drug intend patient 595 population27 agenc encourag sponsor discuss fda avail toxicolog 596 27 guidanc conduct nonclin combin studi support clinic trial combin regimen see follow 1 guidanc industri nonclin safeti evalu drug biolog combin march 2006 2 ich guidanc industri m3r2 nonclin safeti studi conduct human clinic trial market author pharmaceut 3 ich guidanc industri s6r1 preclin safeti evalu biotechnolog deriv pharmaceut may 2012 4 guidanc industri codevelop two new investig drug use combin contain nonbind recommend draft implement 16 data investig drug propos clinic develop combin 597 regimen 598 599 sponsor conduct nonclin toxicolog studi combin regimen consist 600 two investig unapprov drug initi administr combin 601 regimen human base follow 602 603 avail clinic experi individu drug 604 605 avail relev nonclin toxicolog data individu drug 606 propos durat combin regi men 607 608 exist signific toxicolog concern safeti margin 609 observ advers effect level noael individu drug anim 610 toxicolog studi propos human exposur investig drug 611 combin regimen 612 613 potenti drug drug interact base absorpt distribut 614 metabol excret drug 615 616 potenti advers effect involv organ system overlap 617 toxic synergist toxic base review accumul data 618 investig drug 619 620 sponsor discuss fda type durat time nonclin toxicolog 621 studi need support clinic developm nt combin regimen 622 623 3 pkpd consider 624 625 phase 1 phase 2 pk trial 626 627 pk investig drug fulli character singl dose pk multipl 628 dose pk phase 2 pkpd evalu fda recommend character pk 629 specif popul includ subject renal hepat impair well 630 evalu drug effect qt interv 28 631 632 b drug interact 633 634 sponsor conduct n vitro studi determin pote ntial investig drug 635 act substrat inhibitor induc major human metabol enzym relev 636 transport 29 base result drug interact evalu one 637 28 see ich guidanc ind ustri e14 clinic evalu qtqtc interv prolong proarrhythm potenti non antiarrhythm drug question answer r1 octob 2012 29 see guidanc industri vitro drug interact studi cytochrom p450 enzym transport mediat drug interact januari 2020 contain nonbind recommend draft implement 17 antimycobacteri drug use plan combin regimen drug unrel 638 treatment tb like use concomitantli indic eg antiretrovir 639 therapi treatment hiv antivir therapi treatment hepat b c may need 640 initi clinic efficaci trials30 agenc strongli recommend sponsor 641 consult fda drug develop regard appropri drug interact evalu 642 643 c exposur respons 644 645 sponsor explor e xposur respons relationship earli phase drug 646 develop aid select optim dose strategi evalu later trials31 647 fda encourag sponsor explor exposur respons relationship sputum 648 serum drug concentr marker activ eg time tosputum convers 649 sputum convers rate 2 month subject pulmonari tb 650 651 vitro hollow fiber system model 652 653 sult hollow fiber system model combin sourc nonclin data 654 help inform select antimycobacteri drug regimen begin clinic evalu 655 chilukuri et al 2015 hollow fiber system model use si mulat pk 656 characterist drug intend treat tb allow explor concentr 657 effect relationship potenti relev treatment tb clinic set hese 658 model expect provid key inform regim en select evalu 659 model may also play import role evalu contribut drug 660 clinic relev exposur treatment effect 661 662 4 foreign clinic data32 663 664 fda regul permit accept foreign clinic trial support new drug 665 applic nda biolog licens applic bla approv 21 cfr 312120 666 667 5 data standard tb 668 669 studi data standard describ standard ize way exchang clinic nonclin research 670 data comput system data standard develop tb provid 671 30 see guidanc industri clinic drug interact studi cytochrom p450 enzym transport mediat drug interact januari 2020 31 see guidanc industri exposur respons relationship studi design data analysi regulatori applic april 2003 32 see guidanc industri fda staff fda accept foreign clinic studi conduct ind fr equent ask question march 2012 contain nonbind recommend draft implement 18 consist gener framework organ studi data includ templat dataset 672 standard name variabl standard way calcul common variables33 673 674 6 label consider 675 676 gener label indic reflect patient popul enrol clinic 677 trial exampl sponsor consid follow 678 679 drug x indic combin drug z treatment pulmonari 680 tuberculosi 681 682 683 684 drug x indic combin antimycobacteri drug treatment 685 pulmonari tuberculosi 686 687 drug approv acceler approv sponsor must includ addit inform 688 indic usag section see 21 cfr 20157c2ib 34 drug 689 approv l imit popul pathway ntibacteri antifung drug addit 690 inform avail specif label requir recommendations35 36691 33 see exampl tb therapeut area user guid version 2 avail httpswwwcdiscorgstandardstherapeut areastuberculosistuberculosi therapeut areauserguid v20 fda studi data standard resourc web page avail httpswwwfdagovforindustrydatastandardsstudydatastandardsdefaulthtm 34 see guidanc industri expedit program seriou condit drug biolog 35 see section 506h3a fdc act amend 21st centuri cure act 36 see guidanc industri limit popul pathway antibacteri antifung drug august 2020 contain nonbind recommend draft implement 19 refer 692 693 bark cm r dietz okwera et al 2011 clinic symptom mi crobiolog outcom 694 tuberculosi treatment trial tuberculosi 916 601604 695 696 chilukuri mcmaster k bergman et al 2015 hollow fiber system model 697 nonclin evalu antituberculosi drug regimen clin infect di 61 su ppl 698 1s32s33 699 700 dersimonian r n laird 1986 meta analysi clinic trial control clin trial 701 73177188 702 703 east african british medic research council 1981 control c linic trial f ive hort 704 cours 4 month c hemotherapi regimen pulmonari tuberculosi rev respir di 705 1232 165 170 706 707 east central africabritish medic research council fifth collabor studi 1983 708 control clinic rial 4 hortcours r egimen c hemotherapi three 6 month 709 one 8 month p ulmonari uberculosi tubercl 643153 166 710 711 gillespi sh crook td mchugh et al 2014 four month moxifloxacin base regimen 712 drug sensit tuberculosi new engl j med 37117 1577 1587 713 714 johnson jl dj hadad r dietz et al 2009 shorten reatment adult w ith noncavitari 715 tuberculosi 2 month cultur convers j respir crit care med 1806 558 563 716 717 makuch rw rm simon 1980 sampl size consider non random 718 compar studi j chron di 333 175181 719 720 meyvisch p c kambili k andri et al 2018 evalu six month sputum cultur 721 convers surrog endpoint multidrug resist tuberculosi trial plo one 722 137e0200539 723 724 nachman ahm f amanullah et al 2015 toward earlier inclus children 725 tuberculosi tb drug trial consensu statement expert panel lancet infect di 726 156711720 727 728 nahid p se dorman n alipanah et al 2016 offici american thorac societycent 729 diseas control preventioninfecti diseas societi america clinic practic 730 guidelin treatment drug suscept tuberculosi clin infect di 637853 867 731 732 nunn aj pp j phillip sh gillespi 2008 design issu pivot drug trial drug 733 sensit tuberculosi tb tuberculosi 88suppl 1s85 s92 734 735 perez velez cm bj marai 2012 tuberculosi children new engl j med 3674 348 736 361 737 contain nonbind recommend draft implement 20 phillip ppj cm mendel da burger crook aj nunn r dawson et al 2016 limit 738 role c ultur c onvers ecis make ndividu p atient c dvanc 739 novel r egimen c onfirmatori c linic rial bmc med 1419 740 741 phillip ppj k field aj nunn 2013 e valuat c ultur r esult ure 742 treatment tuberculosi urrog e ndpoint reatment f ailur r elaps plo 743 one 85 e63840 744 745 rangaka mx rj wilkinson jr glynn et al 2012 effect antiretrovir therapi 746 diagnost accuraci symptom screen intensifi tuberculosi case find 747 south african hiv clinic clin infect di 5512 16981706 748 749 singapor tuberculosi servicebritish medic research council 1986 long term follow 750 c linica l trial ixmonth fourmonth r egimen c hemotherapi reatment 751 pulmonari uberculosi rev respir di 1335779 783 752 753 walli rs peppard 2015 earli b iomark r egulatori nnovat multidrug 754 resist uberculosi clin infect di 61 suppl 3 s160 s163 755 756 walli rs c wang tm doherti p onyebujoh vahedi h laang et al 2010 biomark 757 uberculosi iseas ctiviti c ure r elaps lancet infect di 102 6869 758 759 walli rs c wang meyer n thoma 2013 month 2 c ultur statu reatment 760 durat predictor uberculosi r elaps r isk etaregress odel plo one 761 88 e71116 762 763 walli rs peppard hermann 2015 month 2 c ultur tatu reatment durat 764 predictor r ecurr p ulmonari uberculosi odel v alid u pdate plo 765 one 104 e0125403 766 767 wejs c p gustafson j nielson et al 2008 tbscore sign symptom tuberculosi 768 patient low resourc set predict valu may use assess clinic 769 cours scand j infect di 402 111120 770 contain nonbind recommend draft implement 21 appendix 771 exampl justif noni nferior margin 772 treatment shorten clinic trial pulmonari tuberculosi 773 774 appendix provid exampl noninferior ni margin justif state 775 guidanc ni margin justif depend specif design ni trial 776 justif specif ni trial w ould compar n investig drug regimen 777 consist new investig drug plu first 4 month standard regimen 778 standard 6month regimen subject drug suscept tuberculosi tb effect 779 investig drug essenti replac effect month 5 6 standard regimen 780 use histor data justif determin effect 2 month therapi 781 histor evid sensit drug e ffect hesd de termin new 782 investig drug effect base result ni trial addit inform 783 avail regard complet discuss ni trial justif margin 1 784 785 identifi two trial allow esti mate effect onth 5 6 786 standard regimen drug suscept tb base comparison standardof care 787 regimen 2 month treatment ethambutol streptomycin isoniazid rifampin 788 pyrazinamid follow 4 month treatment isoniazid rifampin often 789 describ abbrevi terminolog 2ehrz4hr 2shrz4hr 4 month regimen 790 2ehrz2hr 2shrz2hr 2 endpoint unfavor outcom defin one 791 follow 1 subject never becom sputum cultur neg tuberculosi 792 therapi 2 subject microbiolog confirm relaps pulmonari tb within 793 12month period observ follow therapi complet 3 subject die 794 time within clinic trial drug administr period 12month period observ 795 follow therapi complet 796 797 tabl contain result two trial among subject random receiv 798 6 month regimen 4 month regimen comparison two regimen give 799 estim effect final 2 month 6 month regimen 84 percent lower 800 bound 95 percent confid interv 48 percent 48 percent use 801 conserv estim treatment effect month 5 6 treatment 802 803 1 see guidanc industri noninferior clinic trial establish effect novemb 2016 updat guidanc period make sure recent version guidanc check fda guidanc web page httpswwwfdagovregulatori informationsearch fdaguid document 2 see singapor tuberculosi servicebritish medic research council 1986 east central africabritish medic research council fifth collabor studi 1983 east africanbritish medic research council 1981 contain nonbind recommend draft implement 22 tabl result wo treatment shorten tudi 804 805 studi 6month regimen unfavor outcom 4month regimen unfavor outcom treatment effect 4 month regimen minu 6 month regimen 95 ci 1 2shrz4hrz 12 2158 2shrz2hrz 96 15156 84 38 142 2 2shrz4hr 47 8172 2shrz2hrz 132 28212 86 24 146 summari estim 95 ci 84 48 121 ci confid interv 2shrz4h rz 2 month treatment streptomycin isoniazid rifampin 806 pyrazinamid follow 4 month treatment isoniazid rifampin pyrazinamid 2shrz2hrz 807 2 month treatment streptomycin isoniazid rifampin pyrazinamid follow 2 month treatment 808 isoniazid rifampin pyrazinamid 809 number death unknown studi 1 therefor includ outcom 6 month 4 810 month regimen studi 2 separ trial howev similarli design conduct 811 occur close time studi 1 singapor tuberculosi servicebritish medic research council 1986 long 812 term follow clinic trial six month four month regimen chemotherapi treatment 813 pulmonari tuberculosi rev respir di 1335779 783 studi 2 east central africabritish medic 814 research council fifth collabor studi 1983 control clinic trial 4 hort cours regimen 815 chemotherapi three 6 month one 8month pulmonari tuberculosi tubercl 643153 166 east 816 africanbritish medic research council 1981 control clinic trial five short cours 4 month 817 chemotherapi regimen pulmonari tuberculosi rev respir di 1232165 170 818 random effect model per dersimonian r n laird 1986 meta analysi clinic trial control clin 819 trial 73177 188 820 821 ni trial subject drug suscept pulmonari tb tr eatment shorten 822 regimen compar standard 6month regimen select n ni margin 48 percent 823 support histor data ni margin justif present 824 modif justif present nunn et al 2008 3 825 826 although ni margin 48 percent may seem ly conserv fact high 827 proport subject achiev success primari efficaci outcom standard care 828 provid reason estim f sampl size ni trial addit given high 829 proport subject achiev success outcom interest maintain high 830 proport new investig drug regimen exampl identifi trial johnson et 831 al 20094 describ halt trial data monitor committe base 832 approxim 5 percentag point estim differ standard regimen 833 treatment shorten regimen indic clinic expecta tion 834 high proport subject achiev success outcom treatment group make 835 select n ni margin 48 percent feasibl consider 836 837 3 nunn aj ppj phillip sh gillespi 2008 design issu pivot drug trial drug sensit tuberculosi tb tuberculosi 88suppl 1s85 s92 4 johnson jl dj hadad r dietz et al 2009 shorten treatment adult noncavitari tuberc ulosi 2month cultur convers j respir crit care med 1806558 563 contain nonbind recommend draft implement 23 follow exampl provid framework discu sion fda sampl size 838 estim ni trial evalu treatment shorten regimen makuch simon 1980 5 839 total sampl size enrol subject approxim 480 subject per arm base 840 follow ing assumpt 1 identif mycobacterium tuberculosi 90 percent 841 enrol subject primari analysi popul approxim 430 subject per arm 2 two 842 side type error 005 power 90 percent 3 arm rate 5 percent 843 subject endpoint failur convert neg sputum cultur 844 experi relaps tb death 12 month period observ 4 ni margin 845 48 percent 846 847 sponsor discuss fda appropri ni margin specif ni trial 848 propos 849 5 makuch rw rm simon 1980 sampl size consider non random compar studi j chron di 333175 181 
[Document -4] allerg rhiniti develop drug product treatment guidanc industri us depart health human servic food drug administr center drug evalu research cder septemb 2018 clinicalmed allerg rhiniti develop drug product treatment guidanc industri addit copi avail offic commun divis drug inform center drug evalu research food drug administr 10001 new hampshir ave hillandal bldg 4th floor silver spring md 20993 0002 phone 8555433784 301 7963400 fax 3014316353 email druginfofdahhsgov httpswwwfdagovdrugsguidancecomplianceregulatoryinformationguidancesdefaulthtm us depart health human servic food drug administr center drug evalu research cder septemb 2018 clinicalmed tabl content introduct 1 ii backg round 2 iii overal consideratio ns adult program 2 number trial 2 b dose 3 c safeti monitor 3 corticosteroid specif issu 4 e issu specif topic product 4 iv overal consideratio ns pediatr progr 5 pediatr dose select 5 b safeti data 5 c corticosteroid specif issu 5 v protocol issu element 6 trial design 6 b inclu sion criteria 7 c exclus criteria 7 blind 8 e formul dosag regimen 9 f evalu 9 1 assess patient complianc 9 2 assess rescu medic use 9 3 rate system 9 4 record score 10 5 advers event record 10 vi data analysi issu 10 symptom score 10 b onset action 11 vii fix dose combinati product 12 contain nonbind recommend 1 allerg rhiniti develop drug product treatment guidanc industry1 guidanc repres current think food drug administr fda agenc topic establish right person bind fda public use altern approach satisfi requir applic statut regul discuss altern approach contact fda offic respons gui danc list titl page introduct purpos guidanc assist sponsor develop drug product treatment allerg rhiniti children adult 2 guidanc address issu trial design effect safeti new product develop treatment season allerg rhiniti sar perenni allerg rhiniti par recommend guidanc base assess import issu rais revi ew adult pediatr allerg rhiniti clinic trial agenc current understand mechan two relat disord sar par pathophysiolog sar par similar term chemic mediat produc endorgan manifest differ two entiti primarili base caus durat diseas trial design issu pertain sar par trial also similar thu two categori treat collectivel guidanc allerg rhiniti differ recommend design sar par trial indic sponsor encourag discuss detail trial design specif issu relat individu product divis revi w staff conduct clinic trial guidanc contain discuss gener issu statist analysi clinic trial design topic address ich guidanc industri e9 statist principl clinic trial e10 choic control group relat issu clinic 1 guidanc prepar divis pulmonari allergi rheumatolog product center drug evalu research food drug administr 2 purpos guidanc term drug product inclus small larg molecul activ moieti moieti formul along deliveri devic applic contain nonbind recommend 2 trial respect 3 well draft ich guidanc industri e9r1 statist principl clinic trial addendum estimand sensit analysi clinic tri als4 gener fda guidanc document establish legal enforc respons instead guidanc describ agenc current think topic view recommend unless specif regulatori statutori r equir cite use word agenc guidanc mean someth suggest recommend requir ii background inform pathophysiolog treatment allerg rhiniti subtyp sar par grown markedli past decad patient allerg rhiniti may nasal non nasal symptom main nasal symptom allerg rhiniti nasal itch ie nasal pruritu sneez rhinorrhea nasal congest nasal pruritu sneez induc sensori nerv stimul wherea congest result vasodil result engorg cavern sinusoid rhinorrhea induc increas vascular permeabl well direct glandular secret import non nasal symptom commonli associ allerg rhiniti includ eye itch tear eye red itch ear andor palat grow number chemic mediat believ contribut allerg rhiniti desp ite differ caus tempor pattern diseas group chemic mediat appear regul respons sar par reason distinct sar par term clinic trial design made ly clinic relev area iii overal consideratio ns adult program number trial approv new molecular entiti adult agenc recommend least two adequ well control phase 3 clinic trial support either sar par indic altern sponsor submit one sar one par trial support indic adequ well control phase 3 trial demonstr safeti effect drug indicat ion drug approv one two relat indic singl trial may support approv indic exampl singl par trial may support approv par indic drug alreadi approv sar 3 updat guidanc period recent version guidanc check fda guidanc web page httpswwwfdagovregulatoryinformationguidancesdefaulthtm 4 final guidanc repres fda current think topic recent version guidanc check fda guidanc web page httpswwwfdagovregulatoryinformationguidancesdefaulthtm contain nonbind recommend 3 b dose dose respons relationship n investig product evalu trial dedic dose rang trial goal dose explor identifi optim dose dose frequenc balanc benefit risk ideal dose explor conduct real world set exposur model park inhal chamber trial may predict real world clinic respons likewis dose select base clinic meaning endpoint pharmacodynam pd marker may predict c safeti monitor clinic efficaci trial must also address safeti concern monitor advers event perform routin laboratori test ie blood chem istri liver function test complet blood count differenti urinalys electrocardiogram appropri 21 cfr 31223a6 sar par phase 3 trial routin laboratori test recommend trial patient least initi screen last visit product system bioavail agenc recommend safeti program includ thorough cardiac safeti evalu gener risk clinic signific qt prolong would render ri kbenefit unfavor allerg rhiniti product intend symptomat benefit clinic electrocardiograph evalu perform earli clinic develop clinic trial assess potenti product delay cardiac repolar describ detail ich guidanc ndustri e14 clinic evalu qtqtc interv prolong proarrhythm potenti non antiarrhythm drug sponsor encourag contact review divis regard appropr iat cardiac safeti monitor respect develop program class product sponsor may wish provid assess degre sedat compar placebo safeti databas adequ assess sedatio n primarili base individu patient advers event report sedat andor drowsi similar terminolog defin sponsor advers event dictionari need addit evalu drive simul trial depend characterist intend use individu product long term safeti data includ least 300 patient evalu 6 month 100 patient evalu 1 year overal patient databas includ least 1 500 patient recommend suffici number patient receiv highest dose propos market see ich guidanc industri e1a extent popul exposur assess clinic safeti drug intend long term treatment non lifethreaten condit measur efficaci endpoint recommend long term safeti trial secondari assess contain nonbind recommend 4 corticosteroid specif issu import safeti issu intranas corticosteroid ordinarili addr ssed adult clinic program includ assess adren function use either 24 hour urinari free cortisol level 24 hour plasma cortisol area curv level measur pretreat least 6 week treatment inv stigat product placebo activ control recommend trial evalu possibl cataract format long term trial slit lamp examin pre post treatment evalu glaucoma long term trial use ntraocular pressur monitor pre post treatment e issu specif topic product given risk local toxic safeti monitor includ baselin serial nasal examin p respecifi grade criteria assess presenc nasal irrit eg mucos edema erythema epistaxi ulcer septal perfor use document chang cours treatment period whole product includ dedic deliveri system consid drug devic combin product defin 21 cfr 32e chang formul excipi formul flow path within devic devic compon eg dimens materi construct coat alter deliveri characterist affect clinic perform user interfac product therefor recommend key trial develop program includ dose rang trial confirmatori efficaci safeti trial conduct tobemarket product furthermor data provid perform reliabl new deliveri system period intend use vitro clinic bridg data may need support chang formul deliveri system depend natur extent chang alter product may view new product necessit separ develop program efficaci safeti trial recommend sponsor discuss plan chang topic product review divis bridg studi nasal product local action particularli product suspens state substanti undertak principl may appli bridg program outlin n draft guidanc ndustri bioavail bioequival studi nasal aerosol nasal spray local action 5 5 final guidanc repres fda current think topic recent version guidanc check fda guidanc web page httpswwwfdagovregulatoryin formationguidancesdefaulthtm contain nonbind recommend 5 iv overal consideratio ns pediatr progr pediatr age rang propos product particularli young patient justifi sponsor base preval diseas need treatment age group product indic treatment sar gener evalu children age 2 year product indic treatment par evalu children age 6 month opic product appropri deliveri system propos age rang addit consider sponsor encourag discuss specif pediatr program divis case bycas basi begin discuss pediatr formul clinic develop plan earli feasibl sponsor requir submit pediatr studi plan und r pediatr research equiti act later 60 day end ofphas 2 meet recommend sponsor refer pediatr research equiti act amend food drug administr safeti innov act 6 pediatr dose select product alreadi approv andor adequ studi adult yet studi children appropri pediatr dose determin addit adequ short long term safeti inform propos pediatr age group provid oral formul reason pharmacokinet pk pd link efficaci establish pk data children use determin compar exposur adult patient therefor appropri pediatr do e intranas formul efficaci trial pediatr patient recommend plasma drug level consist detect reliabl measur local bioavail topic efficaci b safeti data typic 3 month addit specif pediatr safeti data intranas product 1 month addit specif pediatr safeti data oral product recommend suggest se data collect control trial howev durat number pediatr patient expos investig product safeti monitor determin individu basi product base anticip side effect pediatr pk data safeti concern c corticosteroid specif issu intranas corticosteroid recommend 6 week hypothalam pituitari adren hpa axi trial placebo activ control trial intend evalu influenc 6 see section 505be feder food drug cosmet act amend section 506 food drug administr safeti innov act draft guidanc industri pediatr studi plan cont nt process submit initi pediatr studi plan amend initi pediatr studi plan final guidanc repres fda current think topic recent version guidanc check fda guidanc web page httpswwwfdagovregulatoryinformationguidancesdefaulthtm contain nonbind recommend 6 product hpa axi limit hpa axi suppress alon ethic concern use oral prednison activ control adren respons trial children altern approach may appropri approach includ use approv intranas cortic osteroid suffici caus hpa axi effect base inform indic intranas corticosteroid potenti decreas growth veloc children growth trial recommend prepubert children trial conduct postapprov may use sponsor includ knemometri trial new drug applic provid pd growth data consider initi review recommend regard design conduct growth tri al outlin guidanc ndustri oral inhal intranas corticosteroid evalu effect growth children sponsor encourag discuss detail pediatr growth trial design review divis v protocol issu element trial design follow gener recommend trial design phase 3 allerg rhiniti sar par trial doubl blind placebo control parallel group trial recommend prefer placebo run period placebo run period use assess minimum level complianc symptom sever doubl blind treatment period suggest durat doubl blind treatment period least 2 week sar trial 4 week par trial sar trial agenc recommend protocol includ plan measur pollen count differ trial center final report document exposur patient relev allergen trial period may also help collect data number raini day trial extent patient exposur outdoor air sar trial encourag random patient within center doubl blind portion short time period gener reduc variabl allergen exposur time period random shortest period feasibl given size trial variabl weather mani patient par may concomit sar therefor help par efficaci trial conduct time relev season allergen less abund therefor less like influenc trial result contain nonbind recommend 7 b inclus criteria follow gener recommend inclus criteria phase 3 allerg rhiniti trial sar trial older children adolesc adult recommend patient histori sar minimum 2 year trial entri agenc recommend document sensit posit skin test prick intraderm method adequ valid vitro test specif immunoglobulin e ige eg radioallergosorb test rast paper radioimmunosorb test prist relev season allergen geograph area trial within 12 month enrol gener posit skin test defin wheal greater equal 3 millimet mm larger diluent control eryth ema prick test greater equal 7 mm larger diluent control erythema intraderm test posit vitro test determin standard individu refer laboratori posit skin test vitro test specif ige correl allergi histori result accept meet inclus criteria par trial allergi perenni allergen eg dust mite cockroach cat dog mold demonstr trial pa tient prick intraderm skin test use criteria posit adequ valid vitro test specif ige eg rast prist suggest test perform 12 month enrol pat ient relev allergi histori test allergen agenc recommend patient start immunotherapi chang dose approxim 1 month preced enrol trial ideal p atient maintain sa dose throughout trial patient experienc symptom meet exceed appropri minimum level time trial enrol ensur assess sever symptom primari endpoint requir least moder sever major individu symptom defin trial symptom score scale c exclus criteria follow gener recommend ation exclus criteria phase 3 allerg rhiniti trial asthma except mild intermitt asthma 7 lessen confound asthma medic may modifi allerg rhiniti 7 see nation heart lung blood institut nation asthma educ prevent pro gram expert panel report 3 guidelin diagnosi manag asthma http wwwnhlbinihgovhealth proguidelinescurrentasthma guidelinesindexhtm contain nonbind recommend 8 chronic intermitt use inhal oral intramuscular intraven andor potent topic corticosteroid use leukotrien modifi use long act antihistamin prohibit medic inadequ washout period certain drug class follow washout period gener suffici intranas system corticosteroid 1 mon th leukotrien modifi 1 month intranas cromolyn 2 week intranas system decongest 3 day cetirizin fexofenadin loratadin desloratadin hydroxyzin 5 10 day intranas antihistamin 3 day system antihistamin 3 day document evid acut signific chronic sinus determin individu investig chronic use concomit medic eg tricycl antidepress would affect assess effect inv tigat product histori hypersensit product excipi presenc rhiniti secondari caus presenc ocular herp simplex cataract intranas corticosteroid trial histori glaucoma intr anas corticosteroid anticholinerg trial plan travel outsid trial area substanti portion trial period blind allerg rhiniti trial base subject endpoint blind critic consider process ensur blind investig product describ protocol doubl blind possibl rational provid along discuss mean reduc elimin bia topic n asal formul descript differ appear activ placebo treatment protocol eg differ devic odor characterist formul help determin adequaci trial blind contain nonbind recommend 9 e formul dosag regimen sponsor encourag provid inform protocol specif formul use market product placebo along descript dose regimen recommend dose rang confirmatori trial use bemarket product sponsor address safeti effect studi formul bridg bemarket formul bridg one formul anoth propos inform formul composit trial lot includ final report respect product f evalu follow gener recommend trial assess phase 3 allerg rhiniti trial 1 assess patient complianc protocol final report provid inform complianc investig product use determin document throughout trial noncompli dealt 2 assess rescu medic use rescu medic allow trial protocol document rescu medic use analyz differ treatment group recommend inclus section clinic tr ial report present rescu medic use differ treatment group 3 rate system prefer measur efficaci allerg rhiniti trial patient self rate instantan reflect total nasal symptom score summ score gener includ follow four nasal symptom rhinorrhea nasal congest nasal itch sneez rate 0 3 scale sever addit delet symptom total score appropri base mech anism action chang discuss review divis patient rate score prefer primari measur effect common allerg rhiniti rate system use clinic trial follow 0 3 scale 0 absent symptom signsymptom evid 1 mild symptom signsymptom present minim awar easili toler 2 moder symptom definit awar signsymptom bothersom toler contain nonbind recommend 10 3 sever symptom si gnsymptom hard toler caus interfer activ daili live andor sleep regardless score system chosen detail descript symptom rate scale provid patient includ inst ruction proper complet symptom diari definit differ categori scale 8 4 record score agenc recommend patient instruct record symptom score diari least often daili ose interv collect reflect symptom score ie evalu symptom sever predefin time period 12 hour instantan symptom score ie evalu symptom sever immedi next dose recommend reflect symptom score assess overal degre effect prespecifi time interv wherea instantan score assess effect end ofdos interv use assess onset action 5 advers event record recommend advers event record daili patient diari record addit elicit trial staff clinic visit vi data analysi issu symptom core symptom score collect baselin daili cours trial collect baselin symptom score sever day immedi preced patient random permit evalu baselin compar variou treatment arm well determin treatment effect time appropri primari efficaci endpoint chang baselin reflect total nasal symptom score tnss averag entir doubl blind treatment period 2 week sar 4 week par depend drug class evalu tnss defin total score compos least three follow four nasal symptom rhinorrhea nasal congest nasal itch sneez inclus nasal congest tnss may appropria te intranas corticosteroid decongest may appropri antihistamin anticholinerg cromolyn like agent appropri key secondari endpoint chang baselin instantan tnss across doubl blind treatment period assess appropri dose interv 8 see guidanc industri patient report outcom measur use medic product develop support label claim contain nonbind recommend 11 develop program demonstr signific differ product placebo end dose interv averag across doubl blind treatment p eriod design allerg rhiniti protocol sponsor encourag numer defin clinic meaning chang primari efficaci endpoint provid rational select statist section protocol includ power calcul use valu nd shoul prospect discuss miss data handl analysi plan particular protocol defin primari estimand ie primari measur treatment effect estim ate clinic trial justifi estimand estim minim plausibl assumpt furthermor recommend continu collect efficaci safeti data treatment discontinu rescu medic use faci litat evalu treatment polici estimand addit evalu effect product entir doubl blind period addit data present help evalu effect includ present morn ing even symptom score separ reflect instantan symptom assess present efficaci data first day trial separ reflect instantan symptom assess data present also separ morn even score allow assess onset action present efficaci data week individu reflect instantan symptom assess allow determ inat onset action durabl respons cours clinic trial present efficaci data individu compon symptom score compris total symptom complex patient rate physician rate measur includ secondari efficaci endpoint exampl assess ocular symptom associ allerg rhiniti may applic certain product patient rate reflect instantan total ocular symptom score similar symptom score system use nasal symptom use support inclus relev inform label inform diseas specif qualiti oflif measur also consid inclus label anti cipat r eplic data least two trial support inclus measur label b onset action definit onset action allerg rhiniti product point patient might reason expect see meaning decreas allerg rhiniti symptom purpos allerg rhiniti first time point initi treatment product demonstr greater chang baselin n primari efficaci endpoint compar contain nonbind recommend 12 placebo treatment prove durabl point end propos dose interv onset action inform may includ label least two trial recommend support particular onset action claim use assess onset action develop regardless propos claim two trial ident design evalu sar par onset action larg pd issu number differ trial design use follow three type use 1 standard phase 3 allerg rhiniti efficaci trial symptom score data collect frequent first day 2 singl dose parallel group placebo control trial patient park set patient expos relev outdoor season allergen follow dose nasal symptom evalu hourli basi 3 inhal chamber trial also known environment exposur unit eeu previous asymptomat patient expos relev allergen gener season allergen ragwe control indoor set follow dose nasal symptom evalu hourli basi onset ction data come three design howev eeu andor park trial use support onset action claim shorter onset action seen phase 3 trial agenc recommend result replic co nsider independ inform due shorter durat trial restrict set manner conduct case inform onset action deriv phase 3 trial use support appr oval also includ propos packag insert along data park chamber trial reflect real world set treatment trial vii fix dose combin product addit gener principl outlin 21 cfr 30050 regard develop fix dose combin product consider allerg rhiniti combin product includ follow contribut monotherapi compon support replic appropriatel design conduct trial combin product compar compon treatment differ compon combin product clinic meaning statist signific efficaci safet dose dose regimen individu compon establish ie monotherapi compon test effect dose dose regimen contain nonbind recommend 13 local act topic product pharmaceut differ combin product nd compon may obscur comparison combin product compon use clinic trial result commerci avail compar may appropri purpos factori compari ponsor like need develop monotherapi compar product specif purpos combin product develop program patient alreadi fail one compon combin product exclud unless scientif justif except given complex develop program fix dose local act combin product sponsor encourag discuss detail monotherapi compon trial design view divis earli develop program 
[Document -5]cancer clinic trial elig criteria patient organ dysfunct prior concurr malign guidanc industri us depart health human servic food drug administr oncolog center excel center drug evalu research cder center biolog evalu research cber juli 2020 clinicalmed cancer clinic trial elig criteria patient organ dysfunct prior concurr malign guidanc industri addit copi avail offic commun divis drug inform center drug evalu research food drug administr 10001 new hampshir ave hillandal bldg 4th floor silver spring md 20993 0002 phone 8555433784 301 7963400 fax 3014316353 email druginfofdahhsgov httpswwwfdagovdrugsguid complianc regulatori informationguid drug andor offic commun outreach develop center bi olog evalu research food drug administr 10903 new hampshir ave bldg 7 1 rm 3128 silver spring md 20993 0002 phone 8008354709 240 4028010 email ocodfdahhsgov httpswwwfdagovvaccin blood biologicsguid complianc regulatori inform biologicsbiolog guidanc us depart health human servic food drug administr oncolog center excel center drug evalu research cder center biolog evalu research cber juli 2020 clinicalmed contain nonbind recommend tabl content introduct 1 ii background 2 iii recommend 3 patient organ dysfunct 3 1 renal function recommend 3 2 cardiac function recommend 4 3 hepat function recommend 5 b patient prior con current malign 5 contain nonbind recommend 1 cancer clinic trial elig criteria patient organ dysfunct prior concurr malign guidanc industry1 guidanc repres current think food drug administr fda agenc topic establish right person bind fda public use altern approach satisfi requir applic statut regul discuss altern approach contact fda offic respons guidanc list titl page introduct guidanc one seri guidanc provid recommend regard elig criteria clinic trial drug biolog products2 regul cder cber treatment cancer 3 specif guid anc includ recommend regard inclus patient organ dysfunct prior concurr malign guidanc intend assist stakehold includ sponsor institut review board respons developm ent oversight clinic trial clinic trial elig criteria inclus exclus essenti compon trial defin characterist studi popul variabl investig drug trial object elig criteria develop take consider mechan action drug target diseas patient popul anticip safeti investig drug avail adequ safe ty data abil recruit trial particip patient popul meet object clinic trial howev elig criteria becom commonli accept ti use templat across trial without clear sc ientif clinic rational unnecessarili restrict elig criteria may slow patient accrual limit patient access clinic trial 1 guidanc prepar oncolog center excel center drug evalu research cder center biolog evalu research cber food drug administr 2 purpos guidanc refer drug drug biolog product includ drug approv section 505 feder food drug cosmet act 21 usc 355 biolog product licens section 351 public health servic act 42 usc 262 3 topic three guidanc relat elig criteria patient human immunodefici viru hepat b viru hepat c viru infect pat ient brain metastas regard minimum age consider inclus pedi atric patient contain nonbind recommend 2 lead trial result fulli repres treatment effect patient popul ultim use drug45 broaden cancer trial elig criteria maxim generaliz trial result abil understand therapi benefit risk profil cross patient popul like use drug clinic practic consid avoid jeopard patient safeti trial design methodolog approach import consider enrol broader popul ad dress elsewhere67 address guidanc consider specif enrol patient organ dysfunct prior concurr malign gener fda guidanc document establish legal enforc abl respons instead guidanc describ agenc current think topic view recommend unless specif regulatori statutori requir cite use word agenc guidanc mean hat someth suggest recommend requir ii background patient organ dysfunct often exclud clinic trial regardless knowledg metabol pathway excretori rout investig drug lifespan gener popul increas thu includ increas number patient comorbid renal diseas cardiac diseas hepat dysfunct addit lifespan gener popul increa es greater number patient anticip prior concurr malig nanci exclud individu cancer clinic trial major organ dysfunct previou concurr cancer trial recruit may favor younger patient may fulli repres popul drug indic design cancer clinic trial includ patient organ dysfunct prior concurr malign includ inform label promot safe effect use product across broad er patient popul like use drug clinic practic 4 beaver ja ison g pazdur r 2017 reevalu elig criteria balanc patient protect particip oncolog trial nejm 3761504 1505 5 kim e bruinoog robert et al 2017 broaden elig criteria make clinic trial repres american societi clinic oncolog friend cancer research joint research statement jco 3533 3737 3744 6 see draft guidanc industri enhanc divers clinic trial popul elig criteria enrol practic trial design june 2019 final guidanc repres fda current think th topic updat guidanc period recent version guidanc check fda guidanc web page httpswwwfdagovregulatori informationsearch fdaguid document 7 jin pazdur r sridhara r 2017 evalu elig criteria oncolog clinic trial analysi investig new drug applic 2015 jco 3533 3745 3752 contain nonbind recommend 3 iii recommend thought consider given potenti inclus patient organ dysfunct prior concurr malign cancer clinic trial follow recommend elig criteria patient organ dysfunct cancer clinic trial focu renal function cardiac function hepat function guidanc also includ recommend elig criteria patient cancer prior concurr malign patient organ dysfunct pharmacokinet pk major rout elimin human well understood reason enrol patient rel preserv organ function primarili renal hepat cancer clinic trial data toxic includ nonclin clinic toxic pk pharmacodynam pd becom avail drug develop protocol revis includ patient compromis organ function safe paramet regard dosag adjust determined8 1 renal function recommend elig criteria base contemporari wide accept clinic applic equat estim glomerular filtrat rate measur glomerular filtrat rate rather absolut serum creatinin concentr equ ation use particular patient popul remain consist throughout investig drug develop process sponsor provid adequ justif inclusionexclus patient variou degre renal impairm nt base stage product develop safeti profil product understand effect renal impair elimin drug safeti studi procedur patient renal impair patient renal impair includ trial investig drug avail nonclin clinic data indic inclus patient renal impair would place patient unreason risk andor adequ st ep taken mitig potenti risk expect system exposur increas patient renal dysfunct inclus patient may facilit prospect dose adjust produc similar system exposur seen patient rel preserv kidney function9 8 lichtman harvey r smit et al 2017 modern ize clinic trial elig criteria recommend american societi clinic oncolog friend cancer research organ dysfunct prior concurr malign comorbid work group jco 3533 3753 3759 9 public worksh op evalu inclus exclus criteria clinic trial workshop report juli 2018 workshop date april 16 2018 avail httpswwwfd anewscomextresourcesfiles201808 2218 fdasummarypdf1534970149 access june 23 2020 contain nonbind recommend 4 sponsor address need time studi evalu effect dialysi drug clearanc need dosag adjust patient dialysi adequ represent patient vari degre renal impair well data suffici adequ describ impact renal impair pk drug popul pharmacokinet poppk analys data phase 2 phase 3 clinic trial may suffici character impact renal function 2 cardiac function recommend inclus patient cardiovascular dysfunct may possibl avail nonclin clinic data includ pk pd data indic inclus patient expos unreason risk patient signific clinic cardiac abnorm eg clinic heart failur unstabl angina exclud especi earli phase studi inclus criteria requir investig assess potenti particip risk heart failur valid clinic classif system eg new york heart associ function classif eject fraction e f measur ef measur either echocardiographi multig acquisit scan accept deter mine cardiac ef elig criteria purpos qtc prolong 10 sponsor assess effect drug qtc earli clinic develop sponsor determin whether maximum qtc interv necessari clinic trial elig criteri base whether specif known risk qtc prolong either non clinic eg herg clinic trial data 10 see ich guidanc industri e14 clinic evalu qtqtc interv prolong proarrhythm potenti non antiarrhythm drug octob 20 05 ich guidanc industri e14 clinic evalu qtqtc inter val prolong proarrhythm potenti non antiarrhythm drug question answer r3 june 2017 addit inform regard qtc prolong contain nonbind recommend 5 3 hepat function recommend unlik organ system liver biochem test provid suffici evid adequ liver drug metabol function e stimat hepat function incorpor clinic variabl well function laboratori valu child pugh model end stage liver diseas score system 1112 adopt marker hepat metabol dedic pk studi hepat metabol may also influenc cancer inflamm even set normal score gaug hepat drug transf ormat capac pre exist liver diseas well epidemiolog genet environment histor variabl eg chronic alcohol use past histori advers drug reaction ascertain impair hepat blood flow part icular portal hypertens ev ident critic assess liver metabol drug inclus patient sever hepat impair discuss fda patient mild moder hepat impairment13 defin equival nation cancer institut common terminolog criteria advers event nci ctc ae grade 1 toxic well aspart transaminas ast alanin transaminas alt elev defin grade 3 nci ctcae 5 20 x uln upper limit normal may asymptomat abl toler dose equival patient normal hepat function inclus patient mild moder hepat impair may appropri avail nonclin clinic data includ pk pd data indic inclus patient present unreason risk patient b patient prior concurr malign patient prior malign differ tumor type patient concurr malignanc i differ tumor type refer prior conc urrent malign guidanc whose natur histori treatment potenti interfer safeti efficaci assess investig drug gener elig enrol clinic trial exampl initi dose find preliminari activ estim proof ofconcept studi patient histori prior concurr malign exclud 11 see guidanc industri pharmacokinet patient impair hepat function studi design data analysi impact dose label may 2003 12 see protoco l templat organ dysfunct studi updat februari 5 2020 nci criteria avail httpsctepcancergovprotocoldevelopmenttemplatesappl htm access june 23 2020 13 talal ah venuto cs youni 2017 assess hepat impair implic pharmacokinet substanc use treatment clin pharmacol drug dev 6 206 212 
[Document -6]clinic trial endpoint approv cancer drug biolog guidanc industri us depart health human servic food drug administr oncolog center excel center drug evalu research cder center biolog evalu research cber decemb 2018 clinicalmed clinic trial endpoint approv cancer drug biolog guidanc industri addit copi avail offic commun divis drug inform center drug evalu research food drug administr 10001 new hampshir ave hillandal bldg 4th floor silver spring md 20993 0002 phone 855 5433784 301 7963400 fax 301 4316353 email druginfofdahhsgov httpswwwfdagovdrugsguidancecomplianceregulatoryinformationguidancesdefaulthtm andor offic commun outreach develop center biolog evalu research food drug administr 10903 new hampshir ave bldg 71 room 3128 silver spring md 20993 0002 phone 8008354709 240 4028010 email ocodfdahhsgov httpswwwfdagovbiologicsbloodvaccinesguidancecomplianceregulatoryinformationguidancesdefaulthtm u depart health human servic food drug administr oncolog center excel center drug evalu research cder center biolog evalu research cber decemb 2018 clinicalmed contain nonbind recommend tabl content introduct 1 ii background 2 statutori regulatori requir effect 2 b endpoint support past approv oncolog 3 iii gener endpoint consider 4 overal surviv 7 b endpoint base tumor assess 7 1 diseas free surviv event free surviv 8 2 object respons rate 9 3 complet respons 9 4 time progress progress free surviv 10 5 time treatment failur 11 c endpoint involv symptom assess 11 1 specif symptom endpoint 11 2 problem encount symptom data 12 blood bodi fluid base biomark 12 e emerg endpoint 12 iv clinic trial design analysi consider 13 singl arm studi 13 b random studi design demonstr noninferior 13 c trial design radiotherapi protect chemotherapi protect 14 clinic trial design consider 14 e clinic trial analysi issu 14 v conclus 15 appendix independ review tumor en dpoint 16 contain nonbind recommend 1 clinic trial endpoint approv cancer drug biolog guidanc industry1 guidanc repres current think food drug administr fda agenc topic establish right pe rson bind fda public use altern approach satisfi requir applic statut regul discuss altern approach contact fda offic respons guidanc li ted titl page introduct guidanc provid recommend applic endpoint cancer clinic trial submit food drug administr fda support effect claim new drug applic nda biolog licens applic bla supplement applications2 also provid background inform discuss gener regulatori principl endpoint discuss guidanc drug treat patient exist cancer3 guidanc address endpoint drug prevent decreas incid cancer guidanc revis final guidanc titl publish may 2007 guidanc replac may 2007 guidanc titl gener fda guidanc document establish legal enforc respons instead guidanc describ agenc current think topic view recommend unless specif regulatori statutori requir cite use word agenc guidanc mean someth suggest recommend requir 1 guidanc prepar oncolog center excel center drug evalu research cder center biolog evalu research cber food drug administr 2 purpos guidanc refer drug includ human drug biolog product unless otherwis specifi 3 see guidanc industri clinic trial endpoint approv non small cell lung cancer drug biolog recommend specif non small cell lung cancer clinic trial see guidanc industri patholog complet respons neoadjuv treatment high risk earli stage breast cancer use endpoint support acceler approv recommend specif high risk earli stage breast cancer updat guidanc period make sure recent versio n guidanc check fda w eb page guidanc mention document avail bio logic guidanc w eb page httpwwwfdagovbiologicsbloodvaccinesguidancecomplianceregulatoryinformationguidancesdefaulthtm andor drug guidanc web p age httpwwwfdagovdrugsguidancecomplianceregulatoryinformationguidancesdefaulthtm contain nonbind recommend 2 ii background clinic trial endpoint serv differ purpos convent oncolog drug develop earli phase clinic trial evalu safeti identifi evid biolog drug activ tumor shrinkag endpoint later phase efficaci studi commonli evalu whether drug provid clinic benefit prolong surviv improv symptom follow section discuss gener regulatori requir efficaci influenc endpoint select approv cancer drug later section describ endpoint detail discuss whether might serv measur diseas activ clinic benefit variou clinic set statutori regul requir effect requir new drug show effect base 1962 amend feder food drug cosmet act fdc act law requir substanti evid effect specifi eviden ce must deriv adequ well control clinic investig similarli public health servic act requir biolog product safe pure potent4 clinic benefit support drug approv includ import clinic outcom eg increas surviv symptomat improv also includ effect surrog endpoint known predict clinic benefit eg blood pressur acceler approv regul 21 cfr part 314 subpart h 21 cfr part 601 subpart e promulg 1992 allow use addit endpoint approv drug biolog product intend treat seriou life threaten diseas gener demonstr improv avail ther api provid therapi none exist set fda may grant approv base effect surrog endpoint reason like predict clinic benefit5 surrog endpoint less well establish surrog endpoint tradit approv blood pressur cardiovascular diseas fda may also grant acceler approv base effect clinic endpoint measur earlier irrevers morbid mortal reason like predict effect irrevers morbid mortal clinic benefit ie intermedi clinic endpoint6 drug approv acceler approv regul condit manufactur conduct clinic studi verifi describ actual clinic benefit7 postmarket studi fail demonstr clinic benefit applic demonstr due dilig conduct requir studi among reason fda ay withdraw approv drug indication8 follow discuss term tradit approv denot longstand rout drug approv base demonstr clinic benefit effect surrog endpoint 4 potenc long interpret includ effect 21 cfr 6003 5 section 506c1b fdc act 21 cfr 314510 60141 provid agenc may consid epidemiolog therapeut pathophysiolog evid determin whether endpoint reason like predict clinic benefit food drug administr safeti innov act 2012 provid fda may consid epidemiolog pathophysiolog therapeut pharmacolog evid develop use biomark exampl scientif method tool see guidanc industri expedit program seriou condit drug biolog 6 see guidanc industri expedit program seriou condit drug biolog 7 comprehens discuss condit acceler approv discuss condit approv see guidanc industri expedit program seriou condit drug biolog 8 see section 506c3 fdc act 314530a 60143a contain nonbind recommend 3 known predic clinic benefit term distinguish acceler approv associ use surrog endpoint intermedi clinic endpoint reason like predict clinic benefit support drug approv evid need establish effect discuss guidanc industri provid clinic evid effect human drug biolog product guidanc industri fda approv new cancer treatment use market drug biolog product mani case least two adequ well control clinic investig need certain case evid singl adequ well control clinic investig confirmatori evid suffici eg case singl multicent studi provid highli reliabl statist strong evid import clinic benefit fda may consid data one adequ well control clinic investig con firmatori evid substanti evid fda determin data evid suffici establish effectiveness9 exampl drug approv treatment patient specif stage particular malign evid one adequ well control clinic investig confirmatori evid may suffici support efficaci supplement treatment differ stage cancer b endpoint support past approv oncolog tradit approv applic show direct evid clinic benefit improv surrog endpoint known predict clinic benefit oncolog surviv improv consid appropri measur clinic benefit addit ponsor use endpoint cancer drug approv 1970 fda usual approv cancer drug base object respons rate orr determin tumor assess radiolog test physic examin earli 1980 discuss oncolog drug advisori committe odac fda determin cancer drug approv base direct evid clinic benefit improv surviv improv patient qualiti life impr ove physic function improv tumor relat symptom benefit may alway predict correl orr time larger improv tumor reduct delay tumor growth seen tumor measur endpoint use support tradit acceler approv improv diseas free surviv df support drug approv select adjuv set larg proport patient expect cancer symptom time recurr durabl complet respons support tradit approv leukemia complet respons cr associ less infect bleed blood product support larg improv progress free surviv pf high substanti durabl orr use support tradit approv select malign magnitud effect relief tumor relat symptom drug toxic also consid make approv decision101112 exampl random trial 9 see section 505d amend food rug administr modern act 1997 10 blumenth gm pg klu etz j schneider kb goldberg ae mckee r pazdur 2017 oncolog drug approv evalu endpoint evid era breakthrough therapi oncologist 227 762 767 11 blumenth gm r pazdur 2016 respons rate approv endpoint oncolog back futur jama oncol 26 720 721 12 oshaughnessi witt et al1991 commentari concern demonstr safeti efficaci investig anticanc agent clinic trial j clin oncol 92225 2232 contain nonbind recommend 4 hormon drug breast cancer singl arm trial drug ros1 posit metastat nonsmal cell lung cancer use orr endpoint support traditiona l approv improv tumor relat symptom conjunct improv orr adequ respons durat support tradit approv sever clinic set surrog endpoint acceler approv must reason like predict clinic benefit fdc act 506c1a 21 cfr part 314 subpart h 21 cfr part 601 subpart e durabl orr use tradit approv endpoint circumst orr also commonli use surrog e ndpoint support acceler approv tumor respons wide accept oncologist guid cancer treatment orr directli attribut drug effect singl arm trial conduct patient refractori tumor availa ble therapi exist provid accur assess orr whether tumor measur orr pf use acceler approv tradit approv endpoint depend diseas context magnitud effect among factor see section iiib2 4 iii gener endpoint consider section provid overview gener issu cancer drug develop discuss commonli use cancer endpoint follow discuss pertin issu canc r clinic trial design use endpoint see guidanc referenc footnot 3 regard nonsmal cell lung cancer high risk earli stage breast cancer detail discuss diseas endpoint discuss section includ overal surviv endpoint base tumor assess eg df event free surviv ef orr cr time progress ttp pf endpoint involv symptom assess blood bodi fluid base biomark emerg endpoint tabl 1 2 provid comparison endpoint cancer drug approv mani issu relat proper analysi efficaci endpoint address ich guidanc industri e9 statist principl clinic trial recommend regard use placebo blind random control clinic trial describ draft guidanc industri hematolog malign oncolog diseas consider use placebo bli nding random clinic trial drug product develop 13 cancer patient caregiv experi provid uniqu insight contribut import patient prefer inform identifi relev clinic trial endpoint ultim inform medic product develop program best meet patient need recommend stakehold collect submit patient experi data14 relev inform patient caregiv medic product develop regulatori decis make describ draft guidanc industri fda staff stakehold patient focus drug develop collect ing comprehens repres input 15 13 final guidanc repres fda current think topic address 14 21st centuri cure act httpswwwcongressgov114plawspubl255plaw 114publ255pdf 15 final guidanc repres fda current think topic address contain nonbind recommend 5 tabl 1 comparison import cancer approv endpoint note tabl sever oncolog endpoint serv differ purpos ie clinic endpoint repres clinic benefit tradit approv surrog endpoint support tradit approv surrog endpoint support acceler approv base specif context use determin base specif diseas highli depend upon factor effect size effect durat depth respons eg number cr avail therapi diseas set locat diseas clinic consequ delay prevent diseas progress delay administr toxic therapi risk benefit relationship see text detail see section v regard recommend obtain fda feedback endpoint protocol design endpoint type endpoint studi design recommend clinic endpoint surrog endpoint ta surrog endpoint aa random singl arm independ blind review overal surviv x x symptom endpoint patient report outcom x x diseas free surviv event free surviv x x x x x object respons rate x x x x x x complet respons x x x x x x progress free surviv time progress x x x x x ta tradit approv aa acceler approv alway recommend contain nonbind recommend 6 tabl 2 advantag disadvantag import cancer approv endpoint endpoint advantag disadvantag overal surviv easili precis measur gener base object quantit assess may affect switch control treatment subsequ therapi need longer followup includ noncanc death symptom endpoint patient report outcom gener assess earlier smaller sampl size compar surviv studi blind import assess endpoint potenti subject assess bia particularli open label studi lack valid instrument mani diseas area definit vari among studi balanc time assess among treatment arm critic diseas free surviv event free surviv gener assess earlier smaller sampl size compar surviv studi gener base object quantit assess potenti subject assess bia particularli open label studi definit vari among studi balanc time assess among treatment arm critic includ noncanc death object respons rate gener assess earlier smaller sampl size compar surviv studi effect tumor attribut drug natur histori gener base object quantit assess definit vari among studi frequent radiolog assess may alway correl surviv complet respons gener assess earlier smaller sampl size compar surviv studi effect tumor attribut drug natur histori gener base object quantit assess definit vari among studi frequent radiolog assess may alway correl surviv progress free surviv time progress gener assess earlier smaller sampl size compar surviv studi measur stabl diseas includ gener base object quantit assess potenti subject assess bia particularli openlabel studi es definit vari among studi frequent radiolog assess balanc time assess among treatment arm critic may alway correl surviv contain nonbind recommend 7 overal surviv overal surviv defin time random death caus measur intent totreat popul surviv consid reliabl cancer endpoint studi conduct adequ assess survi val usual prefer endpoint endpoint precis easi measur document date death bia factor endpoint measur surviv improv analyz risk benefit analysi assess clinic benefit overal surviv evalu random control studi data deriv extern control trial seldom reliabl time toevent endpoint includ overal surviv appar differ outcom extern control current treatment group aris differ drug treatment includ patient select improv imag techniqu improv support care random studi minim effect known unknown differ provid direct outcom comparison demonstr statist signific improv overal surviv consid clinic signific toxic profil accept often support new drug approva l difficulti perform analyz surviv studi includ long follow period larg trial subsequ cancer therapi potenti confound surviv analysi b endpoint base tumor assess section discuss sever endpoint base tumor assess mani cancer type radiograph umor assess direct ly measur compon diseas tumor measur commonli trigger treatment decis clinic prac tice therefor tumor measur base endpoint consid clinic relev biomark tumor measurebas endpoint may support either tradit clinic endpoint repres clinic benefit surrog endpoint tradit approv acceler approv includ df ef orr cr ttp pf tumor assess endpoint select includ two judgment first determin whether endpoint may support either acceler approv tradit approv ascertain second endpoint evalu potenti bia uncertainti drug applic use studi reli tumor assess endpoint sole evid efficaci may need confirmatori evid second trial accuraci measur tumor differ among tumor set tumor measur use orr determin imprecis locat lack demarc margin eg pleural periton mesothelioma pancreat cancer brain tumor primari studi endpoint base tumor measur eg pf orr tumor assess gener verifi central review blind studi treatment see appendix ascertain lack assess bia addit detail regard data collect list guidanc industri clinic trial endpoint approv non small cell contain nonbind recommend 8 lung cancer drug biolog appendix a16 altern random sampl base blind central review audit approach could use detail audit plan prespecifi includ strategi detect potenti assess bia bia exclud base upon audit blind central review radiograph imag necessari 17 sponsor seek fda input prior conduct audit base central review central independ verif tumor assess endpoint especi pf df may necessari random trial blind unless advers event profil would substanti unblind trial practic effect size robust larg random trial sensit analysi support lack investig bia 1 diseas free surviv event free surviv gener df defin time random diseas recurr death caus frequent use endpoint adjuv set defi nitiv surgeri radiotherapi df also import endpoint larg percentag patient achiev cr chemotherapi although overal surviv convent endpoint adjuv set df import endpoint situat surviv may prolong make overal surviv endpoint impract endpoint similar df differenti random take place definit surgeri radiotherapi adjuv set ef purpos guidanc ef defin time random follow event progress diseas preclud surgeri local distant recurr death due caus df primari basi approv adjuv breast cancer hormon therapi adjuv colon cancer adjuv cytotox breast cancer therapi wherea ef appropri endpoint evalu neoadjuv breast cancer therapi given prior definit surgeri compar standard cytotox therapi hormon therapi carri minim al side effect thu favor risk benefit relationship treatment effect measur df ef surrog endpoint support acceler approv surrog endpoint support tradit approv repres direct clinic benefit base specif diseas context use magnitud effect diseas set avail therapi risk benefit relat hip decemb 2003 odac consensu df prolong repres clinic benefit magnitud benefit outweigh toxic adjuv treatment may 2004 odac recommend df consid clinic endpoint colon cancer drug surgic adjuv set 18 df use tradit approv diseas breast cancer colorect cancer gastrointestin stromal tumor melanoma renal cell carcinoma import consider evalu df ef potenti endpoint includ estim size treatment effect proven benefit standard therapi protocol 16 appendic guidanc industri clinic trial endpoint approv non smal l cell lung cancer drug biolog regard tumor measur data collect pf analysi also appli broadli oncolog endpoint use conjunct guidanc need 17 discuss juli 24 2012 odac meet transcript avail httpswaybackarch itorg799320170403224012httpswwwfdagovadvisorycommitteescommitteesmeetingmaterialsdrugsoncolo gicdrugsadvisorycommitteedefaulthtm 18 transcript avail httpswaybackarch itorg799320170403224012httpswwwfdagovadvi sorycommitteescommitteesmeetingmaterialsdrugsoncolo gicdrugsadvisorycommitteedefaulthtm contain nonbind recommend 9 care delin definit df ef schedul followup assess visit unschedul assess occur mani reason differ studi arm frequenc time reason unschedul assess introduc bia bia minim blind patient investig tr eatment assign appropri applic definit df ef studi complic particularli death note without prior tumor progress document event score either diseas recurr censor event although method statist analysi death limit consid death caus recurr minim bia df ef overestim use definit especi patient die long period without observ bia introduc frequenc long term follow visit dissimilar studi arm dropout random toxic analys count cancer relat death df ef event censor noncanc death method introduc bia attribut caus death furthermor method censor observ patient whether death last visit assum patient censor bservat risk recurr patient noncensor observ yet experienc event 2 object respons rate orr defin proport patient tumor size reduct predefin amount minimum time period respons durat usual measur time initi respons document tumor progress gener fda defin orr sum partial respons plu cr defin manner orr direc measur drug antitumor activ evalu singlearm studi stabl diseas compon orr stabl diseas reflect natur histori diseas wherea tumor reduct direct therapeut effect also stabl diseas accur assess ttp pf analysi see section iiib4 avail standard criteria use ascertain respons varieti respons criteria consid appropri eg revis recist guidelin version 11 19 respons criteria predefin protocol start studi signific orr assess magnitud durat percentag cr treatment effect measur orr surrog endpoint support acceler approv surrog endpoint support tradit approv repres direct clinic benefit base specif diseas context use magnitud effect number cr durabl respons diseas set locat tumor avail therapi riskbenefit relationship 3 complet respons cr defin detect evid tumor cr gener measur imag studi eg ct can histopatholog assess eg bone marrow biopsi breast cancer resect specimen treatment effect measur cr surrog endpoint support acceler approv surrog endpoint support tradit approv repres direct clinic benefit base specif diseas context use magnitud 19 eisenhau ea p therass j bogaert lh schwartz sargent r ford et al 2009 new respons evalu criteria solid tumour revis recist guidelin version 11 eur j cancer 452228 247 contain nonbind recommend 10 effect effect durat diseas set locat diseas avail therapi risk benefit relationship hematolog malign acut leukemia cr use clinic endpoint tradit approv earli high risk breast cancer patholog cr pcr use surrog endpoint acceler approv 4 time progress progress free surviv ttp pf serv primari endpoint drug approv ttp defin time random object tumor progress ttp includ death pf defin time random object tumor progress death whichev occur first precis definit tumor progress import care detail protocol compar ttp pf prefer regulatori endpoint pf includ death thu better correl overal surviv ttp analysi death event censor either time death earlier visit repres inform censor nonrandom pattern loss studi pf assum death event randomli relat tumor progress pf reflect tumor growth assess determin surviv benefit determin confound subsequ therapi given sampl size magnitud effect pf larger effect overal surviv data usual insuffici allow robust evalu correl effect overal surviv pf cancer trial often small proven surviv benefit existi ng drug gener mo dest treatment effect measur pf surrog endpoint support acceler approv surrog endpoint support tradit approv repres direct clinic benefit base specif diseas context use magnitud effect diseas set locat metastat site avail therapi risk benefit relationship clinic consequ delay prevent progress key diseas site eg delay new lesion brain spine delay administr toxic therapi import care defin tumor progress criteria protocol standard regulatori criteria defin progress applic use varieti differ criteria includ recist criteria broad outlin present publish pf criteria supplement addit detail protocol statist analysi plan sap progress data collect multipl sourc es includ physic exam unschedul visit radiolog scan variou type differ time data collect assess visit limit specifi short time interv around schedul visit difficulti aris determin event date censor date data collect prolong time period recommend assign progress date earliest time progress observ without prior miss assess censor date last radiolog assess determin lack progress guidanc ndustri clinic trial endpoint approv nonsmal cell lung cancer drug biolog appendic c provid set tabl pote ntial analys pf use primari sensit analys plan pf data collect analysi discuss fda endof phase 2 meet contain nonbind recommend 11 5 time treatment failur time treatment failur ttf defin composit endpoint measur time random discontinu treatment reason includ diseas progress treatment toxic death ttf gener recommend regulatori endpoint new molecular entiti drug appr oval c endpoint involv symptom assess symptomat improv consid clinic benefit fda drug approv use patient symptom assess andor physic sign repres symptomat improv eg weight gain decreas effus import efficaci endpoint improv sign symptom clinic outcom assess coa use efficaci endpoint support cancer drug approv symptom assess due cancer rather drug toxic extent possibl 1 specif symptom endpoint symptom improvementpalli direct measur clinic benefit rather surrog endpoint decreas sever cancer symptom use support tradit approv anti cancer agent anti tumor activ also demonstr use symptom palliat endpoint requir popul symptomat baselin problemat mani cancer trial patient often asymptomat baselin endpoint also subject open label respons bia magnitud well describ time progress cancer symptom endpoint similar ttp also direct measur clinic benefit rather potenti surrog endpoint discuss earlier problem measur progress eg miss assess also exist evalu time symptomat progress cancer trial blind symptom assess also subject respons bia delay tumor progress onset cancer symptom occur often altern treatment initi achiev symptom endpoint confound analysi addit tumor symptom difficult differenti drug toxic composit symptom endpoint symptom scale compon similar clinic import analysi contribut compon submit primari analysi overal composit endpoint exampl composit symptom scale includ sever import symptom myelofibrosi myelofibrosi symptom assess fo rm 20 exampl composit endpoint clinic event exist patient cancer metastas skeleton drug approv base delay time skelet relat event defin patholog fractur radiat therapi bone surgeri bone spinal cord compress 20 deisseroth e kamiska j grillo w chen h sabe r hl lu et al 2012 us food drug administr approv ruxolitinib treatment patient intermedi high risk myelofibrosi c lin cancer re 1812 3212 7 contain nonbind recommend 12 select appropri popul critic document symptom benefit patient symptomat studi baselin evalu categor symptom respons analysi asymptomat patient baselin time tofirstsymptom analysi use although approach limit intermitt miss data discontinu studi drug prior symptomat progress 2 problem encount symptom data miss data infrequ assess complic evalu symptom data particularli time deterior analys procedur put place maxim complet rate trial conduct statist analysi plan outlin miss data handl data collect support multipl symptom endpoint address prospect regard multipl hypothes test necessari statist adjust specifi sap addit inform use patientreport outcom found guidanc industri patient report outcom measur use medic product develop support label claim blood bodi fluid base biomark gener b iomark assay blood bodi fluid serv primari endpoint cancer drug approv although paraprotein level measur blood urin use part myeloma respons criteria durabl major molecular respons surrog endpoint use tradit approv therapi chronic myelogen leukemia fda accept bloodbas marker element composit endpoint occurr certain clinic event signific decreas perform statu bowel obstruct conjunct mark increas ca125 consid progress ovarian cancer patient addit bloodbas biomark use identifi prognost factor select patient stratif factor consid studi design e emerg endpoint addit endpoint discuss section fda recogn advanc scienc facilit develop oncolog product may also result identif addit endpoint may use support approv oncolog product exampl minim residu diseas 21 use surrog endpoint acceler approv therapi acut lymphoblast leukemia meta tasisfre surviv use clinic endpoint tradit approv therapi non metastat castrat resist prostat cancer sponsor plan use emerg endpoint clinic develop program recommend discuss use applic fda divis offic prior initi trial see section v 21 see draft guidanc industri hematolog malign regulatori consider use minim residu diseas develop drug biolog product treatment inform assist sponsor planni ng use minim residu diseas support market approv drug biolog product treatment specif hematolog malign final guidanc repres fda current think topic address contain nonbind recommend 13 iv clinic trial design analysi consider per 21 cfr 314126 fda approv drug base substanti evid efficaci adequ well control investig describ regul studi must allow valid comparison control must provid quantit assess drug effect 22 reliabl method demonstr efficaci show statist signific improv clinic meaning endpoint random control trial ie superior follow section discuss approach may indic random control trial demonstr superior feasibl ethic sponsor plan use one approach recommend discuss use applic fda divis offic prior initi trial see section v ingl arm studi set avail therapi major tumor regress presum attribut test drug fda sometim accept orr respons durat observ singl arm studi substanti evid support acceler approv respons rate use set acut leukemia tradit approv cr associ decreas tran sfusion requir decreas infect increas surviv singl arm trial adequ character time event endpoint overal surviv df ef ttp pf variabl natur histori mani ms cancer random studi necessari evalu timetoev endpoint b random studi design demonstr noninferior noninferior ni trial demonstr new drug effect show new drug l ess effect standard regimen activ control prespecifi amount noninferior margin 23 noninferior margin clinic accept loss larger effect activ control drug standard regimen well character clinic benefit surviv benefit new drug inferior activ control noninferior margin presum ineffect ni trial reli extern ly control histor data establish activ control treatment effect size cancer trial effect frequent adequ character ni trial also reli constanc assumpt assumpt includ activ control effect remain constant extern control studi current studi assum constanc patient popul characterist support care measur evalu techniqu current trial extern control data f rom activ control effect deriv estim size activ control treatment effect base compr hensiv meta analysi extern control studi studi reliabl reproduc activ control effect compar placebo arm 22 see 21 cfr 314126b2 7 23 see guidanc industri non inferior clinic trial establish effect see also ich guidanc industri e10 choic control group relat issu contain nonbind recommend 14 difficulti conduct ni trial includ estim activ control effect determin amount effect ni margin retain ni trial usual involv larg sampl size compar superiorit trial involv replic clinic trial result furthermor subsequ therapi crossov activecontrol arm confound ni analysi ni trial endpoint overal surviv orr problemat c trial design radiotherapi protect chemotherapi protect radiotherapi protect chemotherapi protect drug design amelior toxic therapi trial usual two object first assess amelior cancer treatment toxic second object determin whether anticanc activ compromis protect second object usual examin earlier endpoint exampl orr pf rather overal surviv clinic trial design consider methodolog assess measur analyz endpoint detail protocol sap visit radiolog assess applic symmetr two studi arm prevent systemat bia fda applic agre prospect follow item applic final item initi studi extent possibl studi design definit progress sap methodolog handl miss data censor method data record case report form crf oper procedur independ endpoint review committe irc applic see appendix e c linic trial anali issu miss data complic endpoint analysi endpoint base tumor assess protocol defin adequ assess visit patient ie visit schedul tumor assess done analysi plan outlin comparison adequaci follow treatment arm methodolog analyz incomplet andor miss follow visit censor method specifi protocol analysi plan specifi pri mari analysi one sensit analys evalu robust result although analys miss data problemat result strengthen similar result primari sensit analys applic evalu includ number death patient lost follow prolong time period exampl imbal death could bia pf measur overestim pf treatment arm less follow contain nonbind recommend 15 v conclus although gener principl outlin guidanc help applic select endpoint market applic recommend applic meet fda submit protocol intend support nda bla market applic fda ensur meet includ multidisciplinari fda team oncologist statistician clinic pharmacologist extern expert consult need applic submit protocol meet request special protocol assess ment provid confirm accept endpoint protocol design support drug market applic 24 ultim cours market approv depend design clinic trial fda review result data studi drug market applic 24 see guidanc industri special protocol assess contain nonbind recommend 16 appendix independ review tumor en dpoint clinic trial result support drug approv verifi applic food drug administr fda object respons r ate orr determin singl arm studi evalu review limit number imag drug approv base measur progress free surviv pf care plan minim bia enabl applic fda verifi result independ endpoint review committe irc minim bia radiograph interpret radiolog find independ adjud assess clearli written plan charter outlin irc fu nction process independ review charter place initi studi plan describ assur committe independ procedur collect storag transport result charter also includ resolut differ interpret incorpor clinic data final interpret data audit procedur use irc discuss guidanc industri develop medic imagi ng drug biolog product part 3 design analysi interpret clinic studi 
[Document -7]guidanc industri expedit program seriou condit drug biolog us depart health human servic food drug administr center drug evalu research cder center biolog evalua tion research cber may 2014 procedur omb control 09100765 expir date 05312020 note expir date updat 09212017 see addit pra statement section x guidanc guidanc industri expedit program seriou condit drug biolog addit copi avail offic commun divis drug inform wo51 room 2201 center drug evalu research food drug administr 10903 new hampshir ave silver spring md 20993 phone 3017963400 fax 3018478714 druginfofdahhsgov httpwwwfdagovdrugsguidancecomplianc egulatoryinformationguidancesdefaulthtm andor offic commun ou treach develop center biolog evalu research food drug administr 10903 new hampshir ave wo71 room 3128 silver spring md 20993 phone 8008354709 2404027800 ocodfdahhsgov httpwwwfdagovbiologicsbloodvaccinesguidancec omplianceregulatoryinformationguidancesdefaulthtm us depart health human servic food drug administr center drug evalu research cder center biolog evalua tion research cber may 2014 procedur contain nonbind recommend tabl content introduct 1 ii background 1 iii concept expedit program 2 seriou condit 2 b avail therapi 3 c unmet medi cal need 4 iv overview expedit program 7 v fast track design 9 qualifi criteria fast track design 9 b featur fast track design 9 vi breakthrough therap design 10 qualifi criteria breakthrough therapi design 10 b featur breakthrough therapi design 13 vii acceler approv 15 qualifi criteria acceler approv 16 b acceler approv endpoint 17 c evidentiari criteria acceler approv 19 condit acceler approv 2 2 viii prioriti review design 24 qualifi criteria prioriti review design 24 b featur prioriti review design 25 ix gener consider 25 manufactur product qualiti consider 25 b nonclin consider 26 c clinic inspectio n consider 27 companion diagnost 27 x paperwork reduct act 1995 27 appendix 1 process fast track breakthrough therapi prioriti review design 28 process fast tr ack design 28 b process breakthrough therapi design 30 contain nonbind recommend ii c process prioriti view design 33 appendix 2 process fo r roll review 35 agreement propos 35 b portion applic e ligibl earli submiss 35 c submiss user fee 36 commenc review 36 e calcul review time 36 contain nonbind recommend 1guidanc industry1 expedit program seriou co ndition drug biolog guidanc repres food drug administrati on fda current think topic creat confer right pe rson oper bind fda public use altern approach approach satisfi requir applic statut regul want discuss alterna tive approach contact fda staff respons implement guidanc identifi appropri fda staff call appropri number list titl page guidanc introduct follow four fda program intend facilit exp dite develop review new drugs2 address unmet medic need treatment seriou life threatening3 condit fast track design brea kthrough therapi design ation acceler approv prioriti review design see section iv overview program purpos guidanc industri prov ide singl resourc fo r inform fda polici procedur four program well threshol criteria gener applic conclud drug candid th ese expedit develop review program fda guidanc document includ guid anc establish legal enforc respons instead guidanc describ th e agenc current thinki ng topic view recommend unless spec ific regulatori stat utori requir cite use word agenc guidanc mean someth suggest recommend requir ii background program describ guidanc intend help ensur therapi seriou condit approv avail patien ts soon conclud therapi benefit justifi risk ag enci first formal articul think expedit avail promis new therap i regul codifi part 312 subpart e 21 cfr part 312 4 subpart e regul intend speed avail new therapi patient seriou condit especi ther e satisfactori altern therapi preserv appropri standard safeti effect regul 1 guidanc prepar center drug evalu research cder cooper center biolog evalu research cber food drug administr 2 purpos guidanc refer drug drug product includ human drug biolog drug product regul cder cber unless otherwis specifi 3 1 whether condit seriou explain ferenc seriou condit includ lifethreaten condit 4 food drug administr interim rule investig new drug antibiot biolog drug product regul procedur drug intend treat life threaten sever debilit ill 53 fr 41516 octob 21 1988 contain nonbind recommend 2call earlier attent drug pr omis treat c ondit includ earli consult fda sponsor pr oduct effici tr ial design potenti reli wellcontrol phase 2 studi evid effect subpart e regul specif recogn patient physician gener will accept greater risk side effect treatment lifethreaten nd sever debilit diseas would diseas four pr incip program support principl fast track design breakthr ough therapi design acceler approv prioriti review design refer guidanc agenc expedit program fda histori appli philosophi lie subpart e drug rare diseas use agenc expedit program fda recogn ce rtain aspect drug develop feasibl common diseas may feasibl rare diseas develop challeng often greater increas rariti diseas fda continu appli flexibl situati on address particular challeng pose diseas iii concept expedit program program subject guida nce fast track designa tion breakthrough therapi design acceler approv pr ioriti review summar section iv describ individu detail section v vi vii viii four expedit program repres effort address unmet medic need treatment seriou condit discuss follow paragraph seriou condit 1 whether condit seriou fda intend interpret term seriou done past purpos acceler approval5 expand access investig drug treatment use6 seriou diseas condit defin expand access regul follow diseas condit associ morbid substanti impact daytoday fu nction shortliv self limit morbid usual suffici morbid need irrevers persist recurr whether diseas condit seriou matter clinic judgment base impact factor surviv daytoday function likelihood diseas left untreat progress less sever condit seriou one 7 5 food drug administr final rule new drug antibiot biolog drug product regul acceler approv 57 fr 58942 ecemb 11 1992 food drug administr propos rule new drug antibiot biolog cal drug product regul acceler approv 57 fr 13234 april 15 1992 6 part 312 subpart 7 21 cfr 312300b1 contain nonbind recommend 3 note purpos guidanc term condit diseas ill use interchang condit meet de finit lifethreaten set forth 31281a would also seriou condit 2 whether drug intend treat seriou condit referenc section iv statutori regulatori el igibl criteria expedit program requir drug tend treat seriou condit satisfi criterion drug must intend effect se riou condit seriou aspect condit direct effect seriou manifest ation symptom condit intend effect includ follow diagnost product intend improv diagno detect seriou condit way would lead improv outcom product intend mitig prevent se riou treatmentrel side effect eg seriou infect patient ceiv immunosuppress therapi product intend avoid diminish seri ou advers event associ avail therapi seriou condit eg product less cardiotox avail cancer therapy8 product intend prevent seriou c ondit reduc th e likelihood condit progress seriou condi tion advanc stage diseas b avail therapi purpos guidanc fda gener consid avail therapi term exist treatment exist therapi therapi approv licens unit state indic consid new drug9 relev current us standa rd care soc indic 8 sponsor consid expedit drug develop design program drug intend avoid seriou advers event associ avail therapi diminish sever aw need provid data directli support effect correspond th e level evid need meet qualifi criteria relev design program eg phase 3 data demonstr lower incid sever seriou advers reaction compar ava ilabl therapi prioriti review th e requisit data may difficult obtain earli develop particularli purpos breakthrough therapi design 9 may substanti number approv therapi vari relev seriou diseas current treat unit state includ therapi longer use use rare except case treatment approv th e indic use fd aregul eg surgeri consid avail therapi case fda may consid unapprov unlicens therapi constitut avail therapi safeti effect use support compel evid includ extens evid publish literatur eg certain wellestablish oncolog treatment contain nonbind recommend 4 fda avail therapi determin gener focus treatment option reflect current soc specif indi cation includ diseas stage product develop evalu current soc fda consid recommend authorit scientif bodi eg nation comprehen ive cancer network american academi neurolog base clinic eviden ce reliabl inform reflect current clinic practic drug develop program targ et subset broader diseas popul eg subset identifi gene tic mutat soc br oader popul one gener consid avail therapi fo r subset unless evid soc less effect subset cours new drug develop forese soc given condit may evolv eg approv new therapi new inform avail therapi fda determin constitut avail therapi time relev regulatori decis expedit program sponsor intend use eg gener earli develop fast track breakthrough ther api design time biolog licens applic bla new drug pplicat nda submiss fo r prioriti review design bla nda review acceler approv al fda encourag sponsor discuss avail therapi consider agen cy interact fda appropri fda may consult special govern employe expert make avail therapi determin determin whether drug grant accel rate approv approv risk evalu mitig strategi rem clude element assur safe use etasu section 5051 feder food drug nd cosmet act fdc act 21 usc 355 1 consid avail therapi follow principl appli drug would consid avail th erapi drug grant acceler approv base surrog endpoint termedi clinic endpoint clinic benefit verifi postapprov studi see section iiic3 drug would consid avail therapi drug grant acceler approv restrict distribut studi popul new drug develop elig receiv pprove drug restrict distribut program similarli drug would consid ed avail therapi studi popul new drug develop eligib le receiv approv drug etasu rem c unmet medic need unmet medic need condit whose treatment diagnosi address adequ avail therapi unm medic need includ immedi need defin popul ie treat seriou condit limit treatment longerterm need societi eg ddress develop resist antibacteri drug contain nonbind recommend 5 1 avail therapi availabl e therapi seriou c ondit clearli unmet medic need 2 avail therapi avail therapi exist condit ne w treatment gener w ould consid address unmet medic need treatment effect seriou outcom c ondit known influenc avail therapi eg progressi disabl diseas pr ogress avail therapi shown effect symptom shown effect progress disabl diseas progress improv effect seriou outcom condit compar avail therapi eg superior th e new drug avail therapi either use alon combin availa ble therapi ie demon trate addon studi effect seriou outcom condi tion patient unabl toler fail respond avail therapi use effect critic agent combin avail therapi provid efficaci compar av ailabl therapi 1 avoid seriou toxic occur avail thera py 2 avoid less seriou toxic common caus discontinu treatment seriou condit 3 reduc potenti harm drug interact provid safeti efficaci compar availabl e therapi document benefit improv complianc expect lead improv seriou outcom address emerg anticip public health need drug shortag diseas set drug shown provid direct effica cy safeti advantag avail therapi may nonethel ess provid advantag would suffici public health benefit qualifi meet unmet medic need exampl condit approv therapi mode st respons rate signific heterogen respons drug novel echan action comparab le safeti effect could potenti provid advantag avail th erapi patient case novel mechan action wellunderstood relati onship diseas pathophysiolog addit rea onabl basi conclud signific number patient may respond differ th e new drug compar avail therapi thu mechanist divers even without document efficaci safeti advantag could contain nonbind recommend 6advantag diseas set drug becom less effect ineffect time exampl infecti diseas drug target ed cancer therapi novel mechan action although appear efficaci sim ilar avail therapi across diseas popul could benefit patient longer respond avail therapi accordingli fda intend consid rang potenti advantag availa ble therapi beyond shown headtohead comparison 3 avail therapi approv acceler approv program base surrog endpoint intermedi clinic endpoint clinic benefit yet verifi discuss section vii iiib fda recogn gener tter prefer one treatment approv acceler approv provis possibl clinic benefit may rifi postapprov co nfirmatori trial fda therefor consid product address unmet medic need approv treatment grant acceler approv base surrog endpoint intermedi clinic endpoint clini cal benefit veri fie postapprov studiescontain nonbind recommend 7iv overview expedit program tabl provid overview four expedit program addit detail specif program found section follow note drug develop program may qualifi one expedit program comparison fda expedit program seriou condit fast track breakthrough therapi acceler approv prioriti review natur program design design approv pathway design refer section 506b fdc act ad section 112 food drug administr modern act 1997 fdama amend section 901 food drug administr safeti innov act 2012 fdasia section 506a fdc act ad section 902 fdasia 21 cfr part 314 subpart h 21 cfr part 601 subpart e section 506c fdc act amend section 901 fdasia prescript drug user fee act 1992 qualifi criteria drug intend treat seriou condit nonclin clinic data demonstr potenti address unmet medic need drug design qualifi infecti diseas producta drug intend treat seriou condit preliminari clinic evid indic drug may demonstr substanti improv clinic signific endpoint avail therapi drug treat seriou condit gener provid meaning advantag avail therapi demonstr effect surrog endpoint reason like predict clinic benefit clinic endpoint measur earlier irrevers morbid mortal imm reason like predict effect imm clinic benefit ie intermedi clinic endpoint applic origin efficaci supplement drug treat seriou condit approv would provid signific improv safeti effect supplement propos label chang pursuant report pediatr studi 505a b applic drug design qualifi infecti diseas product c applic supplement drug submit prioriti review voucher contain nonbind recommend 8comparison fda expedit program seriou condit fast track breakthrough therapi acceler approv prioriti review natur program design design approv pathway design submit request ind ideal later prebla pre nda meet ind ideal later endofphas 2 meet sponsor ordinarili discuss possibl acceler approv review divis develop support exampl use plan endpoint basi approv discuss confirmatori trial usual alreadi underway time approv origin bla nda efficaci supplement timelin fda respons within 60 calendar day receipt request within 60 calendar day receipt request specifi within 60 calendar day receipt origin bla nda efficaci supplement featur action expedit develop review roll review intens guidanc effici drug develop organiz commit roll review action expedit review approv base effect surrog endpoint intermedi clinic endpoint reason like predict drug clinic benefit shorter clock review market applic 6 month compar 10month standard review addit consider design may rescind longer meet qualifi criteria fast trackf design may rescind longer meet qualifi criteria breakthrough therapyg promot materi confirmatori trial verifi describ anticip effect imm clinic benefit subject expedit withdraw design assign time origin bla nda efficaci supplement file titl viii fdasia gener antibiot incent gain provid incent develop antibacteri antifung drug human use intend treat seriou life threaten infect gain drug may design qualifi infecti diseas product qidp meet criteria outlin statut drug receiv qidp design elig statut fast track design prioriti review howev qidp design beyond scope guidan ce b supplement appl icat section 505 fdc act propo se label chang pursuant report pe diatric studi section shall consid prioriti review supplement per section 505a fdc act amend sectio n 5b best pharmaceut children act c see footnot applic supplement submit prioriti review voucher assign prioriti review prioriti view voucher grant applic applic drug th e treatment prevent certain tropic diseas defin section 524a3 a4 fdc act treatment rare pediatr disea es defin section 529a3 th e fdc act e part commit pdufa v fda establish review model program program appli new molecular entiti nda origin bla includ pplicat resubm it follow refusetofil action receiv oct ober 1 2012 septemb 30 2017 applic file fd program pdufa review clock begin conclus 60 calendar day file review period begin date fda r eceipt origin submiss f sponsor may also withdraw fast track design design longer support emerg data drug deve lopment program longer pursu see section a5 appendix 1 g sponsor may also withdraw breakthrough th erapi design design longer support emerg data drug develop program longer pursu see section b5 appendix 1 contain nonbind recommend 9v fast track design section 506b fdc act provid design drug fast track product intend whether alon comb inat one drug treatment seriou lifethreaten diseas condit demon trate potenti address unmet medic need diseas condit provis intend facilit develop expedit review drug treat seriou lifethreaten condit approv product reach market expediti section describ qualifi criteria featur fast track design appendix 1 describ process fast track design qualifi criteria fast track design fast track design appli drug either alon co mbinat drug specif use studi term drug refer combin two drug combin subject fast track designa tion request appropri fda may grant design de velop new use approv drug 1 seriou condit see section iiia 2 demonstr potenti address unmet medic need type inform need demonstrat e potenti dr ug address unmet medic need depend stage drug de velop fast track design request earli develop evid activ nonclin model mechanist rational pharmacolog data could use demonstr potenti later develop avail clinic data demonstr po tential address unmet medic need see section iiic b featur fast track design 1 action expedit de velop review opportun frequent interact review team fast track product includ meet fda includ pr eind meet endofp hase 1 meet endofphas 2 meet discuss studi design extent safeti data requir support approv doserespons concern use biomark meet may schedul appropri eg discuss acceler approv structur content nda critic issu addit product could elig prioriti review support clinic data time bla nda e fficaci supplement submiss see section viii contain nonbind recommend 102 submiss portion applic roll review fda determin preliminari evalu clinic data submit sponsor fast track product may effect ag enci may consid review portion market applic sponsor submit complet applic see appendix 210 vi breakthrough therapi design section 506a fdc act provid de signat drug breakthrough therapi drug intend alon combina tion 1 drug treat seriou lifethreaten disea e condit prelim inari clinic evid indic drug may demonstr substanti improv exist therapi 1 clinic signific endpoint substanti treatment effect observ earli clinic develop import recogni ze standard breakthrough therapi design standard dr ug approv clinic evid need support breakthrough design preliminari contrast case drug fda review full data submit support approv drug design breakthrough therapi determin whether drug safe effect intend use approv market section describ qualifi criteria featur breakthrough therapi design appendix 1 describ process breakthrough therapi design product design breakthrough ther api ultim shown substanti improv avail therapi uggest preliminari clinic evid time design design longer support subsequ data fda may rescind design 11 fda commit signific resourc work particularli close sponsor breakth rough therapi product agenc need focu resourc breakthrough therapi drug deve lopment program continu meet program qualifi criteria see section b5 appendix 1 qualifi criteria brea kthrough therapi design breakthrough therapi design ap pli drug either alon combin drug specif use studi term drug refer combin two drug co mbinat subject breakthrough therapi design request appropri fda may grant designa tion develop new use approv drug 1 seriou condit see section iiia 10 section 506d1 fdc act 11 sponsor complet develop program th e product may still suffici evid support market approv contain nonbind recommend 112 exist avail therapi see section iiib 3 preliminari clinic evid unlik inform coul support fast track design wh ich could includ theoret rational mechanist rational base nonclin data evid nonclin activ breakthrough therapi design requi re preliminari clinic evid treatment effect may repres substanti improv availa ble therapi treatment seriou condit purpos br eakthrough therapi design preliminari clinic evid mean evid suffici indicat e drug may demonstr substanti improv effect safeti av ailabl therapi case suffici establish safeti effect fo r purpos approv fda expect evid gener would deriv phase 1 2 trial nonclin inform could support clinic evid enc drug activ case preliminari clinic evid demonstr drug may repres ubstanti improv avail therapi involv suffici number patient consid cred ibl howev fda recogn data expect definit time design ideal preliminari clinic evid indica ting substanti improv avail therapi would deriv studi comp are investigationa l drug avail therapi placebo avail therapi clinic test studi compar new treatment plu soc soc alon fda encourag sponsor obtain preliminari compar data type earli develop type clinic data also could persua sive includ singlearm studi co mpare new treatment welldocu histor experien ce gener fda expect histor control data would persuas larg differ new treatment histor experi exampl lung function declin jor manifest diseas singlearm studi data show new drug signifi cantli increas lung function could persuas avail therapi increas lung function data demonstr cancer drug substanti increas overal respons rate compar histor control eg histor al respons rate avail therapi consider durat respons also could persuas sponsor contempl use histor control consult f da ich guidanc industri e10 choic control group relat issu clinic trial moredetail discuss 12 4 may demonstr substantia l improv clinic signific endpoint 12 updat guidanc period make sure recent version guidanc check fda drug guidanc web page httpwwwfdagovdrugsguidancecomplianc egulatoryinform guidancesdefaulthtm biolog guidanc web page httpwwwfdagovbiolog bloodvaccinesguidancecomplianceregulat oryinformationguidancesdefaulthtm contain nonbind recommend 12to support breakthrough therapi design pr eliminari clinic evid enc must show drug may demonstr substanti improvem nt avail therapi one clinic signifi cant endpoint substanti improv determin whether th e improv avail therapi substanti matter judgment depe nd magnitud drug effect clinic signific endpoint whi ch could includ durat th e effect import observ effect treatment seriou condit seriou asp ct condit gener preliminari clinic evid show clear adva ntage avail therapi approach demonstr substan tial improv includ follow direct comparison new drug availa ble therapi show much greater import respons eg complet respons control treatment gener result partial respons trial could conduct treatmentnav patient whose diseas fail spond avail therapi either comparison fail therapi ethi calli accept notreat control studi avail therapi new drug show substanti clinic meaning effect import outcom compar placebo well document histor control new drug ad avail therapi resu lt much greater import respons compar avail therapi control studi welldocu histor control tr ial also could conduct treatmentnav patient whose diseas fail re pond avail therapi new drug substanti clinic meaning effect underli caus diseas contrast avail therap i treat symp tom diseas preliminari clinic evid enc indic drug like diseas modifi effect long term eg su stain clinic benefit compar temporari clinic benefit provi ded avail therapi new drug revers inhibit diseas pr ogress contrast avail therapi provid symptomat improv new drug import safeti advantag e relat seri ou advers reaction eg may result treatment interru ption compar avail therapi similar efficaci clinic signific endpoint purpos breakthr ough therapi design fda consid clinic sign ific endpoint gener refer endpoi nt measur effect irrevers morbid mortal imm symptom repres seriou consequ diseas also refe r find suggest effect imm seriou symptom includ contain nonbind recommend 13 effect establish surrog endpoint typic woul use support tradit approv effect surrog endpoint intermedi clinic endpoint see section viib2 consid reason like predict c linic benefit ie th e acceler approv standard significantli improv safeti profil compar ed avail therapi eg less dose limit toxic oncolog agent evid similar efficaci breakthrough therapi designatio n request sponsor provi de justif endpoint find consid clinic signific rare case pharmacodynam pd biomark may consid cl inic signific endpoint strongli suggest th e potenti clinic mean ing effect underli diseas case sponsor provid evid supporti ng use pd biomark evid includ ex ampl 1 extent understand diseas pathophysiolog 2 whether biomar ker causal pathway diseas process 3 time cours drug e ffect biomark eg biomark measur earlier surrog endpoint us ed acceler approv addit strong evid drug effect pd biomark gener expect fda like reli pd biomark breakthrough therapi de signat diseas se tting avail therapi ev idenc support use b featur breakthr ough therapi design 1 intens guidanc effici drug develop program begin earli phase 1 discuss previous breakthrough therapi design usual mean effect drug larg compar availabl e therapi case develop program breakthrough therapi could consider shorter drug intend treat diseas studi howev fda note compress drug develop program still must gener adequ data demonstr drug safe effect meet statut ori standard approv 13 omit compon drug develop program necessari determin significantli delay even preclud market approv sponsor design effici clinic trial number way fda seek ensur sponsor product design breakthrough thera py receiv time advic interact commun help sponsor design conduct drug develop program 13 section 505d fdc act section 351a public health servic act contain nonbind recommend 14effici possible14 interact ag enci may suggest sponsor may propos altern clinic tr ial design eg adapt design enrich strategi crossov nof1 design use histor control use interim analysi data monitor committee15 trial design may result smaller trial effici trial requir less time complet may help minim number patient expos potenti less efficaci treatment ie co ntrol group treat avail therapi approach may especi use st udi rare diseas exampl singlearm trial may import option rare di seas wellund tood pathophysiolog welldefin diseas cours fda anticip review team sponsor meet interact throughout drug develop address import ssue differ phase develop addit sponsor prepar rapid pace aspect drug develop eg manufactur see section ixa develop necessari companion diagnost see section ixd 2 organiz commit involv senior manag fda intend expedit develop review breakthrough therapi intens involv senior manag e xperienc review regul health project manag staff proactiv collabor crossdisc iplinari review appropri fda also intend assign crossdisciplinar project lead review team facilit effici review drug develop program cr ossdisciplinari project lead serv scientif liaison memb er review team eg medic clinic pharmacolog pharmacologytoxicolog chemistri manufact ure control cmc complianc biostatist facili tate coordin intern interacti on commun sponsor review divis regul atori health project manag 3 submiss portion applic roll review fda determin appropri drug design breakthrough therapi abl obtain roll review therefor fda determin preliminari evalu clinic data submit sponsor br eakthrough therapi product effect agenc may consid review portion rkete applic sponsor submit complet applic see appendix 2 4 action expedit review 14 note ix gener consid erat import sponsor respond promptli fda inquiri may includ exampl request inform variou aspect drug develop program 15 discuss altern clinic trial design see draft guidanc industri adapt design clinic trial drug biolog draft guidanc industri enrich strategi clinic trial support approv human drug biolog product final guidanc repres fda current think topic see also ich e10 guida nce clinic trial sponsor establish oper clinic trial data monitor committe contain nonbind recommend 15in addit product could elig prioriti review support clinic data time bla nda efficaci supplement submiss vii acceler approv acceler approv provis fdasia section 506c fdc act provid fda may grant acceler approv product seriou lifethr aten diseas condit upon determin product effect surrog endpoint reason like predict clinic benef clinic endpoint measur earlier irrevers morbid mortal reason like predict effect irrevers morbid mortal oth r clinic benefit ta king account sever rariti preval condit avail lack altern treatment drug grant acceler appr oval postmarket confirmatori trial requir verifi describ anticip eff ect imm c linic benefit see section viid2 viid3 16 section describ qualifyi ng criteria relev term condit acceler approv provis fdasia facilit mewhat broader use acceler approv expedit patient access import treatment seriou condit fda believ new provis provid addit flex ibil concern implic avail therapi elig acceler approv see section viia2 also provid clarif concern use clinic e ndpoint herein refer int rmediat clinic endpoint basi acceler approv see section viib2 addit new provis make clear fda author consid pharmacolog evid develop use biomark scientif method tool conjunct data determin whether endpoint rea onabl like predict clin ical benefit see section viic 17 indic fda take account sever rariti preval condit consid whether gran acceler approv fdasia reinforc agenc longstand commit regulatori flexibl regard evid requir support product approv treatment seriou lifeth reaten diseas limit therapeut option acceler approv pathway use prim arili set diseas cours long extend period time would quir measur tend clinic benefit drug exampl acceler approv b een use extens approv drug treat varieti cancer human immunod ficienc viru hiv di seas effect 16 section 506c2a fdc act 17 section 506c1b fdc act 21 cfr 314510 60141 provid agenc may consid epidemiolog therapeut pathophysiolog evid determin whether endpoint reason like predict clinic benefit fdasia provid fda may consid epidemiolog pathophysiolog therapeut pharmacolog evid develop use biomark exampl scientif method tool contain nonbind recommend 16on tumor growth viral load ca n assess rapidli demonstr ate effect surviv morbid gener requir lengthi sometim larg trial durat typic diseas cours accelerat ed approv also potenti us eful acut diseas set intend clinic bene fit demonstr larg studi clinic event would need evalu demonstr clin ical benefit occur rare exampl acceler approv could use acut condit effect surrog endpoint could shown small num ber patient much larger studi would need show effect clinic outcom surviv fda encourag sponsor commun th e agenc earli develop concern potenti elig drug accelerat ed approv propos surrog endpoint intermedi clinic en dpoint clinic trial design plan nd conduct confirmatori trial sponsor seek acceler approv also need prepar rapid pace aspect drug develop eg manufactur see section ixa develop necessari companion diagnost see section ixd qualifi criteria acceler approv time product grant acceler approv fda dete rmine effect endpoint use support approvala surrog e ndpoint intermedia te clinic endpointi reason like predict clinic benefit princip risk ap proach possibl patient expos drug u ltimat shown provid actual clinic benefit addit ther e gener fewer smaller shorter clinic trial typic drug receiv tr adit approv may gener mean less inform occurr rare dela yed advers event uncertainti whether clinic benefit verifi possibi liti undiscov risk primari reason acceler approv reserv drug intend treat seriou condit appear provid meaning dvantag avail therapi 1 seriou condit see section iiia 2 meaning advantag ver avail therapi acceler approv regul state acceler approv avail drug provid meaning therapeu tic benefit exist treatments18 acceler approv provis section 901 fdasia amend section 506 fdc act requir fda take account availa biliti lack alt rnativ treatment amend section 506c clarifi agenc flexibl administ acceler approv program exampl altern therapi efficaci compar avail therapi differ mechan action could ad clinic al valu diseas set signific number patient may respond differ new therapi discuss unmet medic need section iiic2 provid exampl situat 18 21 cfr 314500 60140 contain nonbind recommend 17which drug could shown provid meaning advantag avail therapi includ may demon trate direct efficaci safeti advantag section iiib describ constitut avail therapi determin whether drug provid meaning advantag 3 demonstr effect endpoint reason like predict clinic benefit endpoint discuss section viib basi determin whether endpoint reason like predict clinic al benefit discuss section viic b acceler approv endpoint two type endpoint use basi acceler approv 1 surrog endpoint consid reason like predict clin ical benefit 2 clinic endpoint measur earlier th imm reason like predict effect imm c linic benefit also see section viid2 purpos guidanc categori e ndpoint refer surroga te endpoint intermedi clinic endpoint respect clinic endpoint characterist ic variabl directli easur therapeut effect drugan effect patient feel eg symptom relief function eg improv mobil surviv clinic benefit posit therapeut effect clinic meaning context given diseas clinic nefit must weigh treatment risk determin whether overal nefit patient ie posit ive benefitrisk profil 1 surrog endpoint purpos acceler approv surrog endpoint marker laboratori measur radiograph imag physic sign measur thought predict clinic benefit measur c linic benefit dependi ng strength evid support abil marker predict clinic benefit marker may surrog endpoint known predict clinic benefit va lidat surrog endpoint could use tradit approv surrog endpoint reasonab ly like predict drug intend clinic benefit coul therefor use basi acceler approv marker insuffi cient evid support relianc marker either kind surrog e ndpoint therefor use support tradit acceler approv rkete applic exampl surrog endpoint fda us ed support acceler approv includ follow prolong suppress hiv viral load plasma shown reduc morbid mortal associ hiv diseas basi contain nonbind recommend 18tradit approv shorterterm suppress viral load use past surrog support ac celer approv co nsider reason like predict effect morbid mortalit data demonstr shortterm suppress viral load may support fu approv circumstances19 clearanc bacteria blood stream evidenc laboratori measur bacteria blood consid reason like pr edict clinic resolut infect outcom 6month followup treatment e sputum cultur statu infect relaps rate c onsid reason like predict resolut pulmonari tuberculosi decreas iron store patient iron overload caus thalassemia consid reason like predict de creas transfusionrel advers event caus iron overload bodi radiograph evid tumor shrinkag r espons rate certain cancer type consid reason like predict improv overal surviv 2 intermedi clinic endpoint purpos acceler approv interm iat clinic endpoint measur therapeut effect measur earl ier effect imm consid reason like predict drug effect imm cl inic benefit import question whether demonstr therapeuti c effect alon would basi tradit approv approv product seriou c ondit base clinic endpoint imm usual consid tradit appr oval procedur approv base clinic endpoint consid th e acceler approv pa thway essenti determin effect imm clinic benefit order confirm predict clinic benefit led approv although fda limit experi acceler approv base intermedi c linic endpoint fda believ intermedi clinic endpoint gener could use support accel ate approv ituat studi demonstr rel shortterm clinic benefit chronic diseas set assess durabl clinic benefit essenti tradit approv shortterm benefit consid rea onabl like predic longterm benefit clinic endpoint demonstr clinic benefit rea onabl like predict effect imm diseas set essenti confirm effect imm eg avail therapi ha establish effect imm 19 see draft guidanc industri human immunodefici virus1 infec tion develop antiretrovir drug treatment final guidanc repres fda current think topic contain nonbind recommend 19exampl case fda use intermedi clinic endpoint support acceler approv includ follow treatment multipl sclerosi approv base larg therapeut effect relaps rate approxim 13 mont hs treatment uncertainti durabl obser ved effect accel erat approv sponsor requir conti nue exist trial postmarket period confirm durabl observ effect 2 year treatment preterm labor approv base demonstr delay deliveri acceler approv ponsor requir conduct postmarket studi demonstr improv longterm postnat outcom fda grant acceler approv product meet standard tradit approv sponsor consid develop program acceler approv base intermedi clinic endpoint discuss develop program w ith appropri review divis earli drug develop c evidentiari criteria acceler approv drug grant acceler approv must meet th e statutori standard safeti effect grant tradit approv 20 effect standard substanti evid base adequ wellcontrol clinic investigations21 safeti standard suffici inform determin whether drug safe use condit prescrib recommend suggest propos labeling22 acceler approv fda reli particular kind ev idenc drug effect surrog endpoint basi approv fda care evalu evid ensur remain doubt relationship eff ect surrog clinic benefit resolv addit posta pproval studi trials23 applic acceler approv also includ evid propos surr ogat endpoint intermedi clinic endpoint reason like predict th e intend clinic benefit drug determin whether endpoint reason like predict cl inic benefit matter judgment depend biolog plausibi liti relationshi p diseas endpoint desir effect empiri cal evid support relationship empir evid may includ epidem iolog pathophysiolog therapeut pharmacolog evid develop use biomark exampl scientif method tool 24 evid pharmacolog activ alon suffici however25 clinic data provid support conclus lationship effect 20 section 505d fdc act 21 section 505d5 fdc act 22 section 505d1 fdc act 23 57 fr 58942 58948 24 section 506c1b fdc act 25 57 fr 58942 contain nonbind recommend 20surrog endpoint intermedi clinic endpo int effect clinic outcom reason like make judgment whether drug e ffect given endpoint reason like predict clinic benefit fda consid releva nt evid may consult extern expert need guidanc provid overview import factor consid identifi assess predict potenti surrog endpoint intermedi clinic endpoint guidanc howev address specif clinic evid need support conclus particul ar surrog endpoint interm ediat clinic endpoint reason like predict clinic benefit im evid casespecif readili generaliz 1 understand diseas process surrog endpoint often thought measur follow exampl underli caus diseas eg elev ate uric acid gout elev blood pressur hypertens cardiovascular diseas low thyroxin level hypothyroid high ammonia level urea cycl disord effect predict ultim outcom eg tumor shrinkag could expect delay symptomat progress improv su rvival diuresi coul expect improv symptom heart fa ilur effect serum creatin ine glomerular filtrat rate transient revers ar e accept surrog predict effect chronic renal diseas de lay occurr endstag renal diseas state pathophysiolog pathway lead clinic outcom eg low level biomark increas replac miss enzym clot factor case extent pathophysio logi diseas und erstood import factor determin whether en dpoint reason like pr edict clinic benefit diseas process complex multipl pathoph ysiolog causal pathway poorli understood may difficult determin whether effect surrog endpoint repres meaning effect causal pathway fo r exampl reason wellunderstood enzym defici replac defici en zyme reliabl predict clinic benefit contrast enzym deficien cie may involv defect fo r pathophysiolog causal pathway well understood wher e enzym replac measur blood level tissu level reason predict diseas cours treatment result effect wellestablish diseaserel biomark 26 may littl abil predict clinic benefit abil predic benefit may vari depend ing diseas 26 fda cder establish biomar ker qualif program support work extern scientist clinician develop biomark biomark qualif program offer formal process guid submitt develop biomark rigor evalu use regulatori process detail contain nonbind recommend 21intervent exampl patient fever caus infecti diseas fall patient bodi temperatur respons non teroid antiinflammato ry drug predict drug effect diseas howev fa patient bodi temperatur respons antibiot may indicati effect diseas similarli prostat cancer increas level prostatesp ecif antigen psa may sult advanc tumor burden therefor psa may correl progress pro tate cancer risk mortal howev relationship increas psa diseas progress morbid uniform thu abil drug lower psa level necessarili reli upon predict drug clinic benefit 2 understand relationship betw een drug effect diseas process extent drug effect surrog ate endpoint known pr edict effect diseas either effect causal pathway correl clinic outcom critic sometim relationship assess epidemiolog persuas establish know drug affect surrog endpoint also affect clinic outcom thu loweri ng blood pressur shown repeatedli wide varieti drug reduc incid stroke cardiovascular di seas peopl hypertens similarli kill infect bacteria virus l ead cure infecti diseas shrink tumor sustain period lead improv surviv patient cancer surrog endpoint respons ar e thu understood posit effect diseas process exampl factor consid identifi ass ssing surrog endpoi nt thu includ follow whether reliabl consist nt epidemiolog evid support relationship endpoint intend clinic benefit 27 precis epidemiolog relationship endpoint nd clinic outcom defin exampl extent abnorm endpoint correspond wors clinic outcom case fo r blood pressur lo wdensiti lipoprotein ldl cholesterol stronger corr lation abnorm clinic outcom stronger basi conclud th effect endpoint would reason welldefin eff ect clinic outcom whether effect surrog endpoint ha shown predic clinic benefit anoth drug drug factor would gener persuas drug close late pharmacolog class program avail httpwwwfdagovdrugsdevelopmentapprovalpro cessdrugdevelopmenttoolsqualificationprogram ucm284076htm 27 note howev relationship alway pred ict favor effect illustr failur drug effect lower prematur ventri cular beat rate rais highdens lipoprotein hdl cholesterol expect cardiovascular benefit contain nonbind recommend 22 particularli rare diseas th ere may limit inform th e literatur lack indepth epidemiolog histor data littl experi oth r drug inform interpret surrog endpoint interm iat clinic endpoint fda may consult extern expert surrog endpo int intermedi clinic endpoint lack histor data given disease28 condit acceler approv 1 promot materi unless otherwis inform agenc applic must submit agenc consider pr eapprov review period copi promot materi includ promot label well advertis intend dissemin public within 120 day follow market approv 29 120 day follow market approv unless otherwis inform agenc applic must submit promot materi least 30 day prior intend time initi dissemina tion label itial public advertisement30 2 confirmatori trial drug grant acceler appr oval postmarket confirmatori trial requir verifi describ anticip effect imm oth r clinic benefit trial must complet due diligence31 fda interpret due dili genc requir mean postmarket trial intend verifi clinic nefit must conduct promptli facilit determin soon possibl whether clin ical benefit verifi protocol postmarket trial develop earli possibl timelin th e trial specifi exampl timelin enrol trial comp letion stipul ate agreement fda sponsor de sign conduct confirmatori trial clear developmen product intend approv acceler approv basi surrog endpoint intermedi clinic endpoint confirmatori trial underway time market ing applic submit clear shortli submiss mark ting applic surrog endpoint intermedi clinic endpoint propos basi cceler approv agreement design conduct trial approv 28 see exampl section 569a2 b c fdc act consult extern expert rare diseas target therapi genet target treatment describ gener consider consult extern expert topic consultatio n classif speci al govern employe 29 21 cfr 314550 60145 30 21 cfr 314550 60145 31 section 506c3a fdc act 314510 60141 confirmatori trial verifi clinic benefit fda gener termin requir 21 cfr 312560 60146 contain nonbind recommend 23gener confirmatori trial would evalu clinic endpoint th directli measur clinic benefit exampl confirmatori trial popul would ordinarili diseas popul studi support acceler approv case howev commerci avail drug follow accel rate approv may make difficult enrol patient diseas popul case confirmatori trial may conduct differ relat popul capabl verifi predict clinic benefit often case oncolog wher e acceler appr oval drug la testag diseas grant confirmatori trial conduct earlier stage cancer also case addit evalua tion longer durat surrog endpoint use suppor acceler approv rather th clinic endpoint popul could persuas evid c linic benefit ex ampl case hiv treatment effect viral load relati veli short durat 24 week consid reason like predict clinic benefit suppo rting acceler approv effect longer 1 year viral load suppress wa convincingli relat dur abl clinic benefit set lifelong therapi thu use verifi clinic benefit tradit approv 32 possibl use later effect trial verifi effect seen earlier trial support acceler approv clini cal trial use support acceler approv verifi describ clinic benefit case protocol statist analysi plan clearli account anali surrog endp oint data provid support acceler approv w ith continu randomi zed trial obtain data clinic endpoint basi verifi clin ical benefit trial use support acceler approv al verifi clinic benefit data verifi clinic benefit may case nearli complet time acceler approv 3 withdraw acceler approv fda may withdraw approv drug indic approv acceler approv pathway 33 exampl trial requir verifi predict clinic nefit product fail verifi benefit evid demonstr product shown safe effect condit use applic fail conduct requir postapprov trial drug due dilig 32 although effect viral load chang short durat use past surrog endpoint support acceler approv fda consid endpoint accept circumst grant tradit approv base year experi endpoint 33 see section 506c3 fdc act 314530a 60143a part 314 subpart e part 601 subpart h describ addit ground withdraw contain nonbind recommend 24 applic dissemin fals mislead ing promot materi relat product approv drug may withdrawn trial fail verifi clinic benefit demonstr suffici clinic benefit justifi risk ssociat drug eg show significantli smaller magnitud durat benefit wa anticip base observ effect surrog fda determin ground withdr awal agenc may ask applic request withdraw approva l 314150d notifi pplicant fda propos withdraw approv notic opportun hear nooh nooh gener state propos ground withdraw approv 34 upon receipt nooh applic 15 day file written request fo r hear applic request hear within 15 day applic waiv opportun hearing35 applic may also request agenc withdraw approv applic appr ove acceler approval36 viii prioriti review design applic drug recei prioriti review design drug treat seriou condit approv would provid signific improv safeti effect addit specif statutori prov ision provid prioriti review variou type applic describ section iv prioriti design intend direct overal attent resourc evalu su ch applic section describ qualifi criteria featur prioriti review design appendix 1 describ process prioriti review design qualifi criteria prioriti review design 1 seriou condit see section iiia 2 demonstr potenti signific improv safeti effect casebycas basi fda determin time nda bla efficaci supplement file whether propos drug would signific improv safeti effect treatment prevent diagnosi seriou condit signific improv may illustr follow exampl evid increas effect treatm ent prevent diagnosi condit 34 21 cfr 314530b 60143b 35 21 cfr 314530c1 60143c1 36 21 cfr 314150c 6015a contain nonbind recommend 25 elimin substanti reduct treatmentlimit advers reaction document enhanc patient complia nce expect lead improv seriou outcom evid safeti effect new subpopul although evid come clinic trial compar market product investig drug prioriti review design base scientif valid inform gener ther e availa ble therapi see section iiib sponsor compar investig drug avail therapi clinic test ing attempt show superior relat either safeti e ffectiv alternativ eli sponsor could show drug abil effect treat patient unabl toler whose diseas fail respond avail therapi show drug use effect critic agent combin availabl e therapi although show would usual base random trial type cont rol could also persuas exampl histor control 37 b featur prioriti review design prioriti review design mean fda goal take action market applic within 6 month receipt compar 10 month standard review pdufa review clock applic file fda program describ section iv ix gener consider commun agenc critic asp ct expedit program fda strive provid time respons sponsor inquir regard expedit develop program equal critic sponsor respond prom ptli fda inquiries38 appli formal meet relat inquiri written correspond nce interact addit mani type formal meetings39 correspond agenc offer sponsor addit consider sponsor expedit pr ogram highlight section manufactur product qualiti consider sponsor product receiv exp dite drug develop design may need pursu rapid manufactur develop program accommod acceler pace clinic program sponsor product qualiti nd cmc team initi earli 37 sponsor contempl use histor control consult ich e10 moredetail discuss 38 exampl fda may request updat breakthrough therapi design program order provid sponsor guidanc drug develop 39 see guidanc industri formal meet fda sponsor applic also see cder 21st centuri review process desk refer guid access httpwwwfdagovdownloadsaboutfdacentersoffic scdermanualofpoliciesproceduresucm218757htm contain nonbind recommend 26commun fda ensur nufactur develop program time submiss meet agenc expectati on licensur market approval40 sponsor receiv expedit drug developm ent design prepar propos commerci manufactur program w ill ensur avail qualiti product time approv propos consid estim market demand commerci manufactur develop plan th e propos also consid manufactur facil lifecycl approach proce ss valid addit propos includ timelin develop manufact ure capabl goal align clinic develop program initi discuss fo llow design frequent commun develop gener facilit meet manufactur develop goal product qualiti goal sponsor product allow ear lier submiss cmc section includ product qualiti inform time review critic inspect activ 41 coordin sponsor contract nufactur may necessari ensur manufactur facil equi pment readi inspect dur ing review clinic section applic comprehens eet fda product qualiti review group advanc submiss may facilit qualiti assess product design expedit program although sponsor must ensur avail qualiti product time approv fda may exercis flexibl type extent manufactur inform expect time submiss approva l certain compon eg stabil updat valid strategi inspect plan manufactur scaleup level flexibl determin casebycas basi consid erat factor follow 1 product characterist 2 serious condit medic need 3 manufactur process 4 robust sponsor qualiti system 5 strength sponsor riskbas qualiti assess fda consider sponsor propos integr postmarket plan also take account whether element plan may appropri execut postmarket commit requir exampl fda consid impact clinic pe rformanc safeti nd immunogen sponsor meet agenc discuss propos plan soon possibl e later prenda prebla meet b nonclin consider ensur time submiss review nonc linic data sponsor initi earli commun fda nonclin st udi program consider studi 40 see guidanc industri ind meet human drug biolog chemistri manufactur control inform 41 product design fast tr ack breakthrough therap accomplish roll review see 2 submiss portion applic roll review 3 submiss portion applic roll review appendix 2 process roll view product submit nda without design flexibl permit 31450d1 iv bla without design flexibl also allow earli submiss cmc section resourc permit contain nonbind recommend 27protocol modif sequenc schedul studi need specif studi eg longterm toxic may im portant contex expedit drug develop fda provid guidanc sponsor developmen appropri time nonclin data need support applic market approv licensur c clinic inspect consider sponsor anticip agenc need inspect clinic trial includ applic analyt compon bioavail bioequival studi sponsor prepar inspect schedul agenc earli app licat review process inspect result availabl e inform review divis allow time sponsor address signific inspect find ing select site clin ical inspect import review time acc ss adequ accur data bla nda supplement submiss sponsor initi earli commun fda inform requir inspect pl an conduct companion diagnost develop program util one expedit program describ guidanc may involv vitro companion di agnost devic sponsor use one expedit program product involv vitro companion di agnost devic consult fda guidanc topic42 x paperwork reduct act 1995 guidanc contain inform collect provi sion subject review offic manag budget omb paperwork reduct act 1995 44 usc 35013520 time requir complet format collect estim averag 30 hour per respons prepar prioriti revi ew design request 70 hour per respons prepar breakthrough thera py design request includ th e time review instruct search exist data sourc gath er data need compl te review inform collect send comment regard burd n estim suggest reduc burden food drug administr center drug evalu research offic medic polici 10903 new hampshir avenu bldg 51 rm 6360 silver spring md 209930002 42 see draft guidanc industri food drug administr staff vitro companion diagnost devic final guidanc repres fda current think topic guidanc also refer previous pprove collect inform found fda regul collect inform 21 cfr 2021 certain part part 314 part 601 section 506b1 735 736 th e fdc act approv omb control number 09100686 09100001 09100338 09100389 09100297 agenc may conduct sponsor person requir re pond collect inform unless display current valid omb control number omb control number inform collect 09100765 expir 05312020 note expir date updat 09212017 contain nonbind recommend 28appendix 1 process fast track breakthrough therapi prioriti review design appendix describ gener process applic subm ission review fast track breakthrough therapi prio riti review design process fast track design 1 send design submiss sponsor may request fast track design ind first submit time thereaft receiv market approva l bla nda ind potenti fast track design may di scuss ind submissi preind meet decis design would await submiss ind practic matter fda ordinarili receiv fast track design request later sponsor prebla pre nda meet agenc mani th e featur fast tr ack design appli time ponsor drug develop program grant fast track design one indic subsequ obtain data support fast track design anoth indic sponsor shou ld submit separ request 2 send design submiss ind amend sent administr file attent appropri review di vision offic cder cber 3 content design submiss fast track design request contain follow inform case inform could captur approxim 10 20 page fast track design request submit sponsor ind amend identif submiss cover letter request fast track design bold uppercas letter request submit initi ind identif submiss cover letter initi investig new drug submiss request fast track design bold uppercas letter cover letter submiss na sponsor contact person contact person address email addr ss telephon number fax number applic nd applic number avail drug produc ts proprietari name nd activ ingredi biolog product proper name proprietari name divis offic ind submit activ contain nonbind recommend 29 propos indic concis summari inform support fast track desi gnation request indic studi includ follow basi consid drug one intend treat seriou condit basi consid drug ha potenti address unmet medic need explan potenti evalu plan drug develop program eg de scription trial intend evalu potenti applic list document previous submit ind consid relev design request refer submiss date paper submiss resubmit fda appendic design request 4 fda respons fda respond fast track design request within 60 calendar day receipt request design letter agenc determin criteria design fast track drug develop program met design letter state fast track designa tion grant develop product use treat specif seriou condit point sponsor design perform studi show whether product meet unmet medic need alert sponsor need drug develop program continu meet criteria fast track design b nondesign letter agenc determin fast track de signat request incomp lete drug develop program fail meet criteria fast track designati agenc send nondesign letter sponsor nondesi gnation letter state fast track design grant explain th e reason agenc decis 5 continu design fast track develop program cours drug develop expect produ ct grant fast track design continu eet criteria fast track design drug product contain nonbind recommend 30fast track develop program continu meet crit eria drug 1 longer demonstr potenti address unmet medic need 2 studi manner show drug product treat seriou conditi meet unmet medic need drug product may longer demonstr potenti address unmet medic need exampl new product approv tradit approv address need emerg clinic data fail show product fast track develop program anticip advantag avail therapi product fast track drug develop program agenc expect appr opriat consid particular drug develop plan part fast track pr ogram discuss evalu drug develop process includ ing endofphas 2 eet prebla pre nda meet sponsor recogn fast track drug deve lopment program longer pursu sponsor form agenc chang fast track design longer upport emerg data design drug develop program longer pursu ed agenc may choos send letter notifi sponsor progr longer design fast track drug develop program b process breakthrou gh therapi design 1 send design submiss although sponsor may request breakthrough ther api design ind first submit time thereaft send breakthrough therapi design request preliminari clinic evid indic drug may demonstr substanti improv exist therapi 1 clinic signific endpoint 43 fda therefor expect mo st case breakthrough therapi design request would submit amend ind ideal fda receiv breakthrough therapi design request initi clinic trial intend serv primari basi demonstr efficaci benefit design obtain primari intent breakth rough therapi design develop evid need support approv effici po sibl fda anticip th breakthrough therapi design request rare made submiss origin bla nda supplement sponsor drug developm ent program grant breakthrough therapi design one indic subsequ obtain prel iminari clinic evid support breakthrough therapi desi gnation anoth indicatio n sponsor submit separ request sponsor request breakthrough th erapi design fda suggest sponsor consid submit requ st 1 review ava ilabl data inform agenc think drug develop program meet criteria breakthrough therapi design 2 remain drug developmen program review benefit design howev agenc still need review submit request includ preliminari clinic evid determin meet criteria break therapi design suggest agenc sponsor consid submit request 43 section 506a1 fdc act contain nonbind recommend 31breakthrough therapi design advisori interpret guarante breakthrough therapi design request submit review 2 send design submiss ind amend submit nd administr file attent appropri review divis offic cder cber 3 content design submiss breakthrough therapi design request contain follow inform case inform c ould captur approxim 10 20 page breakthrough therapi design request submit sponsor ind amend identif submiss cover letter request breakthrough therapi design bold uppercas letter request submit initi ind id entif submiss cover letter initi investig new drug submiss request breakthrough therapi design bold uppercas letter cover letter submiss na sponsor contact person contact person address email addr ss telephon number fax number applic nd applic number avail drug produc ts proprietari name nd activ ingredi biolog product proper name proprietari name divis offic ind submit activ propos indic concis summari inform support breakthro ugh therapi design request indic studi includ follow basi consid drug one intend treat seriou condit preliminari clinic evid drug may demonstr substanti improv avail therapi 44 fda expect sponsor submit primari data data set th e sponsor describ preliminari clinic evid includ fo r exampl brief descrip tion avail therapi effect justif compar select 44 design submit ind exampl inform could submit support design request includ data foreign clinic tr ial conduct ind differ formul rout administr use unrel indic publish literatur contain nonbind recommend 32for clinic studi studi design populati studi endpoint use brief descript studi result statist analys includ exampl subgroup analysi applic list document previous submit ind consid relev design request refer submiss date paper submiss resubmit fda appendic design request 4 fda respons fda respond breakthrough therapi design ation request within 60 calendar day receipt request design letter agenc determin criteria fo r design breakthr ough therapi develop program met design letter state breakthrough therapi design grant develop product use treat specif seriou condit explain fda work close th e sponsor provid guidanc subsequ develop includ provid advic ge nerat evid need support drug approv effici manner alert sponsor need drug develop program continu meet criteria breakthrough therapi design b nondesign letter agenc determin breakthrough ther api design request wa incomplet drug develop program fail meet th e criteria breakthrough therapi design agenc send nondesign letter sponsor nondesign letter state breakthrough therapi designa tion grant explain reason agenc decis appropri letter may al includ advic sponsor regard subsequ develop includ woul need new breakthrough therapi design request 5 continu design breakthrough therapi develop program cours drug develop expect product grant breakthrough therapi design longer consid breakthrough therapi exampl drug develop program may grant breakthrough therapi design use earli clinic test th show much higher respons rate th avail therapi howev subsequ interim data deriv larger studi may show respons substanti smaller respons seen earli clinic test anot exampl breakthrough contain nonbind recommend 33therapi design grant tw drug develop use one two drug gain tradit ap proval would reta design unless sponsor provid evid drug may demonstr substantia l improv recent approv drug addit spon recogn develop program design breakthrough therapi longer pursu sponsor inform agenc chang breakthrough therapi design longer support emerg data design drug develop program long er pursu agenc may choos send letter notifi sponsor program longer design breakthrough therapi develop program consist fda commit commun frequent interact manner w ith sponsor drug design breakthrough therapi fda notifi sponsor intent rescind nd offer sponsor opportun justifi product continu designati fda recogn sponsor product breakthrough therapi design rescind b ecaus avail data longer support design may still suffici evid complet drug develop program support market approv c process prioriti review design fda determin whether applic qualifi fo r prioriti review versu standard review everi applic prioriti review request applic howev applic may expressli request prioriti review descri bed follow section 1 send design submiss sponsor may request prioriti view design submit origin bla nda efficaci supplement agenc anticip ate prioriti revi ew design request made file bla nda efficaci supplement 2 send design submiss prioriti review design request may subm it origin bla nda efficaci supplement attent th e appropri review divis offic cder cber 3 content design submiss prioriti review design request hould contain follow inform identif submiss cover letter request prioriti review design bold uppercas letter cover letter submiss na sponsor contact person contact person address email address telephon number fax number contain nonbind recommend 34 avail drug produc ts proprietari name nd activ ingredi biolog product proper name proprietari name propos indic concis summari inform support prioriti review design request includ follow basi consid drug intend treat seriou condit basi assert drug w ould signific improv safeti effect treatmen prevent diagnosi seriou condit 4 fda respons fda inform applic write prioriti review design day 60 review divis inform applican write standa rd review design day 74 review applica tion file receiv review design 5 continu prioriti review design prioriti review design assign timelin chang first review cycl even redetermin review stat us made approv drug avail new data submiss request formal disput resolut applic addit applic file protest assign standard review applic resubmit fda refusetofil decis applic withdrawn fda action resubmit fda make determin review design base resubmit applicationcontain nonbind recommend 35appendix 2 process roll review appendix describ gener process applic subm ission review portion applic featur fast track design see section vb2 breakthrough therapi design see section v1b3 agreement propos sponsor obtain preliminari agenc agreemen propos prebla prenda meet earlier product breakth rough therapi design eg endofphas 2 meet meet sponsor review divis discuss 1 data use support effect 2 schedul submiss portion bla nda 3 descript por tion applica tion submit separ request submit portion applicati ordinarili includ inform packag prebla pre nda meet sponsor seek submit portion applic ind prebla prenda meet sponsor make request provid propo ed schedul submissi portion applic ind soon possibl request submiss portion applic ation sent amend ind attach form fda 1571 amendmen clearli identifi request submiss portion applic bold uppercas letter fda respond sponsor request submissi portion pplicat letter fda also respond chang agreement accept portion applic letter b portion applic elig earli submiss gener agenc accept submiss complet section bla nda entir cmc section toxi colog section clinic section 45 section bla nda submit review form adequ includ complet bla nda submiss draft includ submiss final report need updat applic shou ld submit formal amend bla nda revis inform occasiona lli agenc may discret accept less complet section agenc determin subsect would constitut review unit use make review process effici eg less complet section could cmc section lack ing final consist lot data longterm stabil data toxicolog section lack ch ronic toxicolog data final studi report princip control trial without integr summari sponsor confirm subsect ion final report prebla prenda meet agenc sponsor work togeth clearli defin paramet accept incomplet sect ion determin whether 45 form fda 356h may use guid item bla nda contain nonbind recommend 36fda could conduct meaning review submiss receiv miss inform c submiss user fee sponsor requir pay applic fee state section 736 fdc act fda may commenc review portion pplicat applican submit form fda 3397 applic user fee follow th e procedur follow complet applic submit commenc review fda accept portion pplicat necessa rili mean review commenc proceed complet applic ation submit actual commenc schedul review depend mani fact or includ staf workload compet prioriti timelin complet applicatio n perceiv effici commenc review receipt complet submiss e calcul review time review clock begin applic inform agenc complet bla nda submit 46 agenc notifi complet applic make file determin within usual time47 46 section 506d2 fdc act provid time period review human drug applic shall appli date applic complet 47 see 314101 cder mapp 60254 good review practic refus file avail internet httpwwwfdagovdownloadsaboutfdacentersofficesoffi ceofmedicalproductsandtobaccocdermanualofpoliciespr oceduresucm370948htm cber sopp 8404 refus file procedur biolog licens applic august 27 2007 availabl e internet httpwwwfdagovbiolog bloodvaccinesguidancecomplianceregulat oryinformationproceduressoppsucm07 3474htm
[Document -8]guidanc industri rheumatoid arthriti develop drug product treatment draft guidanc guidanc document di stribut comment purpos comment suggest regard draft document submit within 60 day public feder regist notic announc avail draft guidanc submit electron comment httpwwwregulationsgov submit written comment divis docket manag ment hfa305 food drug administr 5630 fisher lane rm 1061 rockvil md 20852 comment identifi docket number list notic avail publish feder regist question regard draft document c ontact cder dr nikolay p nikolov 301796 2300 cber offic co mmunic outreach develop 8008354709 3018271800 cdrh markham luke 3017965556 us depart health human servic food drug administr center drug evalu research cder center biolog evalu research cber center devic ra diolog health cdrh may 2013 clinicalmed revis 1 i8932dftdoc 051313 guidanc industri rheumatoid arthriti develop drug product treatment addit copi avail offic commun divis drug inform center drug evalu research food drug administr 10903 new hampshir ave bldg 51 rm 2201 silver spring md 209930002 tel 3017963400 fax 3018478714 email druginfofdahhsgov httpwwwfdagovdrugsguidancecomplianc egulatoryinformationguidancesdefaulthtm offic commun outrea ch develop hfm40 center biolog evalu research food drug administr 1401 rockvil pike suit 200n rockvil md 208521448 tel 8008354709 3018271800 email ocodfdahhsgov httpwwwfdagovbiologicsbloodvaccinesguidan cecomplianceregulatoryinformationdefaulthtm offic commun educ radiat program divis small manufactur intern consum assist hfz220 center devic radiolog health food drug administr 1350 piccard drive rockvil md 208504307 dsmica email dsmicacdrhfdagov dsmica fax 3014438818 tel manufactur assist 8006382041 3014436597 tel intern staff 3018273993 httpwwwfdagovmedicaldevicesdeviceregulationandguidanceguidancedocumentsdefaulthtm us depart health human servic food drug administr center drug evalu research cder center biolog evalu research cber center devic ra diolog health cdrh may 2013 clinicalmed revis 1 tabl content introduct 1 ii clinic develop program 2 dose dose regimen select considerations2 b efficaci consider 3 c safeti consider 5 drugdevic combin product consider 6 refer 8 contain nonbind recommend draft implement 1 guidanc industry1 2 rheumatoid arthriti 3 develop drug product treatment 4 5 6 7 8 draft guidanc final repres th e food drug administr fda current 9 think topic creat confer right person oper 10 bind fda public use altern pproach approach satisfi requir 11 applic statut regul want discuss altern approach contact fda 12 staff respons implement guidanc identifi appropri fda staff call 13 appropri number list titl page guidanc 14 15 16 17 18 introduct 19 20 purpos guidanc outlin fda current think principl clinic 21 develop relev doseselect ass ssment efficaci safeti support 22 approv drug product treatment patient rheumatoid arthriti ra also 23 address addit consider drug product develop drugdevic combin 24 product guidanc address nonc linic develop develop drug 25 product juvenil idiopath ic arthriti developmen biosimilar product 26 27 guidanc revis guidanc industri clinic develop program drug 28 devic biolog product tr eatment rheumatoid arthriti ra publish 29 februari 1999 2 final gu idanc replac februari 1999 30 guidanc reflect current think fda ra drug product develop 31 fda current think influenc clinic develop program conduct ra 32 sinc 1999 guidanc publish chang standard care ra 33 avail mani effect trea tment revis includ 34 35 dose dose regimen select thr oughout clinic de velop program 36 37 expect establish efficaci ra base sign symptom physic 38 function domain 1 guidanc prepar divis pulmonari allergi rheumatolog product center drug evalu research cder cooper center biolog evalu research cber center devic radiolog hea lth cdrh food drug administr 2 updat guidanc period make sure recent version guidanc check fda drug guidanc web page httpwwwfdagovdrugsguidancecompliancereg ulatoryinformationgu idancesdefaulthtm 1 contain nonbind recommend draft implement 39 40 use efficaci endpoint clinic mission prevent structur damag 41 progress 42 43 limit use placebo 44 45 use activ compar safeti efficaci trial 46 47 principl safeti assess 48 49 develop drugdevic combin product 50 51 guidanc discuss genera l issu statistica l analysi clinic trial design 52 topic address ich guidanc industri e9 statist principl clinic 53 trial e10 choic control group relat issu clinic trial respect 54 guidanc focus specif drug product de velop trial design issu 55 uniqu studi ra 56 57 fda guidanc document includ guid anc establish legal enforc 58 respons instead guidanc describ th e agenc current thinki ng topic 59 view recommend unless spec ific regulatori stat utori requir 60 cite use word agenc guidanc mean someth suggest 61 recommend requir 62 63 64 ii clinic develop program 65 66 dose dose regimen select consider 67 68 select nomin dose dose regimen fundament compon drug 69 product develop recommend dose dose regimen base 70 benefittorisk assess support avail data gather throughout 71 develop program import find appropri nomin dose dose regimen 72 produc efficaci accept long shortterm safeti profil mani drug 73 product intend treat ra potenti caus seriou doserel advers reaction 74 opportunist infecti on malign may appar shortterm 75 clinic trial see section iic disc ussion clinic sa feti databas dose 76 rang explor begin earli develop program often continu 77 throughout definit efficaci safeti studyi smaller earli doserang exploratori 78 studi may adequ select singl dose singl dose regimen 79 80 follow consid design doserang studi 81 82 studi wide rang dose dosi ng regimen base pharmacokinet 83 relev pharmacodynam consider 84 2 contain nonbind recommend draft implement 85 use endpoint sensit chang pr ovid better discriminatori power dose 86 87 respons assess clinic endpoint su ch acr20 respons criteria may optim purpose3 dichotom endpoint use 88 89 proport respond small group pa tient could unrelia ble endpoint das28 4 hybrid acr response5 continu variab le may sensit 90 chang provid suitabl altern acr respond index support 91 pharmacodynam marker consid ed scientif justifi 92 93 time evalu assess steep part doser spons curv dose 94 respons assess endpoint evalu time point therapeut 95 plateau like eg week 2 8 better captur possibl e differ 96 dose later time point evalu eg 12 week may inform estim 97 clinic effect chronic use 98 99 b efficaci consider 100 101 meet regulatori standard approv un der section 505d feder food drug 102 cosmet act sponsor must provid substan tial evid efficaci enrol patient 103 popul demonstr accept riskben efit profil drug product 21 usc 104 355d studi one dosedos regimen use activ compar 105 definit studi facilit interpr tation efficaci overal riskbenefit 106 evalu section outlin principl sponsor follow assess efficaci drug 107 product treatment ra 108 109 1 establish efficaci key ra domain market approv drug product 110 treatment ra sponsor demonstr substanti evid efficaci 111 key ra domain clinic respons physic function 112 113 clinic respons acr20 respons criteria continu accept measur 114 demonstr reduct ra diseas activ addit higher level respons 115 measur acr50 acr70 respons rate measur low diseas 116 activ das28 less 26 use support evid efficaci 117 clinic spons domain 118 3 acr20 50 70 respons criteria american colleg rheumatolog respons criteria dichotom composit endpoint indic proport patient least 20 50 70 percent improv number tender swollen joint three remain five acr coreset measur patient pain patient global assess diseas physician global assess diseas physic function assess health assess questionnairedis dex haqdi acut phase reactant 4 das28 diseas activ score 28 mathemat ly calcul continu composit endpoint differenti weight given follow componen ts tender joint count 28 joint swollen joint count 28 joint acut phase reactant patient global assess arthriti 5 hybrid acr respons continu score mean improv core set measur combin acr20 acr50 acr70 respons rate american colleg rheumatolog committe reevalu improv criteria 2007 3 contain nonbind recommend draft implement 119 physic function health assess questionnairedis index haqdi 120 use demonstr improv physic function6 121 122 data 12week placebocontrol clinic trial gener would accept 123 provid evid efficaci clinic spons physic function domain 124 125 2 domain note item 1 market approv ra 126 foundat demonstr efficaci includ clinic respons physic 127 function use measur acr20 respons rate haqdi respect 128 demonstr efficaci domain import patient health care 129 provid provid character efficaci drug product 130 util clinic practic domain includ 131 132 prevent structur damag progress reduct radiograph evid 133 structur damag progress import predictor longterm benefit 134 delay prevent progress disa biliti relat ra radiograph data 135 use valid score method use demonstr efficaci 136 domain howev demonstr prevent structur damag progress 137 radiograph becom increas ly difficult sever reason 138 139 use placebo control longterm trial usual 6 month longer 140 trial done past demonstrat e effect radiograph outcom 141 longer feasibl see item 3 142 143 extent progress plac ebo group low shortterm 144 trial thu observ treatment e ffect size investig drug 145 product small difficult detect 146 147 limit current analysi method 148 149 therefor sponsor consid altern studi design eg activ compar 150 studi appli differ measur eg proport patient radiograph 151 progress altern analyt met hod assess radiograph benefit 152 imag modal magneti c reson imag ultrasonographi 153 may allow demonstr benefit structur damag progress 154 control studi may shorter studi use radiograph data howev 155 modal valid outcom measur ra date 156 157 clinic remiss remiss import goal ra treatment american 158 colleg rheumatologyeuropean l eagu rheumat acreular 159 provision definit remi ssion criteria may accept use ra clinic 160 develop program acreular 2011 patient achiev remiss 161 follow provid inform th e durabl remiss respons 6 haqdi assess degre difficulti patient experienc past week eight domain daili live activ dress groom aris eat walk hygien reach grip activ 4 contain nonbind recommend draft implement 162 163 aspect ra oth r outcom measur may inform addit 164 endpoint ra clinic develop pr ogram sponsor provid support 165 evid develop select measur sponsor also provid 166 justif use given measur includ import clinic 167 relev nonredund propos outcom measur 168 169 3 use placebo assess efficaci domain may requir longterm 170 control clinic trial data howev avail effect ra therapi 171 shift paradigm treatment ear ly establish ra focu earli 172 control diseas activ singh 2012 provid rational limit 173 exposur patient placebo ineffec tive therapi prolong period time 174 ie beyond 12 week american colleg rheumatolog 2011 therefor studi 175 longer 12 week includ activ co mparat cont rol provis 176 escap rescu treatment patient activ diseas 177 178 c safeti consider 179 180 size safeti databas drug biolog product meet minimum 181 recommend outlin ich guidanc industri e1a extent popul 182 exposur assess clinic safet drug intend long term treatment nonlif 183 threaten condit howev drug product develop ra may potenti 184 seriou advers effect may caus concern unfortun durat trial would 185 support demonstr efficaci may su fficient adequ safeti assess 186 short durat placebocontrol period ie 12 week would limit amount 187 control safeti data therefor better character longterm safeti profil 188 investig drug product uncommon advers event event longer latenc 189 period opportunist infect lignanc may request premarket safeti 190 databas larger size longer durat th recommend ich e1a new molecular 191 entiti intend chronic treatment ra 192 193 request like includ least 1 year control safeti data new molecular entiti 194 activ compar arm facilit interp retat data sa feti data shorter 195 durat may consid drug product new molecular entiti reason 196 compar arm includ use multipl dose investig drug product 197 standardofcar treatment definit clinic trial inclus one dose 198 investig drug product provid importa nt doserespons inform regard 199 efficaci safeti safeti issu terest sponsor consid independ 200 adjud process need detail specif monitor may chang new data 201 emerg sponsor encourag discuss plan specif safeti monitor 202 fda earli stage drug product develop 203 204 approach analys safeti data take account complex studi 205 design eg crossov respons escap prov ision crossov design addit 206 approach analys integr safeti data take account possibl differ 207 patient popul andor differ studi design multipl studi 5 contain nonbind recommend draft implement 208 209 drugdevic combin product consider 210 211 therapi develop treatment ra includ drug product may requir parenter 212 administr use accessori deliveri unit eg autoinjector case 213 manufactur drug product ensur accessori deliveri unit approv 214 clear market devic regulatori process eg 510k process premarket 215 approv center devic radiolog health accessori deliveri unit 216 alreadi approv cl ear market approv clear least 217 concurr drug product approv 218 219 characterist drug product deliveri devic meet 220 definit combin product 21 cfr 32e center primari jurisdict 221 premarket review regul combin product determin base 222 procedur set forth 21 cfr 34 exampl e primari mode action 223 combin product drug product th e entir combin product assign 224 center drug evalu research combin product gener need 225 one market applic eg new drug pplicationbiolog licens applic 226 sponsor encourag contact offic combin product w ith gener question 227 regard drug product jurisdicti regulatori pathway drugdevic combin 228 product 229 230 gener drugdevic combin pr oduct complet chemistri 231 manufactur control databas devic design develop substanti 232 complet clinic develop program support efficaci safeti entir combin 233 product anticip tobemarket drugdevic combin product use 234 pivot studi support efficaci safeti combin product market 235 approv inform drugdevic inject develop see draft guidanc 236 237 industri fda staff technic consider pen je relat injector intend use drug biolog product 7 guidanc includ info rmation issu 238 rootcaus analys devic lfunction may lead potenti al improv devic 239 240 likewis current good manufactur pract ice requir combin product provid 21 cfr part 4 subpart 8 241 242 develop ra drug deliveri syst em sponsor take consider 243 characterist intend user popul use environ product intend 244 selfadministr ra pa tient devic durabl dexter visual 245 acuiti requir use devic hould within capabl ra patient human factor 246 studi assess user late hazard conduct earli develop ideal 247 conduct key doserang safeti efficaci studi consider 7 final guidanc represen fda current think topic recent version guidanc check fda drug guidanc web page httpwwwfdagovdrugsguidancecompliancereg ulatoryinformationgu idancesdefaulthtm 8 see httpswwwfederalregist govarticles20130122201301068c urrentgoodmanufacturingpractic requirementsforcombinationproduct 6 contain nonbind recommend draft implement 248 human factor studi see draft guidanc industri fda staff appli human factor 249 usabl engin optim medic devic design 9 250 251 ongo evalu devic perform incorpor pivot studi 252 combin product exampl eval uation includ king patient report 253 devic perceiv broken malf unction return devic 254 evalu identif problem de vice use perform also evalu 255 direct question defin protocol addit small number devic eg 256 100 appar function normal hould collect use evalu 257 vitro perform test ensur devic robust 258 259 although use tobemarket formul drugdevic combin product 260 throughout develop optim acknowledg chang drug product deliveri 261 system may occur chang formul excipi devic compon may affect 262 drug product deliveri characterist ic clinic perform drugdevic combin 263 product extent clinic data need support chang depend natur 264 chang develop stage exampl transit prefil syring 265 autoinjector deliveri system involv followin g minimum 1 hu man factor studi 266 evalu potenti user late risk modifi comb inat product 2 pharmacokinet 267 bridg studi demonstr similar deliveri drug product th e biospac across 268 rang bodi weight 3 reallif patient handl experi assess devic 269 perform discuss depend extent propos chang addit 270 clinic data may need support efficaci safeti includ immunogen 271 272 sponsor encourag discu type issu appr opriat market applic 273 fda earli develop feasibl 274 9 final guidanc represen fda current think topic recent version guidanc check fda devic guidanc web page httpwwwfdagovmedicaldevicesdev iceregulationandguidanceguidancedocumentsucm198577htm final guidanc supersed guidanc ndustri fda premarket design control review medic devic usesafeti incorpor human factor engin risk manag recent version guidanc chec k fda devic guidanc web page httpwwwfdagovmedicaldevicesd eviceregulationandguidanceguidancedocumentsucm070271htm 7 contain nonbind recommend draft implement 275 refer 276 277 literari 278 279 acreular 2011 provision defini tion remiss rheumatoid arthriti clinic 280 trial arthriti rheum mar63357386 281 282 american colleg rheumatolog 2011 clinic trial prioriti design confer juli 283 2223 2010 arthriti rheu aug63821516 284 285 american colleg rheumatolog committe reevalu improv criteria 2007 286 propos revis acr20 hybrid measur american colleg rheumatolog 287 respons arthriti rheu mar 15572193202 288 289 singh ja 2012 updat 2008 american colleg rheumatolog recommend 290 use diseasemodifi antirheumat drug biolog agent treatment 291 rheumatoid arthriti arthriti care re may64562539 292 293 guidanc 294 295 draft guidanc industri fda staff appli human factor usabl engin 296 optim medic devic design 297 298 draft guidanc industri fda staff technic consider pen jet relat 299 injector intend use drug biolog product 300 301 guidanc industri fda premarket design control review medic devic use 302 safeti incorpor human facto rs engin risk manag 303 304 ich guidanc industri e1a extent popul expo ure assess clinic safeti 305 drug intend longterm treatm ent nonlifethreaten condit 306 8 
[Document -9]ulcer coliti clinic trial endpoint guidanc industri draft guidanc guidanc document di stribut comment purpos comment suggest regard draft document submit within 60 day public feder regist notic announc avail draft guidanc submit electron comment httpwwwregulationsgov submit written comment divis docket manag ment hfa305 food drug administr 5630 fisher lane rm 1061 rockvil md 20852 comment identifi docket number list notic avail publish feder regist question regard draft document contact dr anil rajpal 3017962120 us depart health human servic food drug administr center drug evalu research cder august 2016 clinicalmed 15028dftdoc 072716 ulcer coliti clinic trial endpoint guidanc industri addit copi avail offic commun divis drug inform center drug evalu research food drug administr 10001 new hampshir ave hillandal bldg 4th floor silver spring md 209930002 phone 8555433784 3017963400 fax 3014316353 email druginfofdahhsgov httpwwwfdagovdrugsguidancecomplianc egulatoryinformationguidancesdefaulthtm us depart health human servic food drug administr center drug evalu research cder august 2016 clinicalmed tabl content introduct 1 ii background 2 ulcer coliti 2 b treatment goal 3 iii ideal primari efficaci assess tool 3 iv interim approach efficaci assess 5 stool frequenc rectal bleed subscor 6 1 standard instruct record numb er stool worst rectal bleed 6 2 calcul stool frequenc rectal bleed subscor 7 b endoscop assess 8 c pga assessmentphysici an assess diseas activ 8 v efficaci endpoint definit 8 clinic remiss clinic respons 9 b secondari endpoint interest 9 c assess mucos heal vs e ndoscop appear mucosa 9 corticosteroidfre remiss 10 vi trial procedur timi ng assess 10 vii statist consider 12 miss data 12 b primari analysi 12 c secondari analys 12 viii pediatr drug developm ent consider 13 address pediatr research equiti act requir 13 b extrapol efficaci 14 c data collect pediatr patient 14 pediatr consider 14 glossari histor endpoint 15 refer 16 appendix 1 mayo score 18 appendix 2 ucdai 19 contain nonbind recommend draft implement 1 ulcer coliti c linic trial endpoint 2 guidanc industry1 3 4 5 6 7 draft guidanc final repr esent current think food drug 8 administr fda agenc topic establish right person 9 bind fda public use altern approach satisfi requir 10 applic statut regul discuss al tern approach contact fda staff respons 11 guidanc list titl page 12 13 14 15 16 introduct 17 18 purpos guidanc assist sponsor clinic devel opment drug 19 treatment ulcer coliti uc adult pediatr patients2 specif guidanc 20 address food drug administr fda current think regard efficaci 21 endpoint uc clinic trial draft guida nce intend serv focu continu 22 discuss among divis gastroenterolog inborn error product dgiep 23 pharmaceut sponsor academ commun public3 24 25 guidanc address treatment prevent l ongterm complic uc 26 exampl guidanc intend disc uss endpoint prevent reduct risk 27 colorect cancer 28 29 guidanc also cont discuss gener issu statist analysi 30 clinic trial design topic address th e ich guidanc industri e9 statist 31 principl clinic trial e10 choic control group relat issu clinic 32 trial respectively4 33 1 guidanc prepar divis gastroenterolog inborn error product center drug evalu research food drug administr 2 purpos guidanc refer drug includ human drug therapeut biolog product unless otherwis specifi 3 addit consult guidanc sponsor encourag ed contact dgiep discuss specif issu aris develop given drug 4 updat guidanc period make sure recent version guidanc check fda drug guidanc web page httpwwwfdagovdrugsguidancecompliancereg ulatoryinformationgu idancesdefaulthtm 1 5 sign defin object visual measur eviden ce diseas health condit sign observ measur distinct symptom clinic outcom treatmentrel effect sign usual observ interpret clinician may notic report patient symptom defin subject evid diseas health co ndition treatmentrel effect notic known patient see guidanc industri patientreport outcom measur use medic product develop support label claim patientreport outcom guidanc contain nonbind recommend draft implement 34 gener fda guidanc document establish legal enforc respons 35 instead guidanc describ agenc curren think topic view 36 recommend unless specif ic regulatori stat utori requir cite use 37 word agenc guidanc mean thing suggest recommend 38 requir 39 40 41 ii background 42 43 ulcer coliti 44 45 uc chronic relaps diseas characteri zed diffus mucos flammat colon 46 langan gotsch et al 2007 precis etio logi uc unknown ever thought 47 caus inappropri inflammatori respons gut content genet 48 predispos individu tall abreu et al 2011 abraham cho 2009 estim 49 us incid uc 9 12 case per 10000 0 person per year estim preval 50 205 240 case per 100000 pe rson danes fiocchi 2011 consider 51 variabl incid pr eval uc around world approxim 20 percent 52 patient uc present age 20 kel sen baldassano 2008 pediatr 53 popul age 0 17 year estim us incid uc 32 case per 100000 54 person per year estim preval enc 195 case per 100000 person abramson 55 durant et al 2010 56 57 uc involv rectum may extend proxim contigu pattern affect part 58 colon entir colon c linic manifest activ diseas includ bl oodi diarrhea 59 without mucu urgenc tenesmu abdomin pain weight lo ss fever malais 60 patient extens sever inflamm acu te complic sever bleed 61 toxic megacolon lead perfor may occur danes fiocchi 2011 62 increas risk co lorect cancer uc pa tient compar gener popul risk 63 factor includ long durat diseas extens colon involv sever inflamm 64 epitheli dysplasia nd childhoodonset disea e danes fiocchi 2011 sign 65 symptom uc adult children similar 5 howev abdomin pain diseas involv 66 entir colon extraintestin manifest proctiti ong girl diseas sever 67 necessit colectomi common children kelsen baldassano 2008 malati 68 abraham et al 2013 69 2 contain nonbind recommend draft implement 70 b treatment goal 71 72 shortterm treatment goal activ diseas flare pr ovid relief patient 73 decreas sever achiev resolut sign symptom activ diseas 74 achiev longterm tr eatment goal decr eas frequenc 75 subsequ diseas flare treatment phase treatment activ diseas flare long 76 term treatment relat goal treatment affect diseas process decreas 77 mucos inflamm colon 78 79 80 iii ideal primari efficac assess tool 81 82 test tool instrument defin assess sy stem compris three essenti 83 compon 1 materi measur 2 assay obtain measur 3 84 method andor criteria interpret measurements6 85 86 three clinic outcom assess type relev measur uc sign 87 symptoms7 88 89 1 patientreport outcom measur base report come directli 90 patient ie studi subject statu patien ts health condit without 91 amend interpret patient respons clinicia n anyon els 92 patientreport outcom measur selfreport int rview provid 93 interview record patient respons symptom unobserv 94 concept known patient onl measur patientreport outcom 95 measur patientreport outcom also assess patient perspect 96 function activ also observ other 97 98 2 observerreport outcom measur base report observ sign 99 event behavior relat patient health condit someon 100 patient health profession genera lli observerreport outcom report 101 parent caregiv someon observ patient daili life particularli 102 use patient report selv eg infant individu 103 cognit impair observerreport outcom mea ure includ medic 104 judgment interpret 105 106 3 clinicianreport outcom measur base report come 107 train health care professiona l observ patient health condit 108 clinicianreport outc ome measur involv clinic j udgment interpret 6 fdanih biomark work group best biomark endpoint tool resourc internet maryland food drug administr usna tional institut health us 2016 jan 28 httpwwwncbinlmnihgovbooksnbk338448reportread 7 sourc three clinic outcom assess defi nition best biomark endpoint tool resourc internet fdanih biomark work group 2016 jan 28 httpwwwncbinlmnihgovbooksnbk338448reportread 3 contain nonbind recommend draft implement 109 observ sign behavior manifest relat diseas condit 110 clinicianreport outcom easur directli assess symptom known 111 patient 112 113 fda believ ideal primari efficaci assessm ent tool use clin ical trial support 114 market approv treatment uc would consist follow scales8 115 116 sign symptom assess scale st measur patientreport outcom 117 instrument case young children 5 6 year old unabl provid 118 valid reliabl selfreport observerreport outcom instrument matza patrick 119 et al 2013 120 121 endoscop histolog assess cale best measur clinicianreport 122 outcom instrument claim muco al heal would support 123 endoscopi find provid assess visual appear 124 mucosa claim relat find endoscopi absenc valid 125 histolog assess mucosa woul limit endoscop appear 126 mucosa 127 128 sponsor encourag develop primari efficaci assess tool 9 129 130 intent dual measur ensur observ improv sign 131 symptom relat effect underl ying inflamm vice versa onset 132 achiev target improv two compon would occur 133 concurr one lag behind ever improv whichev compon 134 occur first must sust ain achiev remain compon 135 136 ideal sign symptom assess scale consist welldefin reliabl 137 patientreport outcom instrument observ report outcom instrument measur 138 clinic import sign symptom uc includ stool frequenc rectal bleed 139 identif relev sign symptom confirm qualit research 140 patient caregiv instrument item clear easili interpret addit 141 tool bristol stool scale lew heaton 1997 may use visual 142 evalu diarrhea incorporat ed sign symptom assess 143 adult pediatr version bristol stool scale consid studi 144 children qualit research patient nd caregiv appropri also 145 conduct document understand instrument includ instruct item 8 scale defin system number verbal anchor valu score deriv item exampl includ visual analogu scal es likert scale numer rate scale see patientreport outcom guidanc 9 instrument develop time resourc intens instrument develop sponsor interest parti consid collabor develop publicli avail clinic outcom assess precompetit manner use process describ guidanc industri fda staff qualif process drug develop tool 4 contain nonbind recommend draft implement 146 respons option use event log ite ms short recal period gener 147 recommend sign symptom condit vari frequent 148 149 although patientreport outcom instrument captur patientreport sign 150 symptom observ assess sign may need children abl 151 reliabl report thei r sign symptom eg young children10 sponsor consid 152 separ ageappropri instrum nt score captur patient report symptom 153 observ report sign use children selfreport full rang sign 154 symptom assess observ ask rate unobs rvabl aspect 155 child condit eg abdomin pa sever avoid instead observ 156 ask rate sign havior observ 157 158 welldefin reliabl clinician rate scale measur level mucos 159 inflamm would ideal endoscop histolog assess tool endoscopi 160 use conjunct histolog assess mucos heal endoscopi alon 161 without histolog provid assess visual app earanc mucosa ideal 162 clinician perform rate would agreement definit scale 163 compon procedur necessari perform rate eg procedur 164 video recordingsequip endoscop assess procedur biopsi 165 histolog assess specif criteria guid judgment select 166 respons rate scale 167 168 instrument user manual recommend fo r clinicianreport patientreport 169 observerreport outcom instrument standa rdize instrument administr provid 170 recommend procedur definit use 171 172 173 iv interim approach efficaci assess 174 175 welldefin reliabl clinicianreport patientreport observerreport 176 outcom instrument becom avail use clinic trial spon or consid 177 strategi discuss follo wing section design uc clinic trial tradit 178 mayo score ulcer coliti diseas activ index ucdai 179 commonli use tool support gistrat trial uc see appendix 1 2 180 mayo score ucdai incorp orat score stool frequenc rectal bleed endoscop 181 find physician ass ssment diseas activ 182 183 mayo score ucdai share limit key limit ucdai 184 mayo score physician ssessment diseas activ physician global 185 assess pga subscor respectively11 singl gener item adequ captur 10 see matza patrick et al 2013 11 pga clinicianreport ssessment reflect patient record symptom proctoscop appear rectosigmoid mucosa pertinen clinic index physic find patient perform statu schroeder tremain et al 1987 5 contain nonbind recommend draft implement 186 whether benefit achiev import sign symptom 187 addit previous discu sed sign symptom assess scale best measur 188 patientreport outcom instrument oppos clinicianreport outcom instrument 189 use pga subscorephysician assess diseas activ subscor full mayo 190 score full ucdai incorpor pga subscorephi ician assess diseas 191 activ subscor recommend endpoint measur support market 192 applic although acknowledg limita tion stool frequenc rectal 193 bleed subscor tools1213 recommend use addit endoscopi 194 subscor endpoint measur clinic trial welldefin reliabl endpoint 195 measur becom avail 196 197 data collect procedur assess rectal bleed stool frequenc 198 endoscopi subscor submit review concurr dgiep goal 199 ensur follow issu addr ssed 1 patientrepor ted assess stool 200 frequenc rectal bleed standard across pa tient 2 effect interobserv 201 variabl endoscop ssessment minim 3 limit pga 202 subscor remov see tabl 1 strategi improv reliabl precis 203 compon discuss follo wing modif reco mmend mayo 204 score also ap pli ucdai 205 206 stool frequenc rectal bleed subscor 207 208 patient provid standard instru ction record th e number stool 209 worst rectal bleed 24hour period investigationa l site provid 210 instruct calcul stool fr equenc rectal bleed subscor 211 212 1 standard instruct recordi ng number stool worst rectal 213 bleed 214 215 exampl standard instruct mayo score summar tabl 1 216 howev open consid altern approach long welldefined14 217 standard instruct draft earli drug devel opment share fda 218 comment 219 12 stool frequenc subscor may welldefin primarili reli refer normal number stool per day base number stool patient experienc flare rather report absolut number stool per day 13 rectal bleed subscor may welldefin prim arili requir patient report answer doublebarrel question ask patient choos streak blood stool less half time versu obviou blood stool time higgin 2012 14 instrument develop time resourc intens instrument develop sponsor interest parti consid collabor develop publicli avail clinic outcom assess precompetit manner use process describ guidanc industri fda staff qualif process drug develop tool 6 contain nonbind recommend draft implement 220 tabl 1 exampl standard instructio ns record number stool worst 221 rectal bleed mayo sco 24hour period categori instruct specif instruct patient definit stool patient instruct stool defin trip toilet patient either bowel movement pass blood alon blood mucu mucu refer remiss stool frequenc 24 hour patient ask identifi screen visit mani stool 24hour period remiss uc patient report achiev remiss patient ask identifi number stool per day initi onset sign symptom uc sponsor record refe renc remiss stool frequenc base report stool frequenc patient remiss report stool frequenc befo initi onset sign symptom uc remiss preuc stool frequenc collect baselin allow explor natur histori prediagnosi stool frequenc versu remiss stool frequenc sever categori rectal bleed given 24hour period patient instruct indic sever categori describ amount blood stool given day categori rectal bleed defin follow blood seen streak blood stool less half time obviou blood streak streak blood stool time blood alon pass patient instruct select blood seen rectal bleed section stool given day complet event log diari patient train complet event log diari instruct complet stool frequenc rectal bleed assess incorpor event log diari readi refer patient record rectal bleed stool frequenc assess patient direct captur rectal bleed stool frequenc assess event log daili diari 1 week visit 222 sponsor encourag propos electron data collect method eg voic respons system electron 223 diari webbas system altern pen paper data collect electron data collect 224 method propos sponsor provid instruct train electron method 225 226 2 calcul stool frequenc rectal bleed subscor 227 228 gener sponsor use approach ca pture stool frequenc nd rectal bleed data 229 recent 3day consecut period week visit calcul 230 stool frequenc rectal bleed subscor either averag worst 231 recent 3day consecut period use fo r calcul respect subscor 232 miss data may issu consecut 3 day period avail see section viia 233 miss data altern propos consid ere collec tion data 234 least 3 day includ nonconsecu tive day week visit instruct 7 contain nonbind recommend draft implement 235 investig calcul st ool frequenc rectal bleedi ng subscor draft 236 earli drug develop share fda comment 237 238 b endoscop assess 239 240 endoscop assess document th e endoscopist perform procedur 241 ideal blind central reader review video record th e procedur charter 242 standard procedur video recordingsequip ass ssment endoscopi 243 draft earli drug develop share fda comment protocol 244 specifi discrep assess endoscopist th e central reader 245 handl efficaci anali es particularli import interpret methodolog 246 underli score endoscop characterist may subject element eg 247 friabil 248 249 endoscopi subscor mayo score modifi valu 1 250 includ friabil presenc friabil even consid mild 251 endoscopistcentr reader consist clinic remiss recommend definit 252 endpoint includ yo endoscopi subscor 0 1 see section va clinic 253 remiss clinic respons appendix 1 254 255 c pga assessmentphysician assess diseas activ 256 257 util pga subscor full yo scorephysician assess diseas 258 activ subscor full ucdai questiona ble concept purport measur 259 distinct compon clear use subscor part 260 mayo ucdai result full score incorpor recommend 261 endpoint measur support market applicat ion possibl use modifi global 262 score exploratori endpoint physician globa l could consid 263 264 265 v efficaci endpoint definit 266 267 section focus endpoint definit pha e 3 clinic trial associ claim 268 would support 269 270 trial design issu assess diseas sever entri induct 271 mainten paradigm use prior uc drug approv 15 possibl altern 272 paradigm beyond scope guidanc 273 15 paradigm induct mainten trial use prior uc drug approv ie induct trial conduct demonstr efficaci short duratio n 1 3 month mainten trial conduct demonstr durabl treatment effect longer period 6 month 1 year 8 contain nonbind recommend draft implement 274 clinic remiss clinic respons 275 276 clinic remiss respond definit base abso lute total mayo score absolut 277 mayo endoscopi stool frequenc rectal bleed pga subscor clinic respons 278 respond definit base reduct tota l mayo score reduct rectal bleed 279 subscor accept primari endpoint clinic trial th support prior 280 approv treatment uc16 current recommend primari endpoint clinic 281 remiss respond definit base stool frequenc rectal bleed endoscopi 282 score see section iv interim approach efficaci assess valid patient 283 report outcom instrument uc sign sy mptom valid clinician rate scale 284 mucos inflamm uc becom avail modifi mayo modifi ucdai score 285 omit physician global diseas activ rati ng describ section iv use 286 endpoint measur 287 288 follow definit clinic remiss recommend 289 290 stool frequenc subscor 0 291 rectal bleed subscor 0 292 endoscopi subscor 0 1 modifi mayo score 0 ucdai 293 294 altern stool frequenc subscor 0 definit c linic remiss 295 follow 296 297 least one point decreas stool frequenc subscor baselin start trial 298 achiev stool frequenc subscor 0 1 299 300 inclus maximum score 1 stool frequenc subscor definit clinic 301 remiss would support label claim includ normal stool frequenc 302 303 sponsor discuss propos endpoint phase 3 trial endofphas 2 304 meet see also section vii statist considerat ion sponsor begin discuss 305 endpoint measur fda earli possibl drug develop 306 307 b secondari endpoint interest 308 309 sponsor propos evalu chang treatment arm subscor 310 stool frequenc rectal bleed endoscopi andor total score ie sum stool 311 frequenc rectal bleed nd endoscopi subscor 312 313 c assess mucos heal vs endoscop appear mucosa 314 315 mucos heal base mayo endoscopi subscor includ secondari 316 endpoint mani clinic trial mani clinic trial mucos heal defin 16 see glossari histor endpoint definit clinic remiss clinic respons 9 contain nonbind recommend draft implement 317 mayo endoscop subscor less equal 1 point howev claim mucos 318 heal would support endosco py provid assess 319 visual appear mucosa claim late find endoscopi absenc 320 valid histolog assess mucosa would limit th e endoscop appear 321 mucosa 322 323 current limit histolog sc ore system commun standard 324 definit histolog improv thu th ere current criteria histolog 325 assess mucos heal sponsor intend pursu cl aim mucos heal 326 discuss propos develop plan fda histolog evalu biopsi specimen 327 obtain conduct central ch arter standard biopsi histolog 328 procedur assess eg score histolog dr aft earli drug 329 develop share fda commen method address discrep 330 assess site central reader shou ld prespecifi within protocol 331 grade scale score techniqu di scuss fda use measur 332 valid unlik support label claim 333 334 sponsor evalu histolog effect phase 2 trial inform effect 335 incorpor assess phase 3 trial 336 337 corticosteroidfre remiss 338 339 corticosteroidfre remiss often defin clinic remiss without concomit 340 corticosteroid particular time point patient us ing corticosteroid baselin 341 includ secondari en dpoint mani clinic trial 17 ensur clinic 342 meaning endpoint definit base minimum durat time 343 patient consid ed corticosteroid free clinic remiss 344 adequ justif shoul provid propos minimum durat 345 346 347 vi trial procedur time assess 348 349 screen import pa tient undergo endoscopi biopsi obtain 350 histolog confirm diseas activ sponsor shoul propos maxim time 351 conduct screen endoscopi entri trial sponsor seek claim 352 mucos heal discuss wi th fda propos histolog assess biopsi 353 specimen obtain endoscopi screen endoftreat visit tabl 2 354 summar key assessmen ts throughout trial 355 17 see glossari histor endpoint definit corticosteroidfre remiss 10 contain nonbind recommend draft implement 356 tabl 2 key assess screen treatment endoftreat visit visit key assess screen follow subscor mayo score stool frequenc rectal bleed ubscor calcul patient diari card endoscopi subscor histolog assess diseas activ confirm patient histolog examin endoscop obtain biopsi specimen sponsor seek claim mucos heal discuss propos histolog assess biopsi specimen obtain endoscopi treatment follow subscor mayo score stool frequenc rectal bleed ubscor calcul patient diari card pharmacokinet sampl antidrug antibodi sampl biolog product endoftreat follow subscor mayo score stool frequenc rectal bleed ubscor calcul patient diari card endoscopi subscor ideal histolog assess obtain sponsor seek claim mucos heal discuss propos histolog assess biopsi specimen obtain endoscopi 357 see section iv interim approach e fficaci assess inform 358 sponsor encourag propos electron data collect met hod eg voic respons system electron diari web 359 base system altern paper diari card 360 pharmacokinet sampl antidrug antibodi sampl bi olog product also obtain ontreat 361 visit 362 see also section vc assess mucos heal vs en doscop appear mucosa regard limit 363 histolog score system commun standard defin on histolog improv 364 365 stool frequenc rectal bleed endo copi subscor mayo score 366 obtain screen endof treatment visit stool frequenc rectal bleed 367 subscor mayo score also obta ine ontreat visit see section vb 368 secondari endpoint interest 369 370 appropri assay pharmacokinet antidrug antibodi assess use 371 prospect pl analys data 372 373 sponsor encourag prospect co llect data nonendoscop marker 374 inflamm creactiv protein level fecal calprotectin lactoferrin 375 put biomark throughout trial howev er marker may support label 376 claim sponsor encourag investig use propo ed biomark identifi 377 patient increas like lihood achiev clinic bene fit one approach 378 character biomark ie select say cutoff valu associ 379 clinic benefit earli phase trial valid biomark phase 3 trial 380 sponsor discuss propos approach w ith fda sponsor also encourag 381 consult center devic radiolog health throu gh presubmiss process 11 contain nonbind recommend draft implement 382 develop valid assay propos biomark select studi 383 phase 3 pivot trials18 384 385 386 vii statist consider 387 388 miss data 389 390 sponsor propos method handl miss data eg one miss mayo 391 subscor differ imput method consid ed studi 392 properti analyz simul met hod perhap lead conclus 393 patient nonrespond case abs nt other one possibl method 394 patient miss one mayo su bscore visit wher e primari endpoint 395 assess patient woul consid treatment fa ilur although could also 396 depend reason discontinu see al section iva2 calcul stool 397 frequenc rectal bleed subscor 398 399 number reason patient may protocolmand 400 endoscopi perform assess could intr oduc bia nonrandom 401 miss data regard analys e ndoscop find prot ocol prespecifi 402 follow patient handl respect defin endoscopi respond 403 nonrespond patient drop 19 lost followup disc ontinu investig drug 404 refus endoscopi otherwis deem treatment failur imbal 405 studi arm proport patient meet criteria like 406 endoscop data bias may result invalid estim treatment benefit 407 although like signific pr oblem shortterm trial concern may 408 limit abil trial longer durat provid mean ing endoscop assess data 409 see also section vc assess mucosa l heal vs endoscop appear 410 mucosa 411 412 b primari analysi 413 414 recommend analys binari respon es eg clinic remiss statu base 415 stratifi cochranmantelhaenszel test differ proport primari analysi 416 adjust stratifica tion factor use random 417 418 c secondari analys 419 420 sponsor calcul chan ge baselin stool frequenc rectal bleed 421 endoscopi subscor andor tota l score compar chang treatment arm 422 see section vb secondar endpoint interest secondari analys 18 see guidanc industri food drug administr staff request feedback medic devic submiss presubmiss program meet food drug administr staff 19 protocol specifi patient drop trial obtain endoscopi upon exit trial 12 contain nonbind recommend draft implement 423 424 425 viii pediatr drug deve lopment con ider 426 427 address pediatr research equiti act requir 428 429 compli pediat ric research equiti act prea 21 usc 355c20 new drug 430 applic biolog licens applic must contain data adequ assess 431 safeti effect drug th e claim indic support dose 432 administr relev pediatr subpopul unless th e requir waiv 433 defer addit ageappropri form ulat must develop relev 434 pediatr subpopul sponsor begin discuss pediatr formul 435 clinic develop plan earli developmen requir submit pediatr 436 studi plan later 60 day endofphas 2 meet recommend sponsor 437 refer prea amend food drug administr safeti innov act 438 fdasia2122 439 440 dgiep waiv prea requir pediatr studi uc drug children 441 younger 2 year age studi would imposs highli impractic 442 age group howev request waiver studi specif pe diatric age group eg 443 infant young children must includ appropri justifications23 sponsor consid 444 enrol children age affect ed uc pediat ric studyi 445 446 pediatr studi begin soon ar e adequ data suppo rt safeti expect 447 benefit pediatr patient w ith uc case pediat ric subpopul eg adolesc 448 enrol phase 3 trial adult provid nonclin studi rais specif 449 safeti concern pediatr subpopul 450 451 enrol pediatr patient document di agnosi uc includ 452 confirm endoscop histolog assess addit presenc 453 activ inflamm time entri clinic trial hould confirm 454 visual colon screeni ng period sponsor propos maxim time 455 conduct screen endoscopi entr trial 20 see section 505ba2 feder food drug cosmet act fdc act pediatr assess shall contain data gather use appropri formul age group assess requir adequ assess safeti effect drug biolog product claim indic relev pediatr su bpopul ii support dosi ng administr pediatr subpopul drug biolog product safe effect 21 see prea public law 108155 section 505b fdc act 21 usc 355b amend fdasia public law 112144 22 see draft guidanc industri pediatr studi plan content process submit initi pediatr studi plan amend pediatr studi plan final guidanc repres fda current think topic 23 see section 505ba4 f fdc act 13 contain nonbind recommend draft implement 456 457 b extrapol efficaci 458 459 base suffici similar cours th e diseas effect drug adult 460 pediatr patient uc fda conclu ded partial extrapol efficaci 461 accept adequ wellcontrol studi adult system activ drug 462 suffici exposurerespons data adult pediatr studi drug 463 support approach exposurerespon e relationship popul 464 similar242526 note establish biomark reli 465 upon establish exposurerespons relat hip uc trial design endpoint 466 directli measur clinic nefit ie rectal bleed stoo l frequenc endoscopi 467 use pediatr studi defin expo urerespons relationship import 468 adequ design pediatr clinic trial assess dose exposurerespons relationship 469 ensur adequ dose select pediatr addit pharmacokinet efficaci 470 comparison pediatr adult use support pediatri c dose select fda 471 encourag use model simul design pediatr tr ial leverag 472 knowledg adult clinic program furthermor use innov modelbas 473 approach encourag analyz pediatr doseex posurerespons data 474 475 c data collect pediatr patient 476 477 depend age pediatr patient observerbas report eg report 478 parent caregiv may need sessment sign symptom sponsor 479 discuss propos addr ess agespecif data collect issu fda 480 481 pediatr consider 482 483 growth paramet includ weight ight measur calibr stadiomet 484 appropri patient 2 year age old r includ secondari endpoint 485 pediatr trial 486 24 21 cfr 31455 21 cfr 60127 state cours diseas effect drug suffici similar adult pediatr patient fda may conclud pediatr effect extrapol adequ wellco ntroll studi adult usual supplement inform obtain pediatr patient pharmacokinet studi 25 see pediatr studi decis tree discuss extrapol efficaci dunn rodriguez et al 2011 26 topic discuss gastrointestin drug ad visori committe meet open label trial drug pediatr patient use mayo score prim ari endpoint measur see th e meet materi avail httpwwwfdagovadvisorycommitteescommitteesmeeti ngmaterialsdrugsgastroi ntestinaldrugsadvisorycom mitteeucm235600htm 14 contain nonbind recommend draft implement 487 glossari histor endpoints27 488 489 clinic remiss mayo score less equal 2 individu subscor greater 490 1 491 492 clinic respons reduct mayo score greater equal 3 point greater 493 equal 30 percent baselin accompani decreas rectal bleed subscor 494 greater equal 1 point absolut rectal bleed sub core less equal 1 495 point 496 497 corticosteroidfre remiss clinic remiss patient use oral corticosteroid 498 baselin discontinu corticosteroid nd clinic remi ssion end 499 studi 500 27 defin mani previou clin ical trial see section v efficaci endpoint definit current recommend 15 contain nonbind recommend draft implement 501 refer 502 503 literatur 504 505 abraham c cho jh 2009 infl ammatori bowel diseas n engl j med 36121206678 506 507 abramson durant mow w et al 2010 cidenc preval time trend 508 pediatr inflammatori bowel diseas northern california 1996 2006 j pediatr 509 157233e1239e1 510 511 danes fiocchi c 2011 ulcer coliti n engl j med 3651817131725 512 513 dhaen g sandborn wj feagan bg karel g et al 2007 review activ indic 514 efficaci end point clinic trial medi cal therapi adult ulcer coliti 515 gastroenterolog 132 2763786 516 517 dunn j rodriguez wj et al 2011 extrapol adult data data pediatr 518 drugdevelop program pediatr 128e12421249 519 520 kelsen j baldassano rn 2008 inflammatori bowel diseas differ 521 children adult inflamm bowel di 14 suppl 2 s9s11 2008 522 523 kornbluth sachar db practic paramet committe acg 2010 ulcer 524 coliti practic guidelin adult amer ican colleg gastroenterolog practic 525 paramet committe amer j gastroenterol 105501523 526 527 kugathasan judd rh et al 2003 epidemiol ogic clinic characterist children 528 newli diagnos inflammatori bowel di seas wisconsin statewid popul 529 base studi j pediatr 143525531 530 531 langan rc gotsch pb krafczyk skilli nge dd 2007 ulcer coliti diagnosi 532 treatment american famili physician 76132330 533 534 lewi jd chuai nessel l et al 2008 us e noninvas compon mayo 535 score assess clinic spons ulcer coliti inflamm bowel di 14 1216601666 536 537 lewi sj heaton kw 1997 stool form scale use guid intestin transit time 538 scand j gastroenterol 3299204 539 540 malati hm abraham bp mehta et al 2013 th e natur histori ul cer coliti 541 pediatr popul follow populationbas cohort studi clinic experiment 542 gastroenterolog 67783 543 544 matza ls patrick dl riley aw et al 2013 pe diatric patientreport outcom instrument 545 research support dical product label valu health 16 4461479 546 16 contain nonbind recommend draft implement 547 schroeder kw tremain wj ilstrup dm 1987 coat oral 5am inosalicyl acid 548 therapi mildli moder ly activ ulcer coliti n engl j med 3172616259 549 550 sutherland lr martin f greer et al 1987 5aminosalicyl acid enema treatment 551 distal ulcer coliti pr octosigmoid proctiti gastroenterolog 9218948 552 553 talley nj abreu mt achkar jp et al 2011 evidencebas systemat review 554 medic therapi inflammatori bowel diseas j gastroenterol 106s2s25 555 556 present advisori committe meet 557 558 higgin pdr 2012 measur treatment benefit uc current standard altern 559 gastroenterolog regulatori endpoint advanc therapeut great 560 workshop septemb 21 transcript avail 561 httpwwwregulationsgovdocum entdetaildfda2012n00010093 562 563 gastroenterolog regulatori endpoint advanc therapeut great 564 workshop septemb 21 2012 transcript avail 565 httpwwwregulationsgovdocum entdetaildfda2012n00010093 566 567 gastroenterolog regulatori endpoint advanc therapeut 2 great 2 568 workshop octob 22 2013 569 570 guidanc 28 571 572 draft guidanc industri pediatr studi plan content process submit initi 573 pediatr studi plan end pediatr studi plan 574 575 guidanc industri patientreport outcom measur es use medic product 576 develop support label claim 577 578 guidanc industri provid clinic evid effect human drug 579 biolog product 580 581 guidanc industri fda staff qualif process drug develop tool 582 583 guidanc industri food drug administr staff request feedback 584 medic devic submiss presubmiss program meet food drug 585 administr staff 586 28 guidanc found fda drug guidanc web page httpwwwfdagovdrugsguidancecompliancereg ulatoryinformationgu idancesdefaulthtm 17 contain nonbind recommend draft implement 587 appendix 1 mayo score 588 589 follow taken schroeder tremain et al 1987 590 591 tabl mayo score 592 593 18 contain nonbind recommend draft implement 594 appendix 2 ucdai 595 596 follow taken sutherland martin et al 1987 597 598 tabl b ucdai 599 19